"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_CRO",2000,122,8.04098360655738,3.33606557377049,0.491803278688525,0.39344262295082,0.475409836065574,2.18579234972678,1.51282051282051,1.95833333333333,1.46153846153846,0.327868852459016,2,72,19,7,20,0.59,0.16,0.06,0.16,56.87,1.25452517117146,NA,0.368852459016393,0.860655737704918,0.529,0.474,0.51,0.472,"SILVIA FRANCESCHI;CARLO LA VECCHIA;ANTONINO CARBONE;EVA NEGRI;ANNUNZIATA GLOGHINI;GIANLUCA GAÏDANO;MAURO BOIOCCHI;RENATO TALAMINI;DANIELA CAPELLO;UMBERTO TIRELLI;FABIO LEVI;MICHELE MAIO;CRISTINA BOSETTI;GIUSEPPE IPPOLITO;ALFONSO COLOMBATTI;EMANUELA VACCHER;LUIGINO DAL MASO;RICCARDO DOLCETTI;PAOLO DE PAOLI;DANIELA GASPAROTTO","28;21;20;17;15;10;10;9;8;8;7;7;7;7;6;6;6;6;6;5","SILVIA FRANCESCHI;ANTONINO CARBONE;CARLO LA VECCHIA;EVA NEGRI;ANNUNZIATA GLOGHINI;PAOLO DE PAOLI;GIANLUCA GAÏDANO;MAURO BOIOCCHI;RENATO TALAMINI;MICHELE MAIO;GIUSEPPE IPPOLITO;CRISTINA BOSETTI;ALFONSO COLOMBATTI;LUCA SIGALOTTI;FABIO LEVI;DANIELA CAPELLO;E CAMPAGNUTTA;RENATO CANNIZZARO;GIORGIO GIORDA;UMBERTO TIRELLI","4.54;3.72;3.24;2.61;1.96;1.63;1.4;1.2;1.19;1.18;1.05;1.05;1.01;0.97;0.95;0.94;0.9;0.85;0.83;0.78","SILVIA FRANCESCHI;ANTONINO CARBONE;ANNUNZIATA GLOGHINI;MAURO BOIOCCHI;RENATO TALAMINI;UMBERTO TIRELLI;MICHELE MAIO;GIUSEPPE IPPOLITO;ALFONSO COLOMBATTI;EMANUELA VACCHER;LUIGINO DAL MASO;RICCARDO DOLCETTI;PAOLO DE PAOLI;DANIELA GASPAROTTO;BARBARA PIVETTA;VALLÌ DE RE;LUCA SIGALOTTI;DIANA CRIVELLARI;GIORGIO GIORDA;MARIA DONATELLA MAGRI","28;20;15;10;9;8;7;7;6;6;6;6;6;5;5;5;5;5;5;4","SILVIA FRANCESCHI;ANTONINO CARBONE;ANNUNZIATA GLOGHINI;PAOLO DE PAOLI;MAURO BOIOCCHI;RENATO TALAMINI;MICHELE MAIO;GIUSEPPE IPPOLITO;ALFONSO COLOMBATTI;LUCA SIGALOTTI;E CAMPAGNUTTA;RENATO CANNIZZARO;GIORGIO GIORDA;UMBERTO TIRELLI;RICCARDO DOLCETTI;EMANUELA VACCHER;ROBERTO DOLIANA;DIANA CRIVELLARI;MARIA PARPINEL;LUIGINO DAL MASO","4.54;3.72;1.96;1.63;1.2;1.19;1.18;1.05;1.01;0.97;0.9;0.85;0.83;0.78;0.77;0.74;0.64;0.62;0.58;0.56","SILVIA FRANCESCHI;CARLO LA VECCHIA;EVA NEGRI;ANTONINO CARBONE;UMBERTO TIRELLI;GIUSEPPE IPPOLITO;ANNUNZIATA GLOGHINI;MAURO BOIOCCHI;RENATO TALAMINI;FABIO LEVI;GIOVANNI REZZA;PATRIZIO PEZZOTTI;ANDREA ANTINORI;CRISTINA BOSETTI;ALESSANDRO COZZI‐LEPRI;ANDREA DE LUCA;ANDREW N. PHILLIPS;ANTONELLA D’ARMINIO MONFORTE;FABRICE GRITTI;FABRIZIO SOSCIA","2544;1660;1255;1150;968;937;827;814;778;776;676;674;594;570;550;550;550;550;550;550","SILVIA FRANCESCHI;ANTONINO CARBONE;UMBERTO TIRELLI;MAURO BOIOCCHI;RENATO TALAMINI;ANNUNZIATA GLOGHINI;BARBARA PIVETTA;VALLÌ DE RE;LUIGINO DAL MASO;A. MARZOTTO;ETTORE BIDOLI;DIEGO SERRAINO;EMANUELA VACCHER;ROBERTO DOLIANA;MAURIZIO RUPOLO;SALVATORE DE VITA;ROBERTA MAESTRO;SARA PICCININ;ROBERTO PERRIS;MARIA PARPINEL","2339;1030;968;814;778;667;548;548;495;439;402;398;355;352;335;331;289;289;283;277","SILVIA FRANCESCHI;ANTONINO CARBONE;ANNUNZIATA GLOGHINI;MAURO BOIOCCHI;RENATO TALAMINI;UMBERTO TIRELLI;LUIGINO DAL MASO;EMANUELA VACCHER;BARBARA PIVETTA;GIORGIO GIORDA;MICHELE MAIO;PAOLO DE PAOLI;VALLÌ DE RE;ALFONSO COLOMBATTI;LUCA SIGALOTTI;RICCARDO DOLCETTI;A. MARZOTTO;DIANA CRIVELLARI;DIEGO SERRAINO;ESTER FONSATTI","26;17;11;10;9;9;6;6;5;5;5;5;5;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;GEOGRAPHY;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE","97;62;19;12;12;6;6;4;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;PATHOLOGY;BIOCHEMISTRY;CANCER RESEARCH;GENETICS;ENVIRONMENTAL HEALTH;SURGERY;MOLECULAR BIOLOGY;VIROLOGY;CELL BIOLOGY;GASTROENTEROLOGY;DEMOGRAPHY;ONCOLOGY;GYNECOLOGY;OPTICS;FOOD SCIENCE;DERMATOLOGY;ENDOCRINOLOGY;ORGANIC CHEMISTRY;PALEONTOLOGY","63;51;36;30;27;27;22;19;17;15;12;12;11;11;10;8;7;6;6;5;5","CANCER;LYMPHOMA;GENE;ANTIBODY;VIRUS;ODDS RATIO;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNOHISTOCHEMISTRY;POPULATION;CELL CULTURE;IMMUNE SYSTEM;ANTIGEN;CHEMOTHERAPY;CASE-CONTROL STUDY;INCIDENCE (GEOMETRY);MELANOMA;RISK FACTOR;ALCOHOL;DISEASE;EPIDEMIOLOGY","40;24;22;20;17;12;11;11;11;10;9;8;8;7;7;7;7;6;6;6","MONOCLONAL ANTIBODY;BREAST CANCER;PRIMARY EFFUSION LYMPHOMA;VIRAL DISEASE;B CELL;COLORECTAL CANCER;MUTATION;ESOPHAGEAL CANCER;HEPATITIS C VIRUS;HODGKIN LYMPHOMA;OVARIAN CANCER;RETINOIC ACID;ALLELE;CD8;CELL CYCLE;CLONE (JAVA METHOD);EPSTEIN–BARR VIRUS;FLUOROURACIL;ALCOHOL CONSUMPTION;CHROMOSOME;GENE EXPRESSION;HUMAN HERPESVIRUS;IMMUNODEFICIENCY;OSTEOARTHRITIS;RHEUMATOID FACTOR;VIRAL LOAD","9;8;8;8;7;7;7;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","CRYOGLOBULINEMIA;GERMINAL CENTER;METASTATIC BREAST CANCER;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;EPIRUBICIN;HERPESVIRIDAE;MICROSATELLITE;ARTICULAR CARTILAGE;CARTILAGE OLIGOMERIC MATRIX PROTEIN;CD59;COMPLEMENT MEMBRANE ATTACK COMPLEX;CYCLIN D1;CYTOGENETICS;DNA METHYLATION;DNA MISMATCH REPAIR;GENOME INSTABILITY;GERMLINE MUTATION;IRF4;KARYOTYPE;MONOCLONAL;NODULAR SCLEROSIS;SEXUAL TRANSMISSION;SEXUALLY TRANSMITTED DISEASE;SIDA;TAMOXIFEN","4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MIDDLE AGED;ADULT;MALE;AGED;;HIV INFECTIONS;HODGKIN DISEASE;ITALY;LYMPHOMA, B-CELL;BREAST NEOPLASMS;LYMPHOMA, AIDS-RELATED;TUMOR CELLS, CULTURED;ANTINEOPLASTIC AGENTS;ESOPHAGEAL NEOPLASMS;RISK FACTORS;HERPESVIRUS 8, HUMAN;NEOPLASMS;CASE-CONTROL STUDIES","92;49;44;42;36;35;26;25;25;25;23;21;21;21;19;19;18;17;17;16","VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;SARCOMA RESEARCH AND TREATMENT;GENETIC AND MOLECULAR STUDIES OF CONNECTIVE TISSUE DISORDERS;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYMPHOID NEOPLASMS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;THERAPEUTIC ANTIBODIES: DEVELOPMENT, ENGINEERING, AND APPLICATIONS;ADVANCEMENTS IN LUNG CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MELANOMA;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;BIODEGRADABLE POLYMERS AS BIOMATERIALS AND PACKAGING","16;8;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;1","PRIMARY EFFUSION LYMPHOMA;CANCER INCIDENCE;B-CELL RECEPTOR SIGNALING;ETIOLOGY;CLONE (JAVA METHOD);HEALTHY EATING INDEX;HIV;METASTATIC BREAST CANCER;NUTRITIONAL EPIDEMIOLOGY;ANTIGEN PRESENTATION;ANTIRETROVIRAL THERAPY;CANCER THERAPY;EPIRUBICIN;FOOD GROUP;GAMMAHERPESVIRINAE;HUMAN HERPESVIRUS 8;MICROSATELLITE INSTABILITY;MSH6;RHEUMATOID FACTOR;TUMOR MICROSATELLITE-INSTABILITY","8;7;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","PRIMARY EFFUSION;EFFUSION LYMPHOMA;BREAST CANCER;COLORECTAL CANCER;ESOPHAGEAL CANCER;TYPE II;ADVANCED BREAST;CANCER BIOLOGY;CANCER PATIENTS;CELL LINES;HODGKINS DISEASE;NORTHERN ITALY;OESOPHAGEAL CANCER;PROTECTIN CD;SQUAMOUS CELL;ACID INDUCES;ACIDMEDIATED GROWTH;ACQUIRED IMMUNODEFICIENCY;ALLELIC SHIFTS;ANTIGEN RECEPTOR;ANTIRETROVIRAL THERAPY;ATYPICAL LIPOMATOUS;CANCER RISK;CARTILAGE OLIGOMERIC;CELL ESOPHAGEAL;COLON CANCERS;CONTINUOUS INFUSION;COORDINATED EXPRESSION;CYTOREDUCTIVE SURGERY;DISEASE HISTOGENESIS","7;6;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ESOPHAGEAL CANCER;CROSSREF PUBMED;PUBMED SCOPUS;CELL LINES;UPPER LIMIT;CELLULAR CYCLIN;PKIP EXPRESSION;PUBMED GOOGLE;HHV- V-CYCLIN;CANCER RISK;OLIVE OIL;SQUAMOUS CELL;ALCOHOL DRINKING;TOBACCO SMOKING;KAPOSIS SARCOMA-ASSOCIATED;LYMPHOMATOUS EFFUSIONS;PRIMARY EFFUSION;SCIENCEGOOGLE SCHOLAR;TUMOR CELLS;LYMPHOMA CELL;RAW VEGETABLES;CITRUS FRUIT;HUMAN HERPESVIRUS;PEL CELL;SEROUS BODY;BODY CAVITIES;BODY CAVITY-BASED;MOORE PS;NORTHERN ITALY;CANCER RESEARCH","56;46;42;39;25;24;22;22;21;19;19;18;17;17;16;15;15;15;15;14;14;13;13;13;13;12;12;12;12;11",19,0.16,3,2,0,0,0,1,1,0,1,2,0,0,10,0,1.75,0,0,10,0,0,0,43.5,43.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,3,779,1.74,0,0,71.33,0,0,0,0,3,0,0,0,0,3,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Belgium;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY","3;3;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;ORPHAN DRUG;RARE DISEASES;BRAIN CANCER;BRAIN DISORDERS;COMPARATIVE EFFECTIVENESS RESEARCH;LUNG CANCER;NEUROSCIENCES;PATIENT SAFETY","3;3;3;2;2;2;1;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.4 SURGERY","3;2;1","LUNG CANCER;BRAIN TUMOR;BREAST CANCER;MELANOMA","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2001,86,8.2906976744186,2.90697674418605,0.476744186046512,0.313953488372093,0.465116279069767,1.54320987654321,1.20588235294118,1.28571428571429,1.14285714285714,0.465116279069767,4,49,10,13,11,0.57,0.12,0.15,0.13,61.73,1.35104566469209,NA,0.36046511627907,0.86046511627907,0.505,0.502,0.519,0.496,"SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;LUIGINO DAL MASO;ANTONINO CARBONE;DIEGO SERRAINO;EVA NEGRI;PAOLO DE PAOLI;UMBERTO TIRELLI;ANTONINO DE PAOLI;ALESSANDRA VIEL;STEFANIA ZANUSSI;CARLO RICCARDO ROSSI;GIOVANNI REZZA;ANDREA VERONESI;SILVANO GALLUS;MARIA TERESA BORTOLIN;E. CONTI;M. TROVÒ;MICHELE SPINA","18;13;13;11;9;8;8;6;6;5;5;4;4;4;4;4;4;4;4;4","SILVIA FRANCESCHI;ANTONINO CARBONE;CARLO LA VECCHIA;LUIGINO DAL MASO;RENATO TALAMINI;MICHELE SOZZI;DIEGO SERRAINO;RICCARDO DOLCETTI ANTONINO CARBONE;LUIGI DE MARCO;EVA NEGRI;PAOLO DE PAOLI;UMBERTO TIRELLI;C SCARABELLI;ANTONINO DE PAOLI;STEFANIA ZANUSSI;MARIA TERESA BORTOLIN;SILVANO GALLUS;MICHELE SPINA;E. CONTI;CARLO RICCARDO ROSSI","2.47;2.11;1.79;1.72;1.59;1.2;1.05;1;1;0.98;0.84;0.83;0.62;0.57;0.56;0.56;0.55;0.55;0.53;0.5","SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;LUIGINO DAL MASO;ANTONINO CARBONE;DIEGO SERRAINO;PAOLO DE PAOLI;UMBERTO TIRELLI;ANTONINO DE PAOLI;ALESSANDRA VIEL;STEFANIA ZANUSSI;CARLO RICCARDO ROSSI;ANDREA VERONESI;MARIA TERESA BORTOLIN;E. CONTI;M. TROVÒ;MICHELE SPINA;R. INNOCENTE;VINCENZO CANZONIERI;CINZIA CREPALDI","18;13;13;11;9;8;6;6;5;5;4;4;4;4;4;4;4;4;3;3","SILVIA FRANCESCHI;ANTONINO CARBONE;CARLO LA VECCHIA;LUIGINO DAL MASO;RENATO TALAMINI;MICHELE SOZZI;DIEGO SERRAINO;RICCARDO DOLCETTI ANTONINO CARBONE;LUIGI DE MARCO;PAOLO DE PAOLI;UMBERTO TIRELLI;C SCARABELLI;ANTONINO DE PAOLI;STEFANIA ZANUSSI;MARIA TERESA BORTOLIN;MICHELE SPINA;E. CONTI;CARLO RICCARDO ROSSI;NEREO MENEGUZZO;CHIARA LESTUZZI","2.47;2.11;1.79;1.72;1.59;1.2;1.05;1;1;0.84;0.83;0.62;0.57;0.56;0.56;0.55;0.53;0.5;0.5;0.5","SILVIA FRANCESCHI;CARLO LA VECCHIA;EVA NEGRI;DIEGO SERRAINO;LUIGINO DAL MASO;ANTONINO DE PAOLI;MARIA PARPINEL;ANGELA BUONADONNA;S. FRUSTACI;ALBERTO AZZARELLI;ALESSANDRO COMANDONE;ELENA BARBIERI;F. GHERLINZONI;G. PIGNATTI;GAETANO APICE;HASSAN ZMERLY;MARCO BONETTI;PATRIZIA OLMI;PIERO PICCI;ANTONINO CARBONE","1622;1305;1059;1055;954;737;714;701;701;683;683;683;683;683;683;683;683;683;683;681","DIEGO SERRAINO;LUIGINO DAL MASO;ANTONINO DE PAOLI;ALBERTO AZZARELLI;ALESSANDRO COMANDONE;ANGELA BUONADONNA;ELENA BARBIERI;F. GHERLINZONI;G. PIGNATTI;GAETANO APICE;HASSAN ZMERLY;MARCO BONETTI;PATRIZIA OLMI;PIERO PICCI;S. FRUSTACI;ANTONINO CARBONE;SALVATORE VACCARELLA;MARIA PARPINEL;SILVIA FRANCESCHI;ALESSANDRA VIEL","950;857;737;683;683;683;683;683;683;683;683;683;683;683;683;681;635;621;546;514","RENATO TALAMINI;ANTONINO CARBONE;LUIGINO DAL MASO;UMBERTO TIRELLI;ALESSANDRA VIEL;ANTONINO DE PAOLI;DIEGO SERRAINO;SILVIA FRANCESCHI;CARLO RICCARDO ROSSI;M. TROVÒ;R. INNOCENTE;EMANUELA VACCHER;ANDREA VERONESI;CARLO LA VECCHIA;G. BOZ;MICHELE SPINA;PAOLO DE PAOLI;ALFONSO COLOMBATTI;CHIARA LESTUZZI;DIANA CRIVELLARI","12;9;9;5;5;5;5;5;4;4;4;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;MATHEMATICS;COMPUTER SCIENCE;MATERIALS SCIENCE;PSYCHOLOGY;ART;ECONOMICS;ENGINEERING;HISTORY;PHILOSOPHY","71;29;10;8;6;4;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;IMMUNOLOGY;PATHOLOGY;SURGERY;GENETICS;CANCER RESEARCH;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;BIOCHEMISTRY;GYNECOLOGY;ENDOCRINOLOGY;MOLECULAR BIOLOGY;VIROLOGY;DEMOGRAPHY;CELL BIOLOGY;DENTISTRY;OBSTETRICS;OPTICS;RADIOLOGY","58;24;22;17;16;14;13;13;12;11;9;7;7;7;6;5;4;4;4;4","CANCER;CHEMOTHERAPY;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);POPULATION;CONFIDENCE INTERVAL;LYMPHOMA;ODDS RATIO;CASE-CONTROL STUDY;ANTIBODY;RADIATION THERAPY;CARCINOMA;LOGISTIC REGRESSION;CELL;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;REGIMEN;SARCOMA;VIRUS","43;16;15;12;11;9;9;9;7;6;6;5;5;4;4;4;4;4;4;4","OVARIAN CANCER;BREAST CANCER;COLORECTAL CANCER;VIRAL LOAD;ETOPOSIDE;FLUOROURACIL;MUTATION;ADENOCARCINOMA;ALLELE;CERVICAL CANCER;CYCLOPHOSPHAMIDE;NON-HODGKIN'S LYMPHOMA;SEROLOGY;T CELL;VIRAL DISEASE;ANTIMETABOLITE;CARCINOGENESIS;CD30;CD8;CISPLATIN;DOCETAXEL;DOXORUBICIN;GASTRITIS;GEMCITABINE;GENOTYPE;GLYCEMIC;INSULIN RESISTANCE;INTERLEUKIN 2;MONOCLONAL ANTIBODY;NEUTROPENIA;PHENOTYPE;POLYMERASE CHAIN REACTION;PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;PRIMARY EFFUSION LYMPHOMA;RNA;SEROCONVERSION;SOUTHERN BLOT;VIREMIA;VIRULENCE","11;8;6;6;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;IFOSFAMIDE;METASTATIC BREAST CANCER;CAGA;DNA MISMATCH REPAIR;EPITHELIAL OVARIAN CANCER;FRAMESHIFT MUTATION;GERMLINE MUTATION;GLYCEMIC INDEX;MICROSATELLITE;OVARIAN CARCINOMA;PROBAND;SIDA;SPIRILLACEAE;ANTHRACYCLINE;ANTIFOLATE;BLEEDING TIME;CARBOPLATIN;CERVICAL INTRAEPITHELIAL NEOPLASIA;CERVICAL SCREENING;COLPOSCOPY;CONDOM;CORONARY VASOSPASM;CYCLIN-DEPENDENT KINASE 1;CYTOREDUCTIVE SURGERY;ELECTROPHORETIC MOBILITY SHIFT ASSAY;EPIRUBICIN;FEBRILE NEUTROPENIA;GERMINAL CENTER;HAPLOTYPE;HBSAG;HERPESVIRIDAE;HLA-B ANTIGENS;HYPERINSULINEMIA;IL-2 RECEPTOR;INTERMEDIATE FILAMENT;KAPOSI'S SARCOMA;LACTIDE;LARGE CELL;LENTIVIRUS;LYMPHOCYTE SUBSETS;MACROMONOMER;MESONEPHROS;MONOCLONAL;MONOCLONAL ANTIBODY THERAPY;PAN-T ANTIGENS;PAPILLARY THYROID CANCER;PATHOGENICITY ISLAND;PHENOCOPY;PRONEPHROS;PROPIDIUM IODIDE;RIBONUCLEASE;RIBOSOME;RISTOCETIN;RNASE P;SENTINEL LYMPH NODE;SULFOLOBUS;SULFOLOBUS SOLFATARICUS;TAXANE;VINCRISTINE","4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MIDDLE AGED;MALE;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;OVARIAN NEOPLASMS;ITALY;NEOPLASMS;HIV INFECTIONS;BREAST NEOPLASMS;LYMPHOMA, AIDS-RELATED;HIV SEROPOSITIVITY;CASE-CONTROL STUDIES;LYMPHOMA, NON-HODGKIN;LUNG NEOPLASMS;ODDS RATIO;ADOLESCENT;ALCOHOL DRINKING","74;52;45;44;37;33;26;26;23;23;19;18;18;15;14;14;13;13;12;12","VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;LYMPHOID NEOPLASMS;PANCREATIC CANCER RESEARCH AND TREATMENT;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;ROLE OF AMP-ACTIVATED PROTEIN KINASE IN CELLULAR METABOLISM;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;BIODEGRADABLE POLYMERS AS BIOMATERIALS AND PACKAGING;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CARDIOTOXICITY OF CANCER TREATMENTS;CHEMOTHERAPY-INDUCED DERMATOLOGICAL TOXICITY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DATA QUALITY ASSESSMENT AND IMPROVEMENT","11;8;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","HIV;OVARIAN CANCER;ANTIRETROVIRAL THERAPY;CANCER RISK;REGIMEN;CANCER;HUMAN HERPESVIRUS 8;BODY MASS INDEX;BREAST CANCER;CAGA;CAGA PROTEIN;CANCER INCIDENCE;CONCOMITANT;CYTOREDUCTIVE SURGERY;DERMOSCOPY;DIETARY PATTERNS;DNA MISMATCH REPAIR;GLYCEMIC LOAD;HEALTHY EATING INDEX;HIV INFECTION","6;6;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","OVARIAN CANCER;BREAST CANCER;COLORECTAL CANCER;HUMAN IMMUNODEFICIENCY;ANTIRETROVIRAL THERAPY;CANCER RISK;CASE-CONTROL STUDY;ACTIVE ANTIRETROVIRAL;CONTINUOUS INFUSION;HEREDITARY NONPOLYPOSIS;HIGHLY ACTIVE;NONPOLYPOSIS COLORECTAL;ORAL CAVITY;PHASE II;RADIATION THERAPY;ADULT SOFT;ADVANCED BREAST;CASECONTROL STUDY;CENTRAL NERVOUS;DIETARY GLYCEMIC;EPITHELIAL OVARIAN;EXPERIMENTALLY INFECTED;GLYCEMIC LOAD;HIV-POSITIVE PATIENTS;II STUDY;INFECTED MICE;ITALIAN CASECONTROL;LOCALLY ADVANCED;NERVOUS SYSTEM;NON-HODGKIN LYMPHOMA","8;5;5;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;PUBMED GOOGLE;MICROSATELLITE INSTABILITY;STAGE II;ACTIVATED CYTOTOXIC;COLORECTAL CANCER;GOODWIN GH;STAGE III;HMGAA PROTEIN;BIOL CHEM;CHEM -ABSTRACT;CLINICAL OUTCOME;III DISEASE;SCIENCEGOOGLE SCHOLAR;APOPTOTIC CELLS;HUMAN HERPESVIRUS;REFERENCE CATEGORY;BREAST CANCER;CELL LINES;COLON CANCER;MSI-H TUMORS;CYTOTOXIC IELS;RES -PUBMED;CD CD;GLYCEMIC INDEX;SCHOLAR GIANCOTTI;CYTOTOXIC LYMPHOCYTES;GRB IELS;ROME ITALY","62;49;26;25;21;19;18;17;17;16;15;15;14;14;14;13;13;13;12;12;12;12;11;11;10;10;10;9;9;9",13,0.15,4,3,0,0,0,0,2,0,1,3,0,0,1.75,0,1.25,0,0,2,1,0,0,33,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,15,2243.33,1.94,1,0.33,127.33,0,0,0,0,2,0,0,1,0,3,0,0,0,0,0,0,0,1,2,0,3,0,0,0,0,0,0,0,0,0,"Belgium;Canada;Italy","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","3;3;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;BREAST CANCER;ORPHAN DRUG;RARE DISEASES;UROLOGIC DISEASES","3;3;3;3;2;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","3;1;1","BREAST CANCER;BLADDER CANCER","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","2;1;1",1,499997,49999.7,5,10,6,1,0,9999.94,8.6000516003096,"CANCER REGISTRY OF NORWAY;CENTRO DI RIFERIMENTO ONCOLOGICO;FINNISH CANCER REGISTRY;FINNISH INSTITUTE FOR HEALTH AND WELFARE;GERMAN CANCER RESEARCH CENTER;ICELANDIC CANCER SOCIETY;KAROLINSKA INSTITUTET;LUND UNIVERSITY;NORWEGIAN CANCER SOCIETY;UMEÅ UNIVERSITY","1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES","1;1;1","CANCER;CLINICAL RESEARCH;HEMATOLOGY;PREVENTION","1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","NOT SITE-SPECIFIC CANCER","1","2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY","1","A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2002,105,9.1047619047619,3.47619047619048,0.438095238095238,0.333333333333333,0.457142857142857,2,1.09302325581395,1.63636363636364,1.11363636363636,0.428571428571429,5,63,20,10,10,0.6,0.19,0.1,0.1,72.16,1.30802232073694,NA,0.466666666666667,0.79047619047619,0.549,0.453,0.459,0.439,"ANTONINO CARBONE;SILVIA FRANCESCHI;RENATO TALAMINI;CARLO LA VECCHIA;EVA NEGRI;ANNUNZIATA GLOGHINI;LUIGINO DAL MASO;MICHELE MAIO;VALTER GATTEI;UMBERTO TIRELLI;CRISTINA BOSETTI;ETTORE BIDOLI;MAURO BOIOCCHI;FABIO LEVI;LUCA SIGALOTTI;DONATELLA ALDINUCCI;MASSIMO DEGAN;FRANCESCA COLIZZI;GIANLUCA GAÏDANO;MARESA ALTOMONTE","20;19;18;16;15;12;11;9;9;9;8;8;8;7;7;6;6;6;6;6","RENATO TALAMINI;SILVIA FRANCESCHI;ANTONINO CARBONE;CARLO LA VECCHIA;EVA NEGRI;UMBERTO TIRELLI;MICHELE MAIO;LUIGINO DAL MASO;DIANA CRIVELLARI;ANNUNZIATA GLOGHINI;MICHELE SPINA;ETTORE BIDOLI;VALTER GATTEI;ALESSANDRO RAMBALDI;ALESSANDRO PULSONI;ESTER FONSATTI MICHELE MAIO;MAURO BOIOCCHI;LUCA SIGALOTTI;CRISTINA BOSETTI;DANIELA BERNARDI","2.53;2.47;2.28;2.22;2.13;1.9;1.47;1.31;1.2;1.13;1.07;1.04;1.02;1;1;1;0.95;0.94;0.94;0.9","ANTONINO CARBONE;SILVIA FRANCESCHI;RENATO TALAMINI;ANNUNZIATA GLOGHINI;LUIGINO DAL MASO;MICHELE MAIO;VALTER GATTEI;UMBERTO TIRELLI;CRISTINA BOSETTI;ETTORE BIDOLI;MAURO BOIOCCHI;LUCA SIGALOTTI;DONATELLA ALDINUCCI;MASSIMO DEGAN;FRANCESCA COLIZZI;MARESA ALTOMONTE;ALFONSO COLOMBATTI;MASSIMO LIBRA;ISABELLA MILAN;SANDRA CORAL","20;19;18;12;11;9;9;9;8;8;8;7;6;6;6;6;5;5;5;5","RENATO TALAMINI;SILVIA FRANCESCHI;ANTONINO CARBONE;UMBERTO TIRELLI;MICHELE MAIO;LUIGINO DAL MASO;DIANA CRIVELLARI;ANNUNZIATA GLOGHINI;MICHELE SPINA;ETTORE BIDOLI;VALTER GATTEI;ALESSANDRO RAMBALDI;ALESSANDRO PULSONI;ESTER FONSATTI MICHELE MAIO;MAURO BOIOCCHI;LUCA SIGALOTTI;CRISTINA BOSETTI;DANIELA BERNARDI;ISABELLA MILAN;DONATELLA ALDINUCCI","2.53;2.47;2.28;1.9;1.47;1.31;1.2;1.13;1.07;1.04;1.02;1;1;1;0.95;0.94;0.94;0.9;0.88;0.71","VITTORINA ZAGONEL;DIEGO SERRAINO;ANTONELLA VENTURINO;DENISE DAL LAGO;FLORA GIOIA;LAZZARO REPETTO;LUCIA FRATINO;MARINA VERCELLI;MATTI AAPRO;RICCARDO A. AUDISIO;S. MONFARDINI;STEFANO PARODI;WALTER GIANNI;SILVIA FRANCESCHI;ANTONINO CARBONE;CARLO LA VECCHIA;LUIGINO DAL MASO;EVA NEGRI;RENATO TALAMINI;MICHELE MAIO","1611;1301;1290;1290;1290;1290;1290;1290;1290;1290;1290;1290;1290;1222;1175;1021;948;931;915;794","DIEGO SERRAINO;LUCIA FRATINO;ANTONINO CARBONE;LUIGINO DAL MASO;RENATO TALAMINI;VITTORINA ZAGONEL;MICHELE MAIO;ANTONELLA VENTURINO;DENISE DAL LAGO;FLORA GIOIA;LAZZARO REPETTO;MARINA VERCELLI;MATTI AAPRO;RICCARDO A. AUDISIO;S. MONFARDINI;STEFANO PARODI;WALTER GIANNI;ETTORE BIDOLI;ANNUNZIATA GLOGHINI;LUCA SIGALOTTI","1301;1290;958;941;906;830;794;509;509;509;509;509;509;509;509;509;509;471;450;409","ANTONINO CARBONE;RENATO TALAMINI;LUIGINO DAL MASO;MICHELE MAIO;UMBERTO TIRELLI;ANNUNZIATA GLOGHINI;VALTER GATTEI;ETTORE BIDOLI;LUCA SIGALOTTI;FRANCESCA COLIZZI;MARESA ALTOMONTE;MAURO BOIOCCHI;MASSIMO DEGAN;ALESSANDRA VIEL;ALFONSO COLOMBATTI;DONATELLA ALDINUCCI;ISABELLA MILAN;SANDRA CORAL;CARLO GOBITTI;EMILIO MINATEL","16;16;10;9;9;8;8;7;7;6;6;6;5;5;5;5;5;5;4;4","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;PHYSICS;ECONOMICS;ENGINEERING;MATERIALS SCIENCE","82;62;10;3;3;2;2;1;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;ONCOLOGY;BIOCHEMISTRY;CANCER RESEARCH;SURGERY;MOLECULAR BIOLOGY;PATHOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;VIROLOGY;ENDOCRINOLOGY;PALEONTOLOGY;ECOLOGY;MICROBIOLOGY;ORGANIC CHEMISTRY;RADIOLOGY","68;30;27;25;22;22;21;17;17;16;13;12;10;10;6;6;4;4;4;4","CANCER;GENE;LYMPHOMA;CONFIDENCE INTERVAL;ODDS RATIO;CHEMOTHERAPY;CASE-CONTROL STUDY;ANTIBODY;POPULATION;MELANOMA;RECEPTOR;VIRUS;CELL CULTURE;LOGISTIC REGRESSION;RADIATION THERAPY;TOXICITY;BIOPSY;CARCINOMA;CELL;STAGE (STRATIGRAPHY)","45;30;16;14;14;12;11;8;8;7;7;7;6;6;6;6;5;5;5;5","GENE EXPRESSION;BREAST CANCER;COLORECTAL CANCER;OVARIAN CANCER;HODGKIN LYMPHOMA;B CELL;CERVICAL CANCER;HAZARD RATIO;MONOCLONAL ANTIBODY;MUTATION;CARCINOGENESIS;CELL CYCLE;CHROMOSOMAL TRANSLOCATION;HAEMATOPOIESIS;IMMUNOTHERAPY;NEUTROPENIA;ALCOHOL CONSUMPTION;BLADDER CANCER;CANCER-RELATED FATIGUE;CD34;CELL MIGRATION;CELLULAR DIFFERENTIATION;CHEMOTHERAPY REGIMEN;CHOP;COMPLEMENT SYSTEM;CYCLOPHOSPHAMIDE;DAUNORUBICIN;DNA DAMAGE;DNA REPAIR;ENDOMETRIAL CANCER;EPSTEIN–BARR VIRUS;FIBRONECTIN;FLUOROURACIL;GENE REARRANGEMENT;GENOTYPE;GERIATRIC ONCOLOGY;HEPATITIS C VIRUS;HISTOGENESIS;HODGKIN'S LYMPHOMA;INSULIN RESISTANCE;INTEGRIN;LARYNGEAL NEOPLASM;METHYLATION;MINIMAL RESIDUAL DISEASE;NON-HODGKIN'S LYMPHOMA;PERFORMANCE STATUS;PHENOTYPE;QUARTILE;STAPHYLOCOCCUS AUREUS;SUBCELLULAR LOCALIZATION;TOLERABILITY;TRANSCRIPTION FACTOR;TRANSFECTION;TRANSMEMBRANE PROTEIN;WEIGHT LOSS","7;6;6;6;5;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DNA METHYLATION;BREAKPOINT;NEOPLASTIC TRANSFORMATION;REED–STERNBERG CELL;CD59;DNA MISMATCH REPAIR;ENDODERM;GERMINAL CENTER;HOMEOBOX;MORBID OBESITY;ONCOGENE;TAMOXIFEN;ABDOMINOPERINEAL RESECTION;ACUTE LYMPHOCYTIC LEUKEMIA;ACUTE PROMYELOCYTIC LEUKEMIA;ADENOMATOUS POLYPOSIS COLI;ADENOSINE DIPHOSPHATE;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN RECEPTOR;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;ANTIRETROVIRAL THERAPY;ATAXIA-TELANGIECTASIA;CARBOPLATIN;CARTILAGE OLIGOMERIC MATRIX PROTEIN;CD40;CHIMERIC GENE;COLORECTAL ADENOMA;CYCLIN D1;DISTANT METASTASIS;DNA VIRUS;DNA-BINDING PROTEIN;ENDOGLIN;EPITHELIAL OVARIAN CANCER;FAMILIAL ADENOMATOUS POLYPOSIS;FEBRILE NEUTROPENIA;FUSION PROTEIN;GASTRIC BYPASS;GENETIC RECOMBINATION;GERMLINE MUTATION;GLYCEMIC INDEX;GLYCOPROTEIN IB;HYPERINSULINEMIA;INSULIN RECEPTOR;METHYLENETETRAHYDROFOLATE REDUCTASE;METHYLTRANSFERASE;MICROCOCCACEAE;MOLECULAR MEDICINE;MONOCLONAL;NODULAR SCLEROSIS;NUCLEAR DNA;OPPORTUNISTIC PATHOGEN;OXALIPLATIN;P-GLYCOPROTEIN;PAPILLOMAVIRIDAE;PICORNAVIRUS;PROBAND;PROMOTER;RECTAL CARCINOMA;RETINOBLASTOMA PROTEIN;RIBONUCLEOPROTEIN;RNA-DEPENDENT RNA POLYMERASE;SENTINEL LYMPH NODE;SENTINEL NODE;SEXUAL TRANSMISSION;SIDA;SOMATIC HYPERMUTATION;STAPHYLOCOCCAL INFECTIONS;STAPHYLOCOCCUS;STEM CELL FACTOR;TELEPATHOLOGY;TELOMERASE REVERSE TRANSCRIPTASE;TORQUE TENO VIRUS;TRANSACTIVATION;VERSICAN;VINCRISTINE;VITRONECTIN","4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;ADULT;AGED;MALE;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LARYNGEAL NEOPLASMS;OVARIAN NEOPLASMS;LYMPHOMA, LARGE B-CELL, DIFFUSE;BREAST NEOPLASMS;LYMPHOMA, B-CELL;CASE-CONTROL STUDIES;LYMPHOMA, NON-HODGKIN;NEOPLASM PROTEINS;HIV INFECTIONS;HODGKIN DISEASE;MELANOMA;ADOLESCENT","97;64;59;54;54;45;36;27;23;22;19;18;18;17;17;17;16;16;15;14","LYMPHOID NEOPLASMS;IMMUNOBIOLOGY OF DENDRITIC CELLS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR RESEARCH ON BREAST CANCER;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;MELANOMA;PATHOGENESIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;NATURAL KILLER CELLS IN IMMUNITY;SMOKING CESSATION AND HEALTH EFFECTS OF TOBACCO;;ACUTE MYELOID LEUKEMIA;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS","10;6;5;4;4;4;4;3;3;2;2;2;2;2;2;2;2;1;1;1","CANCER RISK;B-CELL RECEPTOR SIGNALING;HODGKIN'S LYMPHOMA;ANTIGEN PRESENTATION;BREAKPOINT;CANCER INCIDENCE;CONCOMITANT;RADIOTHERAPY;REED–STERNBERG CELL;REGIMEN;ADJUSTABLE GASTRIC BAND;ADJUVANT THERAPY;BLADDER CANCER;BREAST CANCER;CANCER IMMUNOTHERAPY;CANCER IN OLDER ADULTS;CANCER-RELATED FATIGUE;CD59;CELL ADHESION;CERVICAL CANCER","8;5;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","OVARIAN CANCER;CANCER RISK;LARYNGEAL CANCER;CANCER PATIENTS;ALCOHOL DRINKING;BREAST CANCER;CASE-CONTROL STUDY;CELL CARCINOMA;CERVICAL CANCER;MELANOMA CELLS;ACCELERATED HYPERFRACTIONATED;ADDS INFORMATION;ASSESSMENT ADDS;BLADDER CANCER;CANCER TESTIS;CASECONTROL STUDY;CELL LYMPHOMA;COMPLEMENT RESISTANCE;COMPREHENSIVE GERIATRIC;CONFERS COMPLEMENT;COOPERATIVE ONCOLOGY;DEFECTIVE MELANOMA;EASTERN COOPERATIVE;ELDERLY CANCER;GERIATRIC ASSESSMENT;GERIATRIC ONCOLOGY;II STUDY;ITALIAN CASE-CONTROL;ONCOLOGY STUDY;PERFORMANCE STATUS","8;5;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;PUBMED GOOGLE;CROSSREF PUBMED;HODGKINS DISEASE;CELL LINES;GRUSS HJ;BIOL CHEM;CHEM -GOOGLE;MASON DY;ENDOTHELIAL CELLS;CELL LYMPHOMA;CONFIDENCE INTERVAL;LARYNGEAL CANCER;REED-STERNBERG CELLS;SCHOLAR GRUSS;CANCER RISK;DE JUILIIS;LYMPHOMA KINASE;ROSSI FM;WIGHT TN;ALK GENE;DY DELSOL;GENE TFG;HRS CELLS;IL- IL-;ORAL CAVITY;TRK-FUSED GENE;TUMOR CELLS;VERSICAN ISOFORMS;ZIMMERMANN DR","58;52;46;41;24;21;19;19;19;18;14;11;11;11;11;10;10;10;10;10;9;9;9;9;9;9;9;9;9;9",28,0.27,6,5,2.75,0,0,2,9.5,0,1,5.25,0,1,15,0,3.25,1,5.75,9.25,3.25,0,0,59,66,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,7,270.5,1.32,0,0,42,0,0,1,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,1,0,2,0,0,0,0,0,0,0,0,0,"Belgium;Italy","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;2","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ORPHAN DRUG;PATIENT SAFETY;RARE DISEASES","1;1;1;1;1;1","CANCER","2","6.1 PHARMACEUTICALS","1","ENDOMETRIAL CANCER;PANCREATIC CANCER","1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1;1",3,1685850.67,176963.38,4.33333333333333,10,6.33333333333333,1,36,131275.813809524,0.799842689624084,"CENTRO DI RIFERIMENTO ONCOLOGICO;ANTONI VAN LEEUWENHOEK HOSPITAL;CANCER REGISTRY OF NORWAY;CHARLES UNIVERSITY;DÉLÉGATION PARIS 11;ERASMUS UNIVERSITY ROTTERDAM;ESTONIAN BIOCENTRE;EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;INSERM;INSTITUT CATALÀ D'ONCOLOGIA;INSTITUT GUSTAVE ROUSSY;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;NATIONAL HEALTH SERVICE SCOTLAND;NESTLÉ (FRANCE);NEWCASTLE UNIVERSITY;SPANISH NATIONAL CANCER RESEARCH CENTRE;TRINITY COLLEGE DUBLIN;UNIVERSIDADE DE VIGO","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME)","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","3;3;1;1;1;1","CANCER;ALCOHOLISM, ALCOHOL USE AND HEALTH;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;GENETICS;NUTRITION;PREVENTION;SUBSTANCE MISUSE","3;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;STROKE","3;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS","2;1;1;1;1","NOT SITE-SPECIFIC CANCER","2","1.5 RESOURCES AND INFRASTRUCTURE;2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1;1;1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A01 CLINICAL MEDICINE","2;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2003,90,10.0444444444444,3.64444444444444,0.433333333333333,0.311111111111111,0.411111111111111,1.51851851851852,1.18181818181818,1.16666666666667,1.15625,0.377777777777778,4,51,12,6,15,0.57,0.13,0.07,0.17,55.9,1.05615371458591,NA,0.366666666666667,0.811111111111111,0.591,0.378,0.414,0.369,"SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;EVA NEGRI;ANGELA BUONADONNA;CRISTINA BOSETTI;LUIGINO DAL MASO;SILVANO GALLUS;ANTONINO CARBONE;MAURO BOIOCCHI;FABIO LEVI;ALFONSO COLOMBATTI;MASSIMO LIBRA;ANTONINO DE PAOLI;ROBERTO SORIO;VINCENZO CANZONIERI;DAVIDE LOMBARDI;ROBERTO PERRIS;MASSIMILIANO BERRETTA;S. FRUSTACI","17;14;14;13;9;9;8;8;8;8;7;7;6;6;6;5;5;5;5;5","SILVIA FRANCESCHI;CARLO LA VECCHIA;EVA NEGRI;RENATO TALAMINI;DANIELA CAPELLO;LUCA BALESTRERI;VINCENZO CANZONIERI;CRISTINA BOSETTI;CHIARA PRATESI;ANGELA BUONADONNA;PANKAJ TRIVEDI;ANTONINO CARBONE;SILVANO GALLUS;ALFONSO COLOMBATTI;ETTORE BIDOLI;GIUSEPPE TOFFOLI;MAURO BOIOCCHI;FABIO LEVI;ANTONINO DE PAOLI;LUIGINO DAL MASO","1.88;1.71;1.59;1.56;1.26;1.24;1.13;1.12;1.09;1.08;1;0.99;0.97;0.94;0.94;0.9;0.88;0.79;0.78;0.77","SILVIA FRANCESCHI;RENATO TALAMINI;ANGELA BUONADONNA;LUIGINO DAL MASO;SILVANO GALLUS;ANTONINO CARBONE;MAURO BOIOCCHI;ALFONSO COLOMBATTI;MASSIMO LIBRA;ANTONINO DE PAOLI;ROBERTO SORIO;VINCENZO CANZONIERI;DAVIDE LOMBARDI;ROBERTO PERRIS;MASSIMILIANO BERRETTA;S. FRUSTACI;GIUSEPPE TOFFOLI;CARLO RICCARDO ROSSI;ANDREA VERONESI;MARCELLO DE CICCO","17;14;9;8;8;8;8;7;6;6;6;5;5;5;5;5;5;4;4;4","SILVIA FRANCESCHI;RENATO TALAMINI;DANIELA CAPELLO;LUCA BALESTRERI;VINCENZO CANZONIERI;CHIARA PRATESI;ANGELA BUONADONNA;PANKAJ TRIVEDI;ANTONINO CARBONE;SILVANO GALLUS;ALFONSO COLOMBATTI;ETTORE BIDOLI;GIUSEPPE TOFFOLI;MAURO BOIOCCHI;ANTONINO DE PAOLI;LUIGINO DAL MASO;ROBERTO PERRIS;S. FRUSTACI;CARLO RICCARDO ROSSI;MASSIMILIANO BERRETTA","1.88;1.56;1.26;1.24;1.13;1.09;1.08;1;0.99;0.97;0.94;0.94;0.9;0.88;0.78;0.77;0.71;0.7;0.63;0.63","SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;EVA NEGRI;ROBERTA MAESTRO;SILVANO GALLUS;CRISTINA BOSETTI;CLAUDIO DOGLIONI;MAURO BOIOCCHI;ALBERTO ZAMÒ;ALDO SCARPA;ALESSANDRA CANCELLIERI;BRUNO MURER;GIANPIETRO SEMENZATO;LICIA MONTAGNA;MANUELA BERTASO;MARCO CHILOSI;MAURIZIO LESTANI;P PICCOLI;SERENA PEDRON","1293;1111;1051;1015;881;805;780;726;694;655;655;655;655;655;655;655;655;655;655;655","RENATO TALAMINI;ROBERTA MAESTRO;MAURO BOIOCCHI;VALLÌ DE RE;LUIGINO DAL MASO;UMBERTO TIRELLI;ANTONINO CARBONE;MICHELE SPINA;DOMENICO SANSONNO;FELICIA ANNA TUCCI;FRANCO DAMMACCO;GIANFRANCO LAULETTA;EMANUELA VACCHER;ANNUNZIATA GLOGHINI;ALFONSO COLOMBATTI;ROSAMARIA TEDESCHI;ROBERTO DOLIANA;CECILIA SIMONELLI;ROBERTA CINELLI;MARIA PARPINEL","1045;881;623;512;481;406;397;375;370;370;370;370;365;341;339;275;265;244;244;231","RENATO TALAMINI;LUIGINO DAL MASO;ANTONINO CARBONE;MAURO BOIOCCHI;ANGELA BUONADONNA;ANTONINO DE PAOLI;ALFONSO COLOMBATTI;GIUSEPPE TOFFOLI;ROBERTO SORIO;ANDREA VERONESI;ANNUNZIATA GLOGHINI;CLELIA DE GIACOMI;MARCELLO DE CICCO;MARIA ANTONIETTA PIZZICHETTA;MARIA PARPINEL;MASSIMILIANO BERRETTA;ROBERTA MAESTRO;ROBERTO PERRIS;S. FRUSTACI;VALLÌ DE RE","13;8;7;7;7;6;6;4;4;4;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;ENGINEERING;POLITICAL SCIENCE;BUSINESS;ECONOMICS;MATHEMATICS;PHILOSOPHY;SOCIOLOGY","77;38;8;5;5;5;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;CANCER RESEARCH;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GYNECOLOGY;MOLECULAR BIOLOGY;RADIOLOGY;VIROLOGY;CELL BIOLOGY;GENERAL SURGERY;OPTICS;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;PALEONTOLOGY","62;27;20;20;19;18;16;14;13;8;8;8;8;8;7;4;4;3;3;3","CANCER;GENE;ODDS RATIO;CONFIDENCE INTERVAL;CHEMOTHERAPY;RADIATION THERAPY;CASE-CONTROL STUDY;CARCINOMA;LYMPHOMA;ANTIBODY;POPULATION;VIRUS;BODY MASS INDEX;MULTIVARIATE ANALYSIS;PHARYNX;PROPORTIONAL HAZARDS MODEL;CELL;DISEASE;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);SARCOMA","43;21;15;13;11;10;9;8;8;7;7;6;5;5;5;5;4;4;4;4;4","BREAST CANCER;OVARIAN CANCER;COLORECTAL CANCER;ADENOCARCINOMA;GENE EXPRESSION;B CELL;CISPLATIN;GENOTYPE;CARCINOGENESIS;ENDOMETRIAL CANCER;EPSTEIN–BARR VIRUS;ESOPHAGEAL CANCER;FLUOROURACIL;HAZARD RATIO;METHYLATION;PERFORMANCE STATUS;PHASES OF CLINICAL RESEARCH;POLYMERASE CHAIN REACTION;PROSTATE CANCER;THYROID CARCINOMA;UNIVARIATE ANALYSIS","9;8;7;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","DNA METHYLATION;METHYLENETETRAHYDROFOLATE REDUCTASE;BETA-CATENIN;CATENIN;DEBULKING;GERMINAL CENTER;GLYCEMIC INDEX;IFOSFAMIDE;METHYLTRANSFERASE;SOMATIC HYPERMUTATION;TAMOXIFEN;ADULT T-CELL LEUKEMIA/LYMPHOMA;AMPLICON;ANTIRETROVIRAL THERAPY;BDNA TEST;CAGA;CARBOPLATIN;CARMUSTINE;CASPASE;CRYOGLOBULINEMIA;ECTODERM;EPSTEIN–BARR VIRUS INFECTION;ESOPHAGEAL NEOPLASM;ESOPHAGECTOMY;FLAVIVIRIDAE;GASTRIC BYPASS;GASTRULATION;GENE EXPRESSION PROFILING;GERMLINE MUTATION;GSTP1;HEPACIVIRUS;HERPESVIRIDAE;HISTONE DEACETYLASE;HORMONAL THERAPY;IN SITU HYBRIDIZATION;IRINOTECAN;KERATAN SULFATE;MASTECTOMY;MEDULLARY CARCINOMA;MESODERM;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;MORBID OBESITY;NEOPLASTIC TRANSFORMATION;NEURAL PLATE;NEUROENDOCRINE DIFFERENTIATION;OVARIAN CARCINOMA;PERFORIN;PHARMACOGENETICS;PRIMARY TUMOR;PROBAND;RAPD;RECTAL CARCINOMA;SHORT-TERM MEMORY;SPIRILLACEAE;THYMIDYLATE SYNTHASE;TUMOR-INFILTRATING LYMPHOCYTES","3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;ADULT;AGED;MALE;ITALY;STOMACH NEOPLASMS;ADENOCARCINOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RISK FACTORS;ANTINEOPLASTIC AGENTS;CARCINOMA, SQUAMOUS CELL;BREAST NEOPLASMS;ESOPHAGEAL NEOPLASMS;CASE-CONTROL STUDIES;NEOPLASMS;ODDS RATIO;LYMPHOMA, NON-HODGKIN;","77;51;41;40;39;38;37;34;22;21;21;19;18;17;15;14;14;14;13;12","VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;GASTRIC CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;SARCOMA RESEARCH AND TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;HEPATITIS C INFECTION AND TREATMENT;INTEGRIN SIGNALING IN INFLAMMATION AND CANCER;MELANOMA;MOLECULAR RESEARCH ON BREAST CANCER;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;ROLE OF EXTRACELLULAR MATRIX IN BIOLOGICAL SIGNALING;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;CANCER STEM CELLS AND TUMOR METASTASIS","8;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","GASTRIC CANCER;METASTATIC GASTRIC CANCER;HEALTHY EATING INDEX;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE;ADJUVANT THERAPY;BREAST CANCER;CANCER RISK;CHEMORADIOTHERAPY;DNA METHYLATION;PERFORMANCE STATUS;PREOPERATIVE CHEMORADIOTHERAPY;REGIMEN;SOFT TISSUE SARCOMA;UNIVARIATE ANALYSIS;BCL6;BETA-CATENIN;CANCER IMAGING;CANCER INCIDENCE;CANCER SUSCEPTIBILITY;CONCOMITANT","7;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","BREAST CANCER;CANCER RISK;GASTRIC CANCER;OVARIAN CANCER;ABSTRACT NOS;ADVANCED GASTRIC;AERODIGESTIVE TRACT;CONTINUOUS INFUSION;EFFUSION LYMPHOMA;GASTRIC BANDING;GASTRIC TUMORS;GLYCEMIC INDEX;II STUDY;INTRAOPERATIVE RADIATION;LARYNGEAL CANCER;LOCALLY ADVANCED;LYMPHOMA CELLS;LYMPHOPROLIFERATIVE DISORDERS;METHYLENETETRAHYDROFOLATE REDUCTASE;PAPILLARY THYROID;PHASE II;PRIMARY EFFUSION;RADIATION THERAPY;RECTAL CANCER;RETROPERITONEAL SOFT;SOFT TISSUE;THYROID CARCINOMA;TISSUE SARCOMAS;UPPER AERODIGESTIVE;ABDOMINAL RECURRENCE","5;5;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","PUBMED SCOPUS;CROSSREF PUBMED;CELL ADHESION;ACAD SCI;NATL ACAD;BIOL CHEM;IDIOPATHIC PULMONARY;RES -GOOGLE;CHEM -GOOGLE;CANCER RES;PROC NATL;BUFFER PH;CELL DEATH;PULMONARY FIBROSIS;AA AUSSERLECHNER;AUSSERLECHNER MJ;JOHNSTONE RW;KM KOFLER;MED -CROSSREF;MJ BERNHARD;MJ JOHNSTONE;RUEFLI AA;RW PROC;SMYTH MJ;SUTTON VR;TAINTON KM;VR TAINTON;APOPTOTIC RESPONSE;PUBMED GOOGLE;RICHON VM","114;106;29;26;26;25;25;24;23;20;20;18;18;17;16;16;16;16;16;16;16;16;16;16;16;16;16;15;15;15",22,0.24,6.21,4.75,4,4.75,1,20,3,0,1.75,4.75,1,1,5,0,7,2,3,18.75,22,0,0,53.75,58.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,12.25,786.8,2.55,1,0.2,60.8,0,0,1,0,3,0,0,1,0,5,0,0,0,0,0,0,0,1,4,0,5,0,0,0,0,0,0,0,0,0,"United States;Belgium;Italy","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","5;4;1;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;RARE DISEASES;AGING;ESTROGEN;OVARIAN CANCER;PATIENT SAFETY;COMPARATIVE EFFECTIVENESS RESEARCH;CONTRACEPTION/REPRODUCTION;HIV/AIDS;INFECTIOUS DISEASES;INFERTILITY;ORPHAN DRUG;PREVENTION","5;5;5;4;3;2;2;2;2;1;1;1;1;1;1;1","CANCER;INFECTION","5;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.4 SURGERY","5;1;1","BREAST CANCER;OVARIAN CANCER;KAPOSI'S SARCOMA;SARCOMA","3;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","5;3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2004,117,11.017094017094,3.17094017094017,0.41025641025641,0.324786324786325,0.504273504273504,2.48993288590604,1.2972972972973,1.72727272727273,1.31111111111111,0.35042735042735,3,70,17,19,5,0.6,0.15,0.16,0.04,47.7,1.01375540803857,NA,0.461538461538462,0.846153846153846,0.477,0.451,0.385,0.368,"CARLO LA VECCHIA;RENATO TALAMINI;SILVIA FRANCESCHI;EVA NEGRI;LUIGINO DAL MASO;VALTER GATTEI;SILVANO GALLUS;CRISTINA BOSETTI;MICHELE SPINA;UMBERTO TIRELLI;MASSIMO DEGAN;MAURIZIO RUPOLO;ANDREA VERONESI;GIOVANNI DEL POETA;ALESSANDRA TAVANI;ANTONINO CARBONE;MASSIMILIANO BERRETTA;ANDREA ALTIERI;ALFONSO COLOMBATTI;MICHELE DAL BO","27;26;24;19;14;12;11;11;11;10;9;9;8;8;8;7;7;6;6;6","CARLO LA VECCHIA;RENATO TALAMINI;SILVIA FRANCESCHI;EVA NEGRI;SILVANO GALLUS;CRISTINA BOSETTI;LUIGINO DAL MASO;ALFONSO COLOMBATTI;MICHELE SPINA;ALESSANDRA TAVANI;VALTER GATTEI;ANDREA VERONESI;UMBERTO TIRELLI;MARCELLO DECICCO;SAID ACOSTA;ANDREA ALTIERI;LIVIA S. A. AUGUSTIN;MICHELE MAIO;ESTER FONSATTI;MARIA ANTONIETTA PIZZICHETTA","4.01;3.28;3.06;2.59;1.83;1.72;1.54;1.4;1.17;1.16;1.08;1.06;1.05;1;1;0.87;0.87;0.84;0.84;0.81","RENATO TALAMINI;LUIGINO DAL MASO;VALTER GATTEI;SILVANO GALLUS;MICHELE SPINA;UMBERTO TIRELLI;MASSIMO DEGAN;MAURIZIO RUPOLO;ANDREA VERONESI;ANTONINO CARBONE;MASSIMILIANO BERRETTA;ALFONSO COLOMBATTI;MICHELE DAL BO;LIVIA S. A. AUGUSTIN;MARIA ANTONIETTA PIZZICHETTA;ANDRÉS J.M. FERRERI;DAVIDE LOMBARDI;ANTONELLA ZUCCHETTO;RICCARDO DOLCETTI;H. PETER SOYER","26;14;12;11;11;10;9;9;8;7;7;6;6;6;6;6;5;5;5;5","RENATO TALAMINI;SILVANO GALLUS;LUIGINO DAL MASO;ALFONSO COLOMBATTI;MICHELE SPINA;VALTER GATTEI;ANDREA VERONESI;UMBERTO TIRELLI;MARCELLO DECICCO;SAID ACOSTA;LIVIA S. A. AUGUSTIN;MICHELE MAIO;ESTER FONSATTI;MARIA ANTONIETTA PIZZICHETTA;MAURIZIO RUPOLO;MASSIMILIANO BERRETTA;ANTONINO CARBONE;MASSIMO DEGAN;DAVIDE LOMBARDI;SIMON SPAZZAPAN","3.28;1.83;1.54;1.4;1.17;1.08;1.06;1.05;1;1;0.87;0.84;0.84;0.81;0.8;0.79;0.77;0.75;0.71;0.7","SILVIA FRANCESCHI;RENATO TALAMINI;CARLO LA VECCHIA;EVA NEGRI;LUIGINO DAL MASO;ANDRÉS J.M. FERRERI;EMMANUEL VILLA;STEFANIA DELL’ORO;MAURIZIO MONTELLA;RICCARDO DOLCETTI;LAURA CAGGIARI;M BOIOCCHI;CRISTINA BOSETTI;MASSIMO GUIDOBONI;MAURILIO PONZONI;ANTONIA ANNA LETTINI;CARLO DE CONCILIIS;ELISA DAL CIN;KATHARINA FLEISCHHAUER;MASSIMO FRESCHI","1495;1476;1420;1033;970;677;668;668;640;580;564;564;559;544;544;536;536;536;536;536","RENATO TALAMINI;LUIGINO DAL MASO;RICCARDO DOLCETTI;LAURA CAGGIARI;M BOIOCCHI;ANTONIA ANNA LETTINI;ALESSANDRA VIEL;ESTER FONSATTI;MICHELE MAIO;MICHELE SPINA;DIANA CRIVELLARI;ANTONINO CARBONE;MARIA PARPINEL;MARESA ALTOMONTE;FRANCESCA COLIZZI;LUCA SIGALOTTI;MARA FORNASARIG;ETTORE BIDOLI;ELISABETTA FRATTA;SANDRA CORAL","1476;970;580;564;564;536;392;388;388;362;338;324;243;238;231;231;231;214;206;206","RENATO TALAMINI;LUIGINO DAL MASO;MICHELE SPINA;UMBERTO TIRELLI;VALTER GATTEI;MAURIZIO RUPOLO;MASSIMO DEGAN;ANDREA VERONESI;ANTONELLA ZUCCHETTO;ANTONINO CARBONE;ALFONSO COLOMBATTI;MASSIMILIANO BERRETTA;MICHELE DAL BO;MARIA ANTONIETTA PIZZICHETTA;SIMON SPAZZAPAN;ALESSANDRA VIEL;RICCARDO DOLCETTI;ALESSANDRA BEARZ;ANNALISA GIACALONE;DANIELA BERNARDI","26;14;11;10;10;8;7;7;7;7;6;6;5;5;5;5;5;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;PSYCHOLOGY;ENGINEERING;PHILOSOPHY;ART;GEOGRAPHY;MATERIALS SCIENCE;POLITICAL SCIENCE","98;41;10;9;7;6;4;3;3;2;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;IMMUNOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;GENETICS;SURGERY;ENVIRONMENTAL HEALTH;PATHOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;GYNECOLOGY;MOLECULAR BIOLOGY;DERMATOLOGY;NURSING;CELL BIOLOGY;FOOD SCIENCE;VIROLOGY;OPTICS;RADIOLOGY","82;38;32;29;24;24;23;16;16;15;12;11;11;10;7;6;6;6;5;5","CANCER;CHEMOTHERAPY;ODDS RATIO;GENE;LYMPHOMA;CONFIDENCE INTERVAL;CASE-CONTROL STUDY;MELANOMA;POPULATION;ANTIBODY;RISK FACTOR;LEUKEMIA;TOXICITY;ANTIGEN;BODY MASS INDEX;REGIMEN;STEM CELL;LOGISTIC REGRESSION;CONFOUNDING;QUALITY OF LIFE (HEALTHCARE)","59;23;21;20;18;14;13;11;11;10;10;9;9;8;8;8;8;7;6;6","BREAST CANCER;COLORECTAL CANCER;PROSTATE CANCER;CD34;MUTATION;PROSTATE;B CELL;CHRONIC LYMPHOCYTIC LEUKEMIA;OVARIAN CANCER;VIRAL LOAD;ALLELE;GENE EXPRESSION;NEUTROPENIA;PHASES OF CLINICAL RESEARCH;RITUXIMAB;ALCOHOL CONSUMPTION;CISPLATIN;CYCLOPHOSPHAMIDE;DERMATOSCOPY;ENDOMETRIAL CANCER;HEPATITIS C VIRUS;IMMUNOPHENOTYPING;NON-HODGKIN'S LYMPHOMA;PACLITAXEL;PHENOTYPE","14;14;10;8;8;8;7;7;7;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CD38;SOMATIC HYPERMUTATION;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;GERMLINE MUTATION;METASTATIC BREAST CANCER;OXALIPLATIN;DNA METHYLATION;DNA MISMATCH REPAIR;FEBRILE NEUTROPENIA;GERMINAL CENTER;GLYCEMIC INDEX;INSULIN-LIKE GROWTH FACTOR;INTERFERON ALFA;MELANOCYTIC NEVUS;RNA EXTRACTION;SENTINEL LYMPH NODE;SENTINEL NODE;TAXANE;VINORELBINE","6;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MIDDLE AGED;FEMALE;AGED;MALE;ADULT;ITALY;PROSTATIC NEOPLASMS;;BREAST NEOPLASMS;CASE-CONTROL STUDIES;RISK FACTORS;MELANOMA;OVARIAN NEOPLASMS;NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ODDS RATIO;LYMPHOMA, NON-HODGKIN;SKIN NEOPLASMS;AGED, 80 AND OVER","87;58;57;53;52;45;41;31;30;29;25;25;21;21;20;19;19;17;17;14","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;MELANOMA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;HEPATITIS C INFECTION AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;PATHOGENESIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE;ROLE OF AMP-ACTIVATED PROTEIN KINASE IN CELLULAR METABOLISM;CANCER IMMUNOTHERAPY;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MOLECULAR RESEARCH ON BREAST CANCER","9;9;8;6;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER RISK;MELANOMA;REGIMEN;BREAST CANCER;DERMOSCOPY;CANCER INCIDENCE;B-CELL RECEPTOR SIGNALING;CONSUMPTION (SOCIOLOGY);METASTATIC COLORECTAL CANCER;ANTIGEN PRESENTATION;B CELL ABNORMALITIES;CANCER;CANCER SUSCEPTIBILITY;CLINICAL CHARACTERISTICS;DERMATOSCOPY;DIETARY PATTERNS;IMMUNOPHENOTYPING;INSULIN SIGNALING;PROSTATE CANCER;SURGICAL ONCOLOGY","11;8;8;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","PROSTATE CANCER;BREAST CANCER;CANCER RISK;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;OVARIAN CANCER;PHASE II;B-CELL CHRONIC;CASECONTROL STUDY;COLORECTAL CANCER;B-CELL LYMPHOMA;CANCER PATIENTS;CELL TRANSPLANTATION;CUTANEOUS MELANOMA;ELDERLY PATIENTS;ENDOMETRIAL CANCER;II STUDY;LEUKEMIA B-CLL;LUNG CANCER;LYMPHOMA NHL;METASTATIC MELANOMA;PATIENT-TAILORED TREATMENT;PATIENTS PTS;STEM CELL;ACTIVE ANTIRETROVIRAL;ACUTE MYOCARDIAL;ANTIRETROVIRAL THERAPY;BENIGN PROSTATIC;CELL CHRONIC;CLINICAL TRIAL","10;9;7;7;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;FORMALIN-FIXED PARAFFIN-EMBEDDED;PARAFFIN-EMBEDDED TISSUES;PROSTATE CANCER;REAL TIME;PARAFFIN-EMBEDDED TISSUE;CDNA OBTAINED;FAMILY HISTORY;PATHOL -CROSSREF;CORRELATION COEFFICIENT;POLYMERASE CHAIN;PUBMED GOOGLE;QUANTITATIVE RT-PCR;BREAST CANCER;APPLIED BIOSYSTEMS;GENE EXPRESSION;MUTATION FREQUENCY;PE APPLIED;RNA ISOLATION;BODY MASS;CANCER RISK;CHAIN REACTION;CYTOCHEM -CROSSREF;HISTOCHEM CYTOCHEM;ODDS RATIOS;OVARIAN CANCER;PEARSON CORRELATION;RNA EXTRACTION;STANDARD CURVE","43;36;26;24;20;16;15;14;12;12;11;11;11;11;10;9;9;9;9;9;8;8;8;8;8;8;8;8;8;8",18,0.15,3,2.75,0,0,0,1,2,0,1,2.75,0,1,1,1,2,0,0,1,0,0,0,49.75,50,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,5,290.33,3.03,0,0,76.5,0,0,1,0,2,0,0,1,0,3,0,0,1,0,0,0,0,3,1,0,4,0,0,0,0,0,0,0,0,0,"Belgium;Germany;Switzerland","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","4;3;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;AGING;BIOTECHNOLOGY;BREAST CANCER;HIV/AIDS;IMMUNIZATION;INFECTIOUS DISEASES;OSTEOPOROSIS;PREVENTION;RARE DISEASES;VACCINE RELATED","4;4;2;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;MUSCULOSKELETAL","2;1;1","6.1 PHARMACEUTICALS","4","BREAST CANCER;MELANOMA","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1",1,6050000,355882.35,6,17,9,1,10,190589.53929972,0.613884688686962,"CANCER REGISTRY OF NORWAY;CENTRO DI RIFERIMENTO ONCOLOGICO;FINNISH CANCER REGISTRY;FINNISH INSTITUTE FOR HEALTH AND WELFARE;GERMAN CANCER RESEARCH CENTER;ICELANDIC CANCER SOCIETY;IMPERIAL COLLEGE LONDON;INSTITUT SCIENTIFIQUE DE SANTÉ PUBLIQUE;KAROLINSKA INSTITUTET;LUND UNIVERSITY;MARIA SKŁODOWSKA-CURIE MEMORIAL CANCER CENTER AND INSTITUTE OF ONCOLOGY;NATIONAL UNIVERSITY HOSPITAL OF ICELAND;ROYAL MARSDEN HOSPITAL;TAMPERE UNIVERSITY;UMEÅ UNIVERSITY;UNIVERSITY HOSPITAL HEIDELBERG;UPPSALA UNIVERSITY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-2002-LIFESCIHEALTH (CALL FOR PROPOSAL);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME)","1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1","CANCER;PREVENTION","1;1","CANCER","1","2.4 SURVEILLANCE AND DISTRIBUTION","1","NOT SITE-SPECIFIC CANCER","1","2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;6.2 SURVEILLANCE","1;1","B11 COMPUTER SCIENCE AND INFORMATICS","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2005,122,9.47540983606557,3.64754098360656,0.418032786885246,0.401639344262295,0.491803278688525,2.21393034825871,1.34210526315789,1.75,1.3953488372093,0.401639344262295,2,77,19,10,7,0.63,0.16,0.08,0.06,50.43,0.952449531002367,NA,0.459016393442623,0.877049180327869,0.525,0.487,0.424,0.448,"RENATO TALAMINI;SILVIA FRANCESCHI;ANTONINO CARBONE;CARLO LA VECCHIA;ANNUNZIATA GLOGHINI;EVA NEGRI;UMBERTO TIRELLI;LUIGINO DAL MASO;MICHELE SPINA;EMANUELA VACCHER;RICCARDO DOLCETTI;MAURIZIO MONTELLA;VALLÌ DE RE;CRISTINA BOSETTI;DIANA CRIVELLARI;VALTER GATTEI;ROSAMARIA TEDESCHI;MAURO BOIOCCHI;MASSIMO GUIDOBONI;GIOVANNI DEL POETA","24;23;20;20;15;15;13;11;11;10;9;9;8;8;8;8;8;8;7;7","ANTONINO CARBONE;RENATO TALAMINI;SILVIA FRANCESCHI;CARLO LA VECCHIA;ANNUNZIATA GLOGHINI;EVA NEGRI;UMBERTO TIRELLI;EMANUELA VACCHER;MICHELE SPINA;MAURIZIO MONTELLA;MICHELE MAIO;LUIGINO DAL MASO;CRISTINA BOSETTI;RICCARDO DOLCETTI;ANDREA VERONESI;ROSAMARIA TEDESCHI;VALLÌ DE RE;CECILIA SIMONELLI;GUSTAVO BALDASSARRE;SILVANO GALLUS","3.53;2.96;2.69;2.47;2.15;1.89;1.56;1.4;1.21;1.12;1.11;1.08;1.01;0.97;0.97;0.93;0.91;0.88;0.79;0.77","RENATO TALAMINI;ANTONINO CARBONE;ANNUNZIATA GLOGHINI;UMBERTO TIRELLI;LUIGINO DAL MASO;MICHELE SPINA;EMANUELA VACCHER;RICCARDO DOLCETTI;VALLÌ DE RE;DIANA CRIVELLARI;VALTER GATTEI;ROSAMARIA TEDESCHI;MAURO BOIOCCHI;MASSIMO GUIDOBONI;CECILIA SIMONELLI;PAOLO DE PAOLI;ETTORE BIDOLI;MASSIMO LIBRA;ANDREA VERONESI;GIANLUCA GAÏDANO","24;20;15;13;11;11;10;9;8;8;8;8;8;7;7;7;7;6;6;6","ANTONINO CARBONE;RENATO TALAMINI;ANNUNZIATA GLOGHINI;UMBERTO TIRELLI;EMANUELA VACCHER;MICHELE SPINA;MICHELE MAIO;LUIGINO DAL MASO;RICCARDO DOLCETTI;ANDREA VERONESI;ROSAMARIA TEDESCHI;VALLÌ DE RE;CECILIA SIMONELLI;GUSTAVO BALDASSARRE;DIANA CRIVELLARI;MASSIMO GUIDOBONI;MAURO BOIOCCHI;ETTORE BIDOLI;PAOLO DE PAOLI;MASSIMO LIBRA","3.53;2.96;2.15;1.56;1.4;1.21;1.11;1.08;0.97;0.97;0.93;0.91;0.88;0.79;0.77;0.76;0.75;0.74;0.73;0.68","SILVIA FRANCESCHI;LUIGINO DAL MASO;FABIO LEVI;RENATO TALAMINI;JERRY POLESEL;CARLO LA VECCHIA;ANDREA BORDONI;ANDREAS KOFLER;D. DE WECK;ELISABETTA RAPITI;GARY M. CLIFFORD;GERNOT JUNDT;MARTIN RICKENBACH;OLIVIA KEISER;T. FISCH;EVA NEGRI;ANTONINO CARBONE;ANNUNZIATA GLOGHINI;DIANA CRIVELLARI;RICCARDO DOLCETTI","1871;1398;1114;1034;1013;961;841;841;841;841;841;841;841;841;841;733;689;624;570;531","RENATO TALAMINI;JERRY POLESEL;DIANA CRIVELLARI;LUIGINO DAL MASO;ANNUNZIATA GLOGHINI;UMBERTO TIRELLI;RICCARDO DOLCETTI;ANTONINO CARBONE;MAURO BOIOCCHI;GUSTAVO BALDASSARRE;PAOLA SPESSOTTO;MILENA S. NICOLOSO;ALFONSO COLOMBATTI;MASSIMO GUIDOBONI;CESARE MAZZARO;EMANUELA VACCHER;VINCENZO CANZONIERI;ETTORE BIDOLI;BARBARA BELLETTI;MÓNICA SCHIAPPACASSI","1034;1013;570;557;499;480;460;442;393;381;365;354;338;338;337;334;328;322;276;276","RENATO TALAMINI;ANTONINO CARBONE;UMBERTO TIRELLI;MICHELE SPINA;EMANUELA VACCHER;LUIGINO DAL MASO;ANNUNZIATA GLOGHINI;DIANA CRIVELLARI;ROSAMARIA TEDESCHI;VALTER GATTEI;VALLÌ DE RE;PAOLO DE PAOLI;CECILIA SIMONELLI;ANTONELLA ZUCCHETTO;ETTORE BIDOLI;MAURO BOIOCCHI;ANDREA VERONESI;RICCARDO DOLCETTI;JERRY POLESEL;MASSIMO DEGAN","24;18;15;11;10;10;9;8;8;8;7;7;7;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;SOCIOLOGY;PHILOSOPHY;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS","97;60;11;10;6;3;2;1;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;GASTROENTEROLOGY;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;BIOCHEMISTRY;VIROLOGY;MOLECULAR BIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;OPTICS;PALEONTOLOGY;ENDOCRINOLOGY;GYNECOLOGY;OBSTETRICS;DEMOGRAPHY;RADIOLOGY","85;42;40;31;29;28;24;21;17;16;10;9;9;8;8;7;7;5;4;4","CANCER;GENE;LYMPHOMA;CHEMOTHERAPY;ODDS RATIO;CONFIDENCE INTERVAL;VIRUS;CASE-CONTROL STUDY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ANTIBODY;ANTIGEN;INCIDENCE (GEOMETRY);LEUKEMIA;RADIATION THERAPY;CELL;POPULATION;DISEASE;IN VITRO;SARCOMA;STAGE (STRATIGRAPHY)","50;32;24;19;19;17;15;12;9;8;8;8;8;8;7;7;6;6;6;6","BREAST CANCER;COLORECTAL CANCER;VIRAL DISEASE;CELL CYCLE;EPSTEIN–BARR VIRUS;CHRONIC LYMPHOCYTIC LEUKEMIA;DOWNREGULATION AND UPREGULATION;MUTATION;PROSTATE CANCER;VIRAL LOAD;GENOTYPE;ALLELE;B CELL;CYCLOPHOSPHAMIDE;OVARIAN CANCER;PRIMARY EFFUSION LYMPHOMA;PROSTATE;GENE EXPRESSION;HEPATITIS C VIRUS;IMMUNOPHENOTYPING;NEUTROPENIA;NON-HODGKIN'S LYMPHOMA;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;TRANSCRIPTION FACTOR","14;9;9;8;8;7;7;7;7;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;SIDA;CAPECITABINE;CD38;CRYOGLOBULINEMIA;DNA MISMATCH REPAIR;GERMLINE MUTATION;MICROSATELLITE;ONCOGENE;SOMATIC HYPERMUTATION;FEBRILE NEUTROPENIA;GEFITINIB;GENE EXPRESSION PROFILING;GLUTATHIONE S-TRANSFERASE;INTERFERON ALFA;IRINOTECAN;KRAS;METASTATIC BREAST CANCER;MISSENSE MUTATION;MOLECULAR MEDICINE;MORBID OBESITY;PLACENTA;RANKL;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN","5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MIDDLE AGED;MALE;AGED;ADULT;ITALY;;LYMPHOMA, NON-HODGKIN;CASE-CONTROL STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;HIV INFECTIONS;RISK FACTORS;HERPESVIRUS 4, HUMAN;LYMPHOMA, B-CELL;NEOPLASMS;HERPESVIRUS 8, HUMAN;PROSTATIC NEOPLASMS;ODDS RATIO","91;61;61;60;51;43;41;29;29;27;24;23;21;21;17;17;16;15;14;13","VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MOLECULAR RESEARCH ON BREAST CANCER;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;IMMUNOBIOLOGY OF DENDRITIC CELLS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS C INFECTION AND TREATMENT;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;ROLE OF GLUTATHIONE IN OXIDATIVE STRESS RESPONSE;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;SARCOMA RESEARCH AND TREATMENT","19;10;7;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;HUMAN HERPESVIRUS 8;KAPOSI'S SARCOMA;B-CELL RECEPTOR SIGNALING;PRIMARY EFFUSION LYMPHOMA;CANCER RISK;IMMUNOPHENOTYPING;MANTLE CELL LYMPHOMA;REGIMEN;CANCER INCIDENCE;CONCOMITANT;FOLATE;HODGKIN'S LYMPHOMA;IMMUNOGLOBULIN MUTATION;LYMPHOPROLIFERATIVE DISORDERS;METASTATIC BREAST CANCER;MICROSATELLITE INSTABILITY;NK CELL RECOGNITION;TUMOR MICROSATELLITE-INSTABILITY;VIREMIA","7;7;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;PROSTATE CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;ACTIVE ANTIRETROVIRAL;ANTIRETROVIRAL THERAPY;CANCER PATIENTS;CASECONTROL STUDY;HIGHLY ACTIVE;KAPOSIS SARCOMA;NON-HODGKINS LYMPHOMA;OVARIAN CANCER;PHASE II;B-CELL CHRONIC;BENIGN PROSTATIC;BONE MARROW;HERPESVIRUS TYPE;HIV INFECTION;HUMAN HERPESVIRUS;LEUKEMIA B-CLL;PROSTATIC HYPERPLASIA;RADIATION THERAPY;ALCOHOL CONSUMPTION;BONE METASTASIS;CANCER RISK;CANCER STUDY;CASE-CONTROL STUDY;CGA ASSAY;CGA MEASUREMENT;CLINICAL OUTCOME","10;6;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;SOLID LYMPHOMAS;BIOL -CROSSREF;KAPOSIS SARCOMA-ASSOCIATED;KSHV-POSITIVE SOLID;BRESSAN GM;BREAST CANCER;CELL LINES;EMILIN GENE;HUMAN HERPESVIRUS;KB FRAGMENT;KNOWLES DM;PRIMARY EFFUSION;CELL BIOL;SIR CI;HUMAN IMMUNODEFICIENCY;KAPOSIS SARCOMA;SARCOMA-ASSOCIATED HERPESVIRUS;BIOL CHEM;CHEM -ABSTRACT;EFFUSION LYMPHOMA;FAMILY HISTORY;NON-HODGKIN LYMPHOMA;PATHOL -CROSSREF;CES MRNA;IMMUNODEFICIENCY VIRUS;CONFIDENCE INTERVAL;DNASE I-HYPERSENSITIVE;GENE EXPRESSION","75;63;22;20;17;17;15;14;14;14;14;14;14;14;13;13;12;12;12;11;11;11;11;11;9;8;8;7;7;7",31,0.25,5,4.5,1,4.5,1,2,3.5,1,2,4.5,0,1,4,2,3,0,1,7,2,0,0,42,42.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,7.67,636.5,2.19,2,0.5,78.5,0,0,0,0,4,0,0,0,0,4,0,0,0,0,0,0,0,2,2,0,4,0,0,0,0,0,0,0,0,0,"Belgium;Italy;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","4;3;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;CANCER;ORPHAN DRUG;RARE DISEASES;AGING;BREAST CANCER;HEMATOLOGY;OVARIAN CANCER;PREVENTION","4;4;3;2;2;2;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","4;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;STOMACH CANCER","1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2006,155,11.2064516129032,3.54193548387097,0.348387096774194,0.32258064516129,0.470967741935484,2.13229571984436,1.22727272727273,1.66666666666667,1.25862068965517,0.4,1,97,27,16,7,0.63,0.17,0.1,0.05,63.28,1.23896030148831,NA,0.419354838709677,0.909677419354839,0.541,0.485,0.456,0.467,"RENATO TALAMINI;SILVIA FRANCESCHI;CARLO LA VECCHIA;LUIGINO DAL MASO;EVA NEGRI;ANTONINO CARBONE;VALTER GATTEI;GIOVANNI DEL POETA;ANNUNZIATA GLOGHINI;CRISTINA BOSETTI;ANTONELLA ZUCCHETTO;VALLÌ DE RE;UMBERTO TIRELLI;MASSIMO DEGAN;RICCARDO BOMBEN;MAURIZIO MONTELLA;ALESSANDRA VIEL;RICCARDO DOLCETTI;MARIA ILARIA DEL PRINCIPE;VALERIO RAMAZZOTTI","29;27;25;19;19;15;14;13;12;11;10;10;10;9;9;9;9;8;8;7","RENATO TALAMINI;SILVIA FRANCESCHI;CARLO LA VECCHIA;EVA NEGRI;LUIGINO DAL MASO;PAOLO DE PAOLI;CRISTINA BOSETTI;UMBERTO TIRELLI;VALLÌ DE RE;VALTER GATTEI;GIOVANNI DEL POETA;ANTONINO CARBONE;RICCARDO DOLCETTI;MAURIZIO MONTELLA;ANNUNZIATA GLOGHINI;MICHELE SPINA;GIUSEPPE TOFFOLI;ALESSANDRA VIEL;ANDREA VERONESI;ANTONELLA ZUCCHETTO","3.29;3.06;2.86;2.26;2.02;1.66;1.26;1.26;1.24;1.1;1.02;1.01;0.99;0.98;0.96;0.91;0.88;0.85;0.83;0.82","RENATO TALAMINI;SILVIA FRANCESCHI;CARLO LA VECCHIA;LUIGINO DAL MASO;EVA NEGRI;ANTONINO CARBONE;VALTER GATTEI;GIOVANNI DEL POETA;ANNUNZIATA GLOGHINI;ANTONELLA ZUCCHETTO;VALLÌ DE RE;UMBERTO TIRELLI;MASSIMO DEGAN;RICCARDO BOMBEN;ALESSANDRA VIEL;RICCARDO DOLCETTI;MARIA ILARIA DEL PRINCIPE;ANDREA VERONESI;MICHELE DAL BO;DIEGO SERRAINO","29;27;25;19;19;15;14;13;12;10;10;10;9;9;9;8;8;7;7;7","RENATO TALAMINI;SILVIA FRANCESCHI;CARLO LA VECCHIA;EVA NEGRI;LUIGINO DAL MASO;PAOLO DE PAOLI;UMBERTO TIRELLI;VALLÌ DE RE;VALTER GATTEI;GIOVANNI DEL POETA;ANTONINO CARBONE;RICCARDO DOLCETTI;ANNUNZIATA GLOGHINI;MICHELE SPINA;GIUSEPPE TOFFOLI;ALESSANDRA VIEL;ANDREA VERONESI;ANTONELLA ZUCCHETTO;GIUSEPPE CORONA;ATTILIO GIACOSA","3.29;3.06;2.86;2.26;2.02;1.66;1.26;1.24;1.1;1.02;1.01;0.99;0.96;0.91;0.88;0.85;0.83;0.82;0.79;0.79","AARON BENSIMON;ANGELO CICALESE;CATHERINE SCHURRA;CHIARA LUISE;FABRIZIO D’ADDA DI FAGAGNA;MARZIA FUMAGALLI;MASSIMILIANO GARRÈ;PAOLO NUCÍFORO;PATRIZIA GASPARINI;PIER GIUSEPPE PELICCI;RAFFAELLA DI MICCO;ROBERTA MAESTRO;SARA PICCININ;SILVIA FRANCESCHI;CARLO LA VECCHIA;RENATO TALAMINI;LUIGINO DAL MASO;EVA NEGRI;ANTONIO PALUMBO;CLOTILDE CANGIALOSI","1682;1682;1682;1682;1682;1682;1682;1682;1682;1682;1682;1682;1682;1681;1639;1575;1205;1134;1007;1007","ROBERTA MAESTRO;SARA PICCININ;RENATO TALAMINI;LUIGINO DAL MASO;PELLEGRINO MUSTO;DIANA CRIVELLARI;ANTONINO CARBONE;VALTER GATTEI;ANTONELLA ZUCCHETTO;VINCENZO CANZONIERI;GIUSEPPE TOFFOLI;MASSIMO DEGAN;RICCARDO BOMBEN;ROBERTO BORTOLUS;SANDRO MORASSUT;GIUSEPPE CORONA;UMBERTO TIRELLI;RICCARDO DOLCETTI;ANGELA BUONADONNA;S. FRUSTACI","1682;1682;1566;1166;1007;557;545;497;471;426;370;366;366;362;355;353;352;347;346;346","RENATO TALAMINI;LUIGINO DAL MASO;VALTER GATTEI;ANTONELLA ZUCCHETTO;ANNUNZIATA GLOGHINI;ANTONINO CARBONE;UMBERTO TIRELLI;ALESSANDRA VIEL;MASSIMO DEGAN;RICCARDO BOMBEN;VALLÌ DE RE;RICCARDO DOLCETTI;DIEGO SERRAINO;MICHELE DAL BO;ANDREA VERONESI;CHIARA LESTUZZI;GIUSEPPE TOFFOLI;MICHELE SPINA;ROBERTO SORIO;PAOLO DE PAOLI","28;16;14;12;11;10;10;9;9;9;9;8;7;7;7;6;6;6;6;6","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;PHILOSOPHY;PHYSICS;BUSINESS;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;GEOGRAPHY;ART;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY;MATERIALS SCIENCE","129;71;11;10;6;6;6;4;4;4;4;2;2;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;ONCOLOGY;GENETICS;SURGERY;GASTROENTEROLOGY;CANCER RESEARCH;BIOCHEMISTRY;PATHOLOGY;ENVIRONMENTAL HEALTH;VIROLOGY;MOLECULAR BIOLOGY;GYNECOLOGY;RADIOLOGY;ENDOCRINOLOGY;UROLOGY;CELL BIOLOGY;NURSING;PALEONTOLOGY;WORLD WIDE WEB","94;41;40;39;29;27;22;21;21;19;19;14;11;7;6;6;5;5;5;5","CANCER;GENE;CHEMOTHERAPY;ODDS RATIO;LYMPHOMA;CONFIDENCE INTERVAL;ANTIBODY;LEUKEMIA;VIRUS;POPULATION;CASE-CONTROL STUDY;BODY MASS INDEX;ANTIGEN;CONFOUNDING;FAMILY HISTORY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;STEM CELL;IMMUNE SYSTEM;MYELOID LEUKEMIA","57;37;24;24;22;20;15;15;15;14;13;8;7;7;7;7;7;7;7;6;6","BREAST CANCER;COLORECTAL CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;MUTATION;HEPATITIS C VIRUS;B CELL;GENE EXPRESSION;VIRAL DISEASE;ALLELE;GENOTYPE;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;CD34;HAZARD RATIO;MINIMAL RESIDUAL DISEASE;NEUTROPENIA;CYCLOPHOSPHAMIDE;HEPATITIS B VIRUS;LYMPHOPROLIFERATIVE DISORDERS;MONOCLONAL ANTIBODY;PROSTATE","17;15;10;9;8;7;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4","DNA MISMATCH REPAIR;GERMLINE MUTATION;PROBAND;CRYOGLOBULINEMIA;HAPLOTYPE;HERPESVIRIDAE;IRINOTECAN;METASTATIC BREAST CANCER;SEROPREVALENCE;TRASTUZUMAB;ALPHA (FINANCE);ANTHRACYCLINE;CARBOPLATIN;DNA METHYLATION;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;GENE EXPRESSION PROFILING;GENE MUTATION;GERMINAL CENTER;HBSAG;IMMUNOGLOBULIN M;KAPOSI'S SARCOMA;MELANOCYTIC NEVUS;METHYLENETETRAHYDROFOLATE REDUCTASE;MHC CLASS I;MISSENSE MUTATION;MONOCLONAL;REVERSE TRANSCRIPTASE;SIDA;WAIST–HIP RATIO","4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RISK FACTORS;CASE-CONTROL STUDIES;NEOPLASMS;AGED, 80 AND OVER;HIV INFECTIONS;LYMPHOMA, NON-HODGKIN;COLORECTAL NEOPLASMS;BIOMARKERS, TUMOR;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;SARCOMA, KAPOSI","111;86;72;72;62;58;46;40;40;34;30;29;27;22;20;19;18;17;17;16","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;LYMPHOID NEOPLASMS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATITIS C INFECTION AND TREATMENT;ACUTE MYELOID LEUKEMIA;CARDIOTOXICITY OF CANCER TREATMENTS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;BIFURCATIONS IN PLANAR POLYNOMIAL SYSTEMS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;EPIDEMIOLOGY OF MULTIPLE PRIMARY CANCERS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GLIOMAS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY","10;10;8;6;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2","KAPOSI'S SARCOMA;B CELL ABNORMALITIES;BREAST CANCER;CANCER INCIDENCE;DNA MISMATCH REPAIR;MINIMAL RESIDUAL DISEASE;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE;TREATMENT;CONCOMITANT;LYMPHOPROLIFERATIVE DISORDERS;MLH1;PROBAND;REGIMEN;ACUTE MYELOID LEUKEMIA;B-CELL RECEPTOR SIGNALING;CANCER RISK;CANCER THERAPY;ETIOLOGY;HEPATITIS C;HEPATOCELLULAR CARCINOMA","7;6;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","BREAST CANCER;CHRONIC LYMPHOCYTIC;COLORECTAL CANCER;LYMPHOCYTIC LEUKEMIA;CANCER PATIENTS;CANCER RISK;ACUTE MYELOID;B-CELL CHRONIC;MYELOID LEUKEMIA;RENAL CELL;CELL CANCER;ELDERLY PATIENTS;KAPOSIS SARCOMA;MINIMAL RESIDUAL;NON-HODGKINS LYMPHOMA;OVARIAN CANCER;PHASE II;RESIDUAL DISEASE;CASECONTROL STUDY;FAMILY HISTORY;GENE EXPRESSION;HEPATOCELLULAR CARCINOMA;NON-HODGKIN LYMPHOMA;PROSTATE CANCER;TYPE II;ANTITUMOR ACTIVITY;APOPTOSIS-INDUCING LIGAND;ATYPICAL NEVUS;BENIGN PROSTATIC;CANCER FAMILIES","13;9;8;8;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","BREAST CANCER;PUBMED SCOPUS;CANCER PATIENTS;CROSSREF PUBMED;METASTATIC BREAST;RESPONSE RATE;ADVANCED BREAST;IDA CTROUGH;CANCER RISK;COLORECTAL CANCER;IDOL CTROUGH;PHASE II;ODDS RATIOS;ORAL IDARUBICIN;ELDERLY PATIENTS;LOGISTIC REGRESSION;CIRCUMFERENTIAL EXTENT;CTROUGH LEVELS;II STUDY;MEDIAN AGE;CLIN ONCOL;INVERSE ASSOCIATION;LYMPHOMA NHL;NHL RISK;OVARIAN CANCER;PATIENTS TREATED;POSTMENOPAUSAL PATIENTS;PUBMED GOOGLE;BODY MASS;CONFIDENCE INTERVAL","52;27;19;19;19;19;17;17;16;16;15;15;13;13;11;11;10;10;10;10;9;9;9;9;9;9;8;8;7;7",36,0.23,6.25,6.25,11.25,2.5,10.25,3.5,7.25,0,3,7.25,1.75,1,8,2.25,2,3,5,8,1.75,0,0,95.25,95.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,6.67,572.67,2.42,0,0,82.33,0,0,2,0,2,0,1,1,0,5,1,0,0,0,0,0,0,4,2,0,6,0,0,0,0,0,0,0,0,0,"Canada;Italy","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","6;6;3;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY;BIOMEDICAL IMAGING;BREAST CANCER;CARDIOVASCULAR;GENETICS;HEART DISEASE;LUNG;LUNG CANCER;ORPHAN DRUG;OVARIAN CANCER;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","6;6;5;4;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","6","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION","5;2;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;OVARIAN CANCER","3;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","5;1;1;1",1,276413,19743.79,4,14,4,1,9,110036.321918767,1.40862578189796,"CENTRO DI RIFERIMENTO ONCOLOGICO;FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;IMPERIAL COLLEGE LONDON;INSERM;MEDICAL RESEARCH COUNCIL;NEWCASTLE UNIVERSITY;QUEEN MARY UNIVERSITY OF LONDON;TU DRESDEN;UNIVERSITY OF CALABRIA;UNIVERSITY OF COLOGNE;UNIVERSITY OF DUNDEE;UNIVERSITY OF MILAN;UNIVERSITY OF OXFORD;UNIVERSITY OF ROME TOR VERGATA","1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICAL RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","FELLOWSHIP (PROJECT CATEGORY)","1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1;1","CANCER;CLIMATE-RELATED EXPOSURES AND CONDITIONS;CLINICAL RESEARCH;GENETICS","1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.1 PHARMACEUTICALS","1;1;1","MELANOMA","1","1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2007,134,10.8805970149254,3.55970149253731,0.425373134328358,0.343283582089552,0.58955223880597,2.18348623853211,1.32558139534884,1.53333333333333,1.54901960784314,0.402985074626866,2,82,25,10,11,0.61,0.19,0.07,0.08,46.89,0.888435420470244,NA,0.447761194029851,0.873134328358209,0.502,0.5,0.506,0.464,"RENATO TALAMINI;SILVIA FRANCESCHI;CARLO LA VECCHIA;LUIGINO DAL MASO;UMBERTO TIRELLI;EVA NEGRI;MICHELE SPINA;VINCENZO CANZONIERI;VALTER GATTEI;CRISTINA BOSETTI;VALERIO RAMAZZOTTI;MAURIZIO MONTELLA;ANTONELLA ZUCCHETTO;VALLÌ DE RE;DIEGO SERRAINO;ALFONSO COLOMBATTI;MASSIMO DEGAN;ALESSANDRA BEARZ;ALESSANDRA TAVANI;RICCARDO BOMBEN","31;27;24;18;14;14;13;12;12;10;9;9;8;8;8;7;7;7;7;7","RENATO TALAMINI;VINCENZO CANZONIERI;SILVIA FRANCESCHI;CARLO LA VECCHIA;LUIGINO DAL MASO;UMBERTO TIRELLI;EVA NEGRI;MICHELE SPINA;VALTER GATTEI;CRISTINA BOSETTI;VALLÌ DE RE;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;MAURIZIO MONTELLA;ALFONSO COLOMBATTI;ALESSANDRA BEARZ;DIEGO SERRAINO;VALERIO RAMAZZOTTI;GUSTAVO BALDASSARRE;LAURA CAGGIARI","3.14;3;2.71;2.44;1.68;1.42;1.41;1.35;1.12;1.08;1.07;1;1;0.94;0.92;0.91;0.88;0.87;0.82;0.82","RENATO TALAMINI;LUIGINO DAL MASO;UMBERTO TIRELLI;MICHELE SPINA;VINCENZO CANZONIERI;VALTER GATTEI;ANTONELLA ZUCCHETTO;VALLÌ DE RE;DIEGO SERRAINO;ALFONSO COLOMBATTI;MASSIMO DEGAN;ALESSANDRA BEARZ;RICCARDO BOMBEN;FRANCESCO BUCCISANO;ANTONELLA ZUCCHETTO;RICCARDO DOLCETTI;ANNUNZIATA GLOGHINI;RENATO CANNIZZARO;LAURA CAGGIARI;SERGIO AMADORI","31;18;14;13;12;12;8;8;8;7;7;7;7;6;6;6;6;6;6;6","RENATO TALAMINI;VINCENZO CANZONIERI;LUIGINO DAL MASO;UMBERTO TIRELLI;MICHELE SPINA;VALTER GATTEI;VALLÌ DE RE;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;ALFONSO COLOMBATTI;ALESSANDRA BEARZ;DIEGO SERRAINO;GUSTAVO BALDASSARRE;LAURA CAGGIARI;ANNUNZIATA GLOGHINI;MARIA PAOLA SIMULA;M. MAZZUCATO;ANTONELLA ZUCCHETTO;MASSIMO DEGAN;ANTONELLA ZUCCHETTO","3.14;3;1.68;1.42;1.35;1.12;1.07;1;1;0.92;0.91;0.88;0.82;0.82;0.74;0.7;0.65;0.64;0.59;0.59","SILVIA FRANCESCHI;CARLO LA VECCHIA;LUIGINO DAL MASO;FABIO LEVI;RENATO TALAMINI;A.F. OLSHAN;ALEXANDER W. DAUDT;ANA B MENEZES;CHEN X. CHEN;D. M. WINN;DANA MATEȘ;E. MATOS;E. SMITH;ELEONÓRA FABIÁNOVÁ;ERICH M. STURGIS;J. BERTHILLER;JOSHUA MUSCAT;JOSÉ ELUF‐NETO;M. HASHIBE;MARÍA PAULA CURADO","2408;2199;1973;1203;1195;1041;1041;1041;1041;1041;1041;1041;1041;1041;1041;1041;1041;1041;1041;1041","RENATO TALAMINI;ALEXANDER W. DAUDT;R. TALAMINI;LUIGINO DAL MASO;UMBERTO TIRELLI;ANTONELLA ZUCCHETTO;VALTER GATTEI;JERRY POLESEL;ANNUNZIATA GLOGHINI;MASSIMO DEGAN;MICHELE SPINA;MICHELE DAL BO;ANTONINO CARBONE;ALFONSO COLOMBATTI;VINCENZO CANZONIERI;DIEGO SERRAINO;MARIA ANTONIETTA PIZZICHETTA;PIETRO BULIAN;FRANCESCA MARIA ROSSI;MARIAGRAZIA MICHIELI","1195;1041;1041;932;791;490;435;421;418;405;312;309;298;281;274;272;271;250;249;249","RENATO TALAMINI;LUIGINO DAL MASO;ANTONELLA ZUCCHETTO;UMBERTO TIRELLI;VALTER GATTEI;MICHELE SPINA;VINCENZO CANZONIERI;DIEGO SERRAINO;ALESSANDRA BEARZ;VALLÌ DE RE;RICCARDO BOMBEN;ALFONSO COLOMBATTI;JERRY POLESEL;MASSIMO DEGAN;RENATO CANNIZZARO;ANNUNZIATA GLOGHINI;RICCARDO DOLCETTI;LAURA CAGGIARI;M. MAZZUCATO;MICHELE DAL BO","31;17;13;13;12;11;11;8;7;7;6;6;6;6;6;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;GEOGRAPHY;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY","110;64;15;9;7;4;2;1;1;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;ONCOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;PATHOLOGY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;CELL BIOLOGY;VIROLOGY;ENDOCRINOLOGY;RADIOLOGY;DEMOGRAPHY;GYNECOLOGY;MOLECULAR BIOLOGY;OPTICS;PALEONTOLOGY;PHARMACOLOGY;PHYSIOLOGY;UROLOGY","95;37;37;30;29;28;26;25;24;15;13;8;7;7;6;6;6;6;6;6;6;6","CANCER;CHEMOTHERAPY;GENE;ODDS RATIO;CONFIDENCE INTERVAL;ANTIBODY;LEUKEMIA;LYMPHOMA;RADIATION THERAPY;BODY MASS INDEX;CASE-CONTROL STUDY;LOGISTIC REGRESSION;STEM CELL;RECEPTOR;TRANSPLANTATION;POPULATION;ANTIGEN;IMMUNE SYSTEM;REGIMEN;TOXICITY;VIRUS","43;23;21;20;19;14;13;13;13;12;10;10;10;8;8;7;6;6;6;6;6","CHRONIC LYMPHOCYTIC LEUKEMIA;BREAST CANCER;CISPLATIN;COLORECTAL CANCER;CD34;CYCLOPHOSPHAMIDE;EPIDERMAL GROWTH FACTOR RECEPTOR;MUTATION;RITUXIMAB;T CELL;B CELL;METASTASIS;MONOCLONAL ANTIBODY;NEUTROPENIA;OVARIAN CANCER;ADENOCARCINOMA;ALEMTUZUMAB;CD5;CELL CYCLE;CUMULATIVE INCIDENCE;CYTOTOXIC T CELL;DOCETAXEL;GEMCITABINE;GENE EXPRESSION;GENOTYPE;HAZARD RATIO;HEPATITIS C VIRUS;LIVER TRANSPLANTATION;PHASES OF CLINICAL RESEARCH;PROSTATE","12;11;11;9;8;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CD38;ERLOTINIB;IGHV@;CARBOPLATIN;CETUXIMAB;CRYOGLOBULINEMIA;EGFR INHIBITORS;GEFITINIB;PEMETREXED;PROBAND;ADENOMATOUS POLYPOSIS COLI;ANTHOCYANIDINS;CD40;CYCLIN-DEPENDENT KINASE 1;ESTROGEN RECEPTOR;FAMILIAL ADENOMATOUS POLYPOSIS;FLAVONOLS;FLUDARABINE;GERMLINE MUTATION;GLYCOPROTEIN IB;IFOSFAMIDE;IL-2 RECEPTOR;TAMOXIFEN;VINORELBINE;WAIST–HIP RATIO","6;5;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MIDDLE AGED;FEMALE;AGED;ADULT;ITALY;MALE;;CASE-CONTROL STUDIES;RISK FACTORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;AGED, 80 AND OVER;CRYOGLOBULINEMIA;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;ADOLESCENT;BIOMARKERS, TUMOR;HIV INFECTIONS;LIVER NEOPLASMS;CARCINOMA, HEPATOCELLULAR","92;62;57;51;50;48;46;37;25;24;19;19;18;17;17;15;15;15;15;14","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATITIS C INFECTION AND TREATMENT;MELANOMA;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;REGULATION AND FUNCTION OF MICROTUBULES IN CELL DIVISION;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY OF MULTIPLE PRIMARY CANCERS;GYNECOLOGIC ONCOLOGY;HEALTH EFFECTS OF SOY ISOFLAVONES AND PHYTOESTROGENS","11;8;5;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","CANCER INCIDENCE;REGIMEN;CANCER RISK;IGHV@;TREATMENT GUIDELINES;B-CELL RECEPTOR SIGNALING;CARBOPLATIN;RADIOTHERAPY;RITUXIMAB;CD5;CUMULATIVE INCIDENCE;DIETARY PATTERNS;EGFR;EGFR INHIBITORS;HEALTHY EATING INDEX;HEPATOCELLULAR CARCINOMA;IMAGE-GUIDED RADIOTHERAPY;MITOTIC CHECKPOINT;PEMETREXED;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE","7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;BREAST CANCER;RENAL CELL;CANCER RISK;CASE-CONTROL STUDY;PROTEIN EXPRESSION;ADVANCED NSCLC;B-CELL CHRONIC;CELL LUNG;COLORECTAL CANCER;GROWTH FACTOR;HEPATOCELLULAR CARCINOMA;II MIXED;LEUKEMIA CLL;LOCALLY ADVANCED;LUNG CANCER;NON-SMALL CELL;NSCLC PATIENTS;OVARIAN CANCER;PATIENTS TREATED;RISK FACTORS;TYPE II;ADENOMATOUS POLYPOSIS;ALCOHOL DRINKING;AUTOLOGOUS PERIPHERAL;BODY MASS;CANCER DEVELOPMENT;CANCER STUDY;CARBOPLATIN PC","11;11;10;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","BREAST CANCER;ODDS RATIOS;PHARYNGEAL CANCER;BODY MASS;LOGISTIC REGRESSION;MASS INDEX;RR CI;ALCOHOL DRINKING;CONFIDENCE INTERVAL;CONFIDENCE INTERVALS;FAMILY HISTORY;REGRESSION MODELS;HISTOLOGICALLY CONFIRMED;INTERVAL CI;LARYNGEAL CANCER;NECK CANCER;ODDS RATIO;CASECONTROL STUDIES;EDA FN;ENERGY INTAKE;INCREASED RISK;MELANOMA CELLS;RISK FACTORS;STUDY CENTRE;TOBACCO SMOKING;ACUTE NONNEOPLASTIC;ALCOHOL CONSUMPTION;CASECONTROL STUDY;CDK ACTIVITY;ENDOMETRIAL CANCER","16;12;12;11;11;10;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5",28,0.21,6.63,3.25,1,1,1,3.25,2,1,2,4.25,0,1,1.5,0,4.5,0,0,1,1.75,0,0,58,58.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,8.2,1282,5.7,5,0.45,108.45,0,0,3,0,6,0,0,2,0,9,1,0,0,0,0,0,0,8,3,0,10,1,0,0,0,0,0,0,0,0,"Belgium;Canada;Italy;United States","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","11;10;4;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;PATIENT SAFETY;RARE DISEASES;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA;AGING;CARDIOVASCULAR;DIGESTIVE DISEASES;ESTROGEN;HEART DISEASE;ORPHAN DRUG;PANCREATIC CANCER;PREVENTION","10;10;10;4;4;4;2;2;2;2;1;1;1;1;1;1;1;1","CANCER","10","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES","8;2;1","BREAST CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;SARCOMA","4;3;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","8;3;2;1",1,2050500,292928.57,4,7,5,1,11,137481.81477591,0.974674361248536,"ARETA INTERNATIONAL (ITALY);CENTRO DI RIFERIMENTO ONCOLOGICO;KAROLINSKA INSTITUTET;PEPSCAN (NETHERLANDS);PROIMMUNE (UNITED KINGDOM);UNIVERSITY OF OSLO;UNIVERSITY OF PADUA","1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-2005-LIFESCIHEALTH-7 (CALL FOR PROPOSAL);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);STREP - SPECIFIC TARGETED RESEARCH PROJECT (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","BIOTECHNOLOGY;CANCER;HEMATOLOGY;IMMUNIZATION;LYMPHOMA;RARE DISEASES;VACCINE RELATED","1;1;1;1;1;1;1",NA,NA,"5.1 PHARMACEUTICALS","1","NON-HODGKIN'S LYMPHOMA","1","3.4 VACCINES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1","A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2008,138,12.6521739130435,2.8695652173913,0.369565217391304,0.311594202898551,0.384057971014493,2.29651162790698,1.21428571428571,1.65384615384615,1.26190476190476,0.471014492753623,2,86,24,17,2,0.62,0.17,0.12,0.01,71.25,1.29854554428459,NA,0.543478260869565,0.891304347826087,0.501,0.445,0.456,0.443,"RENATO TALAMINI;SILVIA FRANCESCHI;CARLO LA VECCHIA;LUIGINO DAL MASO;VALTER GATTEI;EVA NEGRI;GIANLUCA GAÏDANO;VINCENZO CANZONIERI;ALFONSO COLOMBATTI;VALLÌ DE RE;ANTONINO CARBONE;UMBERTO TIRELLI;DAVIDE ROSSI;RICCARDO DOLCETTI;ANNUNZIATA GLOGHINI;CLAUDIO DOGLIONI;DIEGO SERRAINO;GUSTAVO BALDASSARRE;JERRY POLESEL;PAUL BRENNAN","27;19;16;13;13;13;11;9;9;9;9;9;8;8;8;8;8;8;8;7","RENATO TALAMINI;UMBERTO TIRELLI;SILVIA FRANCESCHI;CARLO LA VECCHIA;DIANA CRIVELLARI;VALLÌ DE RE;EVA NEGRI;LUIGINO DAL MASO;ANTONINO CARBONE;RICCARDO DOLCETTI;ROBERTO PERRIS;ALFONSO COLOMBATTI;GIANLUCA GAÏDANO;VALTER GATTEI;VINCENZO CANZONIERI;MARIANGELA DE ZORZI;MICHELE SPINA;ANNUNZIATA GLOGHINI;LAURA CAGGIARI;DONATELLA ALDINUCCI","2.61;1.85;1.83;1.58;1.38;1.35;1.31;1.19;1.19;1.09;1.07;0.95;0.94;0.94;0.85;0.82;0.82;0.81;0.8;0.78","RENATO TALAMINI;LUIGINO DAL MASO;VALTER GATTEI;VINCENZO CANZONIERI;ALFONSO COLOMBATTI;VALLÌ DE RE;ANTONINO CARBONE;UMBERTO TIRELLI;RICCARDO DOLCETTI;ANNUNZIATA GLOGHINI;DIEGO SERRAINO;GUSTAVO BALDASSARRE;JERRY POLESEL;MICHELE SPINA;ANTONELLA ZUCCHETTO;ANTONELLA ZUCCHETTO;MONICA CASTIGLIONE‐GERTSCH;ALESSANDRA BEARZ;RENATO CANNIZZARO;RICHARD D. GELBER","27;13;13;9;9;9;9;9;8;8;8;8;8;7;6;6;5;5;5;5","RENATO TALAMINI;UMBERTO TIRELLI;DIANA CRIVELLARI;VALLÌ DE RE;LUIGINO DAL MASO;ANTONINO CARBONE;RICCARDO DOLCETTI;ROBERTO PERRIS;ALFONSO COLOMBATTI;VALTER GATTEI;VINCENZO CANZONIERI;MARIANGELA DE ZORZI;MICHELE SPINA;ANNUNZIATA GLOGHINI;LAURA CAGGIARI;DONATELLA ALDINUCCI;ETTORE BIDOLI;JERRY POLESEL;GUSTAVO BALDASSARRE;ALESSANDRA BEARZ","2.61;1.85;1.38;1.35;1.19;1.19;1.09;1.07;0.95;0.94;0.85;0.82;0.82;0.81;0.8;0.78;0.78;0.76;0.75;0.74","RENATO TALAMINI;PAUL BRENNAN;LENKA FORETOVÁ;PAOLO VINEIS;MIA HASHIBE;LUIGINO DAL MASO;ΠΑΓΏΝΑ ΛΆΓΙΟΥ;PAOLO BOFFETTA;ANTONIO AGUDO;ARIANA ZNAOR;FRANCO MERLETTI;LORENZO SIMONATO;DANA MATEȘ;ELEONÓRA FABIÁNOVÁ;JOLANTA LISSOWSKA;NEONILIA SZESZENIA‐DABROWSKA;ДАВИД ЗАРИДЗЕ;DAVID I. CONWAY;GARY J. MACFARLANE;KRISTINA KJÆRHEIM","2860;2333;1809;1809;1773;1746;1711;1640;1622;1622;1622;1622;1582;1582;1582;1582;1582;1564;1564;1564","RENATO TALAMINI;LUIGINO DAL MASO;ANTONELLA ZUCCHETTO;GUSTAVO BALDASSARRE;MILENA S. NICOLOSO;ROBERTA MAESTRO;SARA PICCININ;JERRY POLESEL;DIEGO SERRAINO;VALTER GATTEI;ANTONINO DE PAOLI;RICCARDO DOLCETTI;FRANCESCA MARIA ROSSI;RICCARDO BOMBEN;TIZIANA PERIN;JESSICA DAL COL;RENATO CANNIZZARO;MASSIMO GUIDOBONI;CARLA GIORDANO;UMBERTO TIRELLI","2805;1746;1137;1095;822;748;685;665;589;513;489;461;426;424;393;263;248;247;228;228","RENATO TALAMINI;LUIGINO DAL MASO;ANTONELLA ZUCCHETTO;VALTER GATTEI;UMBERTO TIRELLI;VALLÌ DE RE;DIEGO SERRAINO;JERRY POLESEL;RICCARDO DOLCETTI;MICHELE SPINA;VINCENZO CANZONIERI;ALFONSO COLOMBATTI;GUSTAVO BALDASSARRE;ANTONINO CARBONE;ALESSANDRA BEARZ;DIANA CRIVELLARI;ETTORE BIDOLI;LAURA CAGGIARI;MARIANGELA DE ZORZI;RENATO CANNIZZARO","26;13;12;12;9;9;8;8;8;7;7;6;6;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;MATHEMATICS;ENGINEERING;COMPUTER SCIENCE;PSYCHOLOGY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;HISTORY;PHILOSOPHY;ECONOMICS;GEOLOGY;POLITICAL SCIENCE","97;75;20;12;9;6;5;4;4;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;GENETICS;ONCOLOGY;CANCER RESEARCH;IMMUNOLOGY;BIOCHEMISTRY;SURGERY;CELL BIOLOGY;PATHOLOGY;GASTROENTEROLOGY;MOLECULAR BIOLOGY;GYNECOLOGY;ENVIRONMENTAL HEALTH;VIROLOGY;OPTICS;ORGANIC CHEMISTRY;PALEONTOLOGY;DEMOGRAPHY;RADIOLOGY;CHROMATOGRAPHY","83;46;41;35;34;26;23;21;18;17;13;12;9;9;7;7;7;6;6;5","CANCER;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;ODDS RATIO;LYMPHOMA;CASE-CONTROL STUDY;LEUKEMIA;RADIATION THERAPY;ANTIBODY;STEM CELL;CELL;ANTIGEN;LOGISTIC REGRESSION;MULTIVARIATE ANALYSIS;SIGNAL TRANSDUCTION;VIRUS;CELL GROWTH;CONTEXT (ARCHAEOLOGY);INCIDENCE (GEOMETRY);POPULATION;RECEPTOR;TOXICITY","66;35;21;20;16;15;12;12;11;10;9;8;7;7;7;7;7;6;6;6;6;6;6","BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;CELL CYCLE;METASTASIS;B CELL;CD34;CYCLOPHOSPHAMIDE;ALLELE;HAZARD RATIO;UNIVARIATE ANALYSIS;BREAKPOINT CLUSTER REGION;CANCER CELL;CISPLATIN;ENDOMETRIAL CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;GENE EXPRESSION;HEAD AND NECK CANCER;HEPATITIS C VIRUS;MUTATION;PHASES OF CLINICAL RESEARCH;PI3K/AKT/MTOR PATHWAY;PROTEIN KINASE B;VIRAL DISEASE","23;11;10;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","IGHV@;CD38;BREAST CARCINOMA;ESTROGEN RECEPTOR;TAMOXIFEN;ANTIRETROVIRAL THERAPY;AROMATASE;B-CELL ACTIVATING FACTOR;CELL CYCLE CHECKPOINT;COMPARATIVE GENOMIC HYBRIDIZATION;CYCLIN D1;DNA MISMATCH REPAIR;ERLOTINIB;GEFITINIB;GERMLINE MUTATION;MISSENSE MUTATION;PTEN;SIDA;ADJUVANT CHEMOTHERAPY;ANTHOCYANIDINS;ANTIGEN PRESENTATION;APHIDICOLIN;B-CELL RECEPTOR;CANCER IMMUNOTHERAPY;CARBOPLATIN;CCL2;CHEMICAL IONIZATION;CHLAMYDOPHILA PNEUMONIAE;CHROMOSOMAL FRAGILE SITE;CHROMOSOME INSTABILITY;COMMUNICATION DISORDER;COMPLEMENTARITY DETERMINING REGION;CYCLIN;DNA METHYLATION;E2F1;ELISPOT;EPIRUBICIN;EPITHELIAL–MESENCHYMAL TRANSITION;ESOPHAGEAL CANDIDIASIS;ESOPHAGECTOMY;ESOPHAGITIS;FEBRILE NEUTROPENIA;FLAVONOLS;FRAMESHIFT MUTATION;GENE EXPRESSION PROFILING;GENOME INSTABILITY;GENOTYPING;GSTP1;HBSAG;HERPESVIRIDAE;HISTOCOMPATIBILITY;HORMONE THERAPY;IFOSFAMIDE;IMMUNOGLOBULIN M;IN SITU HYBRIDIZATION;INELASTIC ELECTRON TUNNELING SPECTROSCOPY;INTERNATIONAL PROGNOSTIC INDEX;IONIZATION CHAMBER;IRINOTECAN;KARYOTYPE;LASER CAPTURE MICRODISSECTION;LYMPHANGIOGENESIS;LYMPHATIC VESSEL;LYMPHEDEMA;MAMMOGRAPHY;MARGINAL ZONE;METASTATIC BREAST CANCER;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MICROSATELLITE;MUCINOUS CARCINOMA;MUCOSA-ASSOCIATED LYMPHOID TISSUE;NEOADJUVANT THERAPY;NICOTINIC ACETYLCHOLINE RECEPTOR;NOTTINGHAM PROGNOSTIC INDEX;NUCLEAR EXPORT SIGNAL;ONCOGENE;OXALIPLATIN;PAPILLARY THYROID CANCER;PDGFRA;PEMETREXED;PLACENTA;REPOPULATION;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;REVERSE TRANSCRIPTASE;RIBAVIRIN;RPTOR;SELECTED REACTION MONITORING;SOMATIC HYPERMUTATION;SOMATOSTATIN RECEPTOR 2;SUPRACLAVICULAR LYMPH NODES;TELOMERASE REVERSE TRANSCRIPTASE;THYMIDYLATE SYNTHASE;TRASTUZUMAB;TUMOR SUPPRESSOR GENE;V600E;VARIABLE NUMBER TANDEM REPEAT;VENETOCLAX;VINCRISTINE;VINORELBINE;VIRAL ENTRY;VITRONECTIN;WAIST–HIP RATIO;ZEAXANTHIN","6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;BREAST NEOPLASMS;MIDDLE AGED;MALE;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;;FLUOROURACIL;CASE-CONTROL STUDIES;RISK FACTORS;ADENOCARCINOMA;AGED, 80 AND OVER;NEOPLASMS;CARCINOMA, SQUAMOUS CELL;LUNG NEOPLASMS;ANIMALS;BIOMARKERS, TUMOR","104;75;59;56;50;48;46;38;37;32;25;24;22;20;19;19;16;15;14;14","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;MOLECULAR RESEARCH ON BREAST CANCER;HER2 SIGNALING IN BREAST CANCER TREATMENT;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PATHOGENESIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE;ATP SYNTHASE FUNCTION AND REGULATION;CANCER STEM CELLS AND TUMOR METASTASIS;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES","10;8;8;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER RISK;B-CELL RECEPTOR SIGNALING;IGHV@;DIETARY PATTERNS;UNIVARIATE ANALYSIS;BREAKPOINT CLUSTER REGION;BREAST CARCINOMA;CANCER;CANCER INCIDENCE;DIET QUALITY;HEALTHY EATING INDEX;HEPATITIS C;HIV;MANTLE CELL LYMPHOMA;NEOADJUVANT THERAPY;REGIMEN;TREATMENT;ADJUVANT THERAPY;CANCER STEM CELLS","10;7;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3","BREAST CANCER;CANCER RISK;CHRONIC LYMPHOCYTIC;LOCALLY ADVANCED;CASECONTROL STUDY;COLORECTAL CANCER;LYMPHOCYTIC LEUKEMIA;LUNG CANCER;ACTIVE ANTIRETROVIRAL;ANTIRETROVIRAL THERAPY;CANCER CELL;CANCER STUDY;CELL CANCER;CELL LUNG;CELL LYMPHOMA;CELL PROLIFERATION;DIET DIVERSITY;ENDOMETRIAL CANCER;HIGHLY ACTIVE;INDEPENDENT RISK;LYMPHOCYTIC LEUKAEMIA;NON-SMALL CELL;OVARIAN CANCER;RENAL CELL;RISK FACTORS;ACUTE MYELOID;ADVANCED RECTAL;ALCOHOL CONSUMPTION;CANCER PATIENTS;CASE-CONTROL STUDY","18;9;8;6;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;GROWTH FACTOR;BREAST CANCER;EPIDERMAL GROWTH;FACTOR RECEPTOR;GCQ DOMAIN;LUNG CANCER;EMILIN GCQ;CELL LINES;BIOL CHEM;CHEM -ABSTRACT;KINASE DOMAIN;MUTATION STATUS;ENDOCRINE THERAPY;ENDOTHELIAL CELLS;LASER CAPTURE;OVARIAN CANCER;WILD TYPE;CELL LUNG;EXTRACELLULAR MATRIX;FAMILY HISTORY;NON-SMALL CELL;RES -CROSSREF;TYROSINE KINASE;BIOL -CROSSREF;BRESSAN GM;CONFIDENCE INTERVAL;LIOTTA LA;MUCIGNAT MT","80;63;47;42;37;32;24;24;23;19;18;18;11;11;10;10;10;10;10;9;9;9;9;9;9;8;8;8;8;8",42,0.3,7.85,4.75,1,1.5,0,3,4,1,1,4.75,0,1,4,1,6,1,1,2.75,4,0,0,68.5,69.5,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,32,4,1.01,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CAGGIARI LAURA;DE RE VALLI;GLOGHINI ANNUNZIALA;SIMULA MARIA PAOLA","1;1;1;1","IRCCS CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY","2;1","AUTOIMMUNE DISEASE;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;IMMUNIZATION;INFECTIOUS DISEASES;LIVER DISEASE","1;1;1;1;1;1;1;1",NA,NA,"A61K39/395;A61P31/12;A61P35/00;A61P37/00;C07K16/10;C07K16/18;C07K16/34;C12N5/12;C12N5/22;C12N7/01","1;1;1;1;1;1;1;1;1;1","A61K2039/505;A61P31/12;A61P35/00;A61P37/00;C07K16/109;C07K2317/21;C07K2319/30","1;1;1;1;1;1;1",11,8.12,586.89,7.38,5,0.45,61.45,0,1,2,1,6,0,0,1,0,9,0,0,0,0,0,0,0,7,4,0,9,2,0,0,0,0,0,0,0,0,"Germany","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE","11;10;4;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;OVARIAN CANCER;DIGESTIVE DISEASES;LUNG;LUNG CANCER;BIOMEDICAL IMAGING;COLO-RECTAL CANCER;HEMATOLOGY;LYMPHOMA;ORPHAN DRUG;PATIENT SAFETY;STEM CELL RESEARCH;TRANSPLANTATION","9;8;8;5;4;2;2;2;1;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL","10;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","9;2;1;1;1","OVARIAN CANCER;LUNG CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;NON-HODGKIN'S LYMPHOMA;SARCOMA;STOMACH CANCER","4;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","5;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"AMERICAN CHEMICAL SOCIETY","2","34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY","4;2","BIOTECHNOLOGY","2","GENERIC HEALTH RELEVANCE","2",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2009,147,13.9115646258503,3.06802721088435,0.360544217687075,0.312925170068027,0.666666666666667,2.31282051282051,1.26190476190476,1.4375,1.84905660377358,0.380952380952381,1,86,22,17,7,0.59,0.15,0.12,0.05,57.65,1.24621098574544,NA,0.482993197278912,0.931972789115646,0.493,0.509,0.519,0.482,"VALTER GATTEI;RENATO TALAMINI;LUIGINO DAL MASO;SILVIA FRANCESCHI;DIEGO SERRAINO;CARLO LA VECCHIA;GIANLUCA GAÏDANO;DAVIDE ROSSI;GIOVANNI DEL POETA;EVA NEGRI;VINCENZO CANZONIERI;FRANCESCO FORCONI;ANTONELLA ZUCCHETTO;GIUSEPPE TOFFOLI;UMBERTO TIRELLI;JERRY POLESEL;VALLÌ DE RE;MICHELE DAL BO;PIETRO BULIAN;ANTONINO CARBONE","23;22;19;19;18;17;16;14;13;12;11;11;10;10;10;9;8;8;8;8","RENATO TALAMINI;SILVIA FRANCESCHI;LUIGINO DAL MASO;VALTER GATTEI;DIEGO SERRAINO;CARLO LA VECCHIA;EVA NEGRI;GIUSEPPE TOFFOLI;VALLÌ DE RE;VINCENZO CANZONIERI;ANTONINO CARBONE;TOFFOLI;GIOVANNI DEL POETA;GIANLUCA GAÏDANO;JERRY POLESEL;CRISTINA BOSETTI;UMBERTO TIRELLI;DAVIDE ROSSI;MARCO TROVÒ;ANTONELLA ZUCCHETTO","1.94;1.66;1.62;1.61;1.55;1.47;1.27;1.12;1.11;1.06;1.01;1;0.96;0.93;0.86;0.83;0.82;0.79;0.72;0.71","VALTER GATTEI;RENATO TALAMINI;LUIGINO DAL MASO;SILVIA FRANCESCHI;DIEGO SERRAINO;CARLO LA VECCHIA;EVA NEGRI;VINCENZO CANZONIERI;ANTONELLA ZUCCHETTO;GIUSEPPE TOFFOLI;UMBERTO TIRELLI;JERRY POLESEL;VALLÌ DE RE;MICHELE DAL BO;PIETRO BULIAN;ANTONINO CARBONE;CRISTINA BOSETTI;RICCARDO BOMBEN;ANTONELLA ZUCCHETTO;DANIA BENEDETTI","23;22;19;19;18;17;12;11;10;10;10;9;8;8;8;8;8;8;7;7","RENATO TALAMINI;SILVIA FRANCESCHI;LUIGINO DAL MASO;VALTER GATTEI;DIEGO SERRAINO;CARLO LA VECCHIA;EVA NEGRI;GIUSEPPE TOFFOLI;VALLÌ DE RE;VINCENZO CANZONIERI;ANTONINO CARBONE;TOFFOLI;JERRY POLESEL;CRISTINA BOSETTI;UMBERTO TIRELLI;MARCO TROVÒ;ANTONELLA ZUCCHETTO;ANTONELLA ZUCCHETTO;ALFONSO COLOMBATTI;MAURIZIO MONTELLA","1.94;1.66;1.62;1.61;1.55;1.47;1.27;1.12;1.11;1.06;1.01;1;0.86;0.83;0.82;0.72;0.71;0.68;0.66;0.64","SILVIA FRANCESCHI;RENATO TALAMINI;LUIGINO DAL MASO;CARLO LA VECCHIA;PAUL BRENNAN;MIA HASHIBE;XAVIER CASTELLSAGUÉ;FABIO LEVI;ALEXANDER W. DAUDT;ELAINE SMITH;JOSHUA MUSCAT;JOSÉ ELUF‐NETO;MARK P. PURDUE;MARÍA PAULA CURADO;PAOLO BOFFETTA;PHILIP LAZARUS;RICHARD B. HAYES;STEFANIA BOCCIA;ZUO‐FENG ZHANG;MICHELE MAIO","2219;2162;2058;2023;1632;1545;1545;1436;1308;1308;1308;1308;1308;1308;1308;1308;1308;1308;1308;1143","RENATO TALAMINI;LUIGINO DAL MASO;MICHELE MAIO;VALTER GATTEI;DIEGO SERRAINO;VINCENZO CANZONIERI;GIUSEPPE TOFFOLI;JERRY POLESEL;ELENA DE MATTIA;ERIKA CECCHIN;ANTONELLA ZUCCHETTO;ANGELA BUONADONNA;FEDERICO INNOCENTI;MARIO D’ANDREA;UMBERTO TIRELLI;ALFONSO COLOMBATTI;PAOLA BIASON;DEBORA LORENZON;ALESSANDRA BEARZ;M. LISE","2162;2058;1142;995;737;544;530;490;470;470;436;371;371;371;351;304;275;272;269;260","VALTER GATTEI;RENATO TALAMINI;DIEGO SERRAINO;LUIGINO DAL MASO;ANTONELLA ZUCCHETTO;VINCENZO CANZONIERI;JERRY POLESEL;UMBERTO TIRELLI;MICHELE DAL BO;PIETRO BULIAN;RICCARDO BOMBEN;MICHELE SPINA;FRANCESCA MARIA ROSSI;DANIA BENEDETTI;GIUSEPPE TOFFOLI;ALFONSO COLOMBATTI;MARIAGRAZIA MICHIELI;MASSIMO DEGAN;VALLÌ DE RE;MASSIMILIANO BERRETTA","23;22;18;18;17;11;9;9;8;8;8;7;7;7;7;6;6;6;6;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;ENGINEERING;MATERIALS SCIENCE;PSYCHOLOGY;BUSINESS;GEOGRAPHY;PHILOSOPHY;POLITICAL SCIENCE","116;70;16;15;8;4;3;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;IMMUNOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;BIOCHEMISTRY;CELL BIOLOGY;OPTICS;COMPUTATIONAL BIOLOGY;GYNECOLOGY;MOLECULAR BIOLOGY;PALEONTOLOGY;VIROLOGY;DEMOGRAPHY;RADIOLOGY;BIOINFORMATICS;PEDIATRICS","97;50;49;43;37;26;25;24;21;20;12;9;8;8;8;8;8;7;7;6;6","CANCER;GENE;POPULATION;LEUKEMIA;CONFIDENCE INTERVAL;ODDS RATIO;CHEMOTHERAPY;LYMPHOMA;CASE-CONTROL STUDY;ANTIBODY;RADIATION THERAPY;DISEASE;EPIDEMIOLOGY;INCIDENCE (GEOMETRY);LOGISTIC REGRESSION;LUNG CANCER;MELANOMA;STEM CELL;ANTIGEN;FLOW CYTOMETRY","62;39;23;21;20;20;19;17;13;11;11;10;9;9;9;8;8;8;7;7","CHRONIC LYMPHOCYTIC LEUKEMIA;BREAST CANCER;COLORECTAL CANCER;GENOTYPE;CD34;HAZARD RATIO;PHENOTYPE;CELL CYCLE;CISPLATIN;ALLELE;B CELL;CARCINOGENESIS;MUTATION;ENDOMETRIAL CANCER;HEAD AND NECK CANCER;DIFFUSE LARGE B-CELL LYMPHOMA;DOWNREGULATION AND UPREGULATION;OVARIAN CANCER;PANCREATIC CANCER;RITUXIMAB;TOLERABILITY","20;14;9;9;8;8;8;7;7;6;6;6;6;5;5;4;4;4;4;4;4","CD38;SINGLE-NUCLEOTIDE POLYMORPHISM;VINORELBINE;GERMLINE MUTATION;HAPLOTYPE;IFOSFAMIDE;CAPECITABINE;CCL2;CRYOGLOBULINEMIA;GERMINAL CENTER;HBSAG;IGHV@;IRINOTECAN;TUMOR SUPPRESSOR GENE;ABSOLUTE NEUTROPHIL COUNT;ANGIOPOIETIN 2;ANTHRACYCLINE;AXILLA;B-CELL RECEPTOR;BRCA MUTATION;CASPASE;CD23;CD3;CD40;CELL CYCLE PROGRESSION;CELLULAR SENESCENCE;CHEMOIMMUNOTHERAPY;CHEMOKINE RECEPTOR;CIRCULATING TUMOR CELL;COLLAGEN RECEPTOR;CYCLIN;CYCLIN D1;CYCLIN-DEPENDENT KINASE 1;DEMENTIA WITH LEWY BODIES;DNA METHYLATION;DNA MISMATCH REPAIR;ELISPOT;EPITHELIAL OVARIAN CANCER;ESTROGEN RECEPTOR;FILGRASTIM;FLUDARABINE;GENETIC STRUCTURE;GENOTYPING;GERMLINE MOSAICISM;GPVI;GROUND-GLASS OPACITY;HEMATOPOIETIC STEM CELL;HISTONE DEACETYLASE;HPV INFECTION;HUMAN PROTEOME PROJECT;IDIOTYPE;IL-2 RECEPTOR;INTERFERON ALFA;INTERFERON REGULATORY FACTORS;INTERNATIONAL PROGNOSTIC INDEX;INTRAOPERATIVE RADIOTHERAPY;IPILIMUMAB;IRF4;KAPOSI'S SARCOMA;KARYOTYPE;LAMIVUDINE;LEUKAPHERESIS;MAGNETIC RELAXATION;MAMMOGRAPHY;MASTECTOMY;METASTATIC BREAST CANCER;METHYLENETETRAHYDROFOLATE REDUCTASE;MICROVESICLES;MOLECULAR MEDICINE;MONOCLONAL;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;NATIONAL DEATH INDEX;NIVOLUMAB;ONCOGENE;OVARIAN CARCINOMA;PDGFRA;PEMETREXED;PENETRANCE;PEPTIDE MASS FINGERPRINTING;PERIPHERAL BLOOD STEM CELLS;PHYLOGEOGRAPHY;PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;POLY ADP RIBOSE POLYMERASE;POLYCYSTIC OVARY;POLYMORPHISM (COMPUTER SCIENCE);PROANTHOCYANIDIN;REED–STERNBERG CELL;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETINOBLASTOMA PROTEIN;REVERSION;RNA EXTRACTION;SELECTED REACTION MONITORING;SENTINEL LYMPH NODE;SENTINEL NODE;SEXUAL TRANSMISSION;SMALL INTERFERING RNA;SUPERPARAMAGNETISM;TAQMAN;TAXANE;TRANSCRIPTOME;VENETOCLAX;VINCRISTINE","7;6;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;ITALY;MALE;AGED;ADULT;NEOPLASMS;;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;BREAST NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RISK FACTORS;CASE-CONTROL STUDIES;SMOKING;YOUNG ADULT;COLORECTAL NEOPLASMS;FLUOROURACIL;MELANOMA","102;75;61;58;57;54;50;45;41;30;23;22;22;21;20;18;18;17;16;16","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;LYMPHOID NEOPLASMS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MELANOMA;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GYNECOLOGIC ONCOLOGY;HEPATITIS B INFECTION AND TREATMENT;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR RESEARCH ON BREAST CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;ROLE OF GALECTINS IN IMMUNITY AND DISEASE","23;11;6;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER RISK;MELANOMA;RADIOTHERAPY;B-CELL RECEPTOR SIGNALING;CANCER INCIDENCE;CANCER SUSCEPTIBILITY;CANCER THERAPY;METASTATIC COLORECTAL CANCER;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE;REFRACTORY (PLANETARY SCIENCE);SNP;TOLERABILITY;TRANSPLANT RECIPIENTS;VINORELBINE;BRCA1;BREAKPOINT CLUSTER REGION;CHEMOTHERAPY REGIMEN;CLINICAL ENDPOINT;IMAGE-GUIDED RADIOTHERAPY","5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;CANCER RISK;BREAST CANCER;COLORECTAL CANCER;B-CELL CHRONIC;LUNG CANCER;OVARIAN CANCER;CASE-CONTROL STUDY;ELDERLY PATIENTS;HODGKIN LYMPHOMA;HODGKINS LYMPHOMA;LEUKEMIA CLL;NECK CANCER;RADIATION THERAPY;AERODIGESTIVE TRACT;BRCA MUTATION;CANCER PATIENTS;DE NOVO;ENDOMETRIAL CANCER;GENE EXPRESSION;LEUKEMIA CELLS;MELANOMA PATIENTS;MUTATION CARRIERS;NON-HODGKINS LYMPHOMA;PANCREATIC CANCER;PHASE II;RICHTER SYNDROME;TOBACCO SMOKING;UPPER AERODIGESTIVE","19;18;8;7;7;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","DKO CELLS;PUBMED SCOPUS;CROSSREF PUBMED;CELL DEATH;BREAST CANCER;MUTATION CARRIERS;BRCA MUTATION;CANCER RISK;CELLS TREATED;UADT CANCER;CANCER CELLS;TP MUTATIONS;STEREOTYPED BCR;WT CELLS;CANCER RES;GENETIC DIVERSITY;NECK CANCER;OVARIAN CANCER;THOMPSON CB;BIOL -CROSSREF;CANCER PATIENTS;CASE-CONTROL STUDY;CELL ADHESION;CELL BIOL;CELL LINES;COLORECTAL CANCER;CONFIDENCE INTERVALS;HAZARD RATIO;HL RISK;HODGKIN LYMPHOMA","48;34;31;28;23;14;12;12;12;12;10;10;9;9;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6",33,0.22,6,3,5.75,1.75,0,3,3,1,2,3,0,1,3,2.5,2,0,1,8.5,1,0,0,94,94,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,4,3,0.67,2,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DE MARCO LUIGINO;MAZZUCATO MARIO;STEFFAN AGOSTINO","1;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;SEDICIDODICI SRL","1;1","34 CHEMICAL SCIENCES;40 ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING","1;1;1","BRAIN DISORDERS;CARDIOVASCULAR","1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","G01N33/49;G01N33/86","1;1","G01N33/4905","1",11,6.36,464.09,6.51,3,0.27,67.55,1,0,3,0,4,0,0,3,0,8,3,0,0,0,0,0,0,9,2,0,11,0,0,0,0,0,0,0,0,0,"United States;Canada;Japan","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","11;11;4;3","CANCER;CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;PEDIATRIC;ORPHAN DRUG;OVARIAN CANCER;STEM CELL RESEARCH;AGING;BIOTECHNOLOGY;BRAIN CANCER;BRAIN DISORDERS;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;LUNG;LUNG CANCER;NEUROSCIENCES","11;11;10;6;4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER","9","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","8;2;2;1;1","NON-HODGKIN'S LYMPHOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;LUNG CANCER;OVARIAN CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;SARCOMA","4;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","8;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"AMERICAN ASSOCIATION FOR CANCER RESEARCH","2","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","4;2","HEMATOLOGY","2",NA,NA,NA,NA,NA,NA,NA,NA,"LEUKEMIA / LEUKAEMIA","2",NA,NA
"IRCCS_CRO",2010,171,14.3040935672515,3.16374269005848,0.35672514619883,0.298245614035088,0.555555555555556,2.14285714285714,1.41860465116279,1.54545454545455,1.63793103448276,0.421052631578947,4,88,36,18,13,0.51,0.21,0.11,0.08,45.04,0.996688294202875,NA,0.473684210526316,0.941520467836257,0.525,0.474,0.533,0.494,"RENATO TALAMINI;VALTER GATTEI;CARLO LA VECCHIA;LUIGINO DAL MASO;SILVIA FRANCESCHI;DIEGO SERRAINO;DAVIDE ROSSI;GIANLUCA GAÏDANO;FRANCESCO FORCONI;MICHELE SPINA;FRANCESCO BERTONI;UMBERTO TIRELLI;ANTONELLA ZUCCHETTO;GIOVANNI DEL POETA;ROBERTO MARASCA;CRISTINA BOSETTI;JERRY POLESEL;EVA NEGRI;ALESSANDRA VIEL;MICHELE MAIO","24;19;17;16;16;16;15;15;13;13;12;12;11;11;11;10;10;10;9;8","RENATO TALAMINI;CARLO LA VECCHIA;DIEGO SERRAINO;SILVIA FRANCESCHI;CHIARA LESTUZZI;ALESSANDRA VIEL;LUIGINO DAL MASO;ANTONELLA ZUCCHETTO;ANNALISA GIACALONE;ANTONINO CARBONE;MICHELE SPINA;EVA NEGRI;UMBERTO TIRELLI;JERRY POLESEL;CRISTINA BOSETTI;VALTER GATTEI;LINO DEL PUP;MASSIMILIANO BERRETTA;RICCARDO DOLCETTI;GIUSEPPE TOFFOLI","2.24;1.88;1.75;1.65;1.51;1.49;1.48;1.34;1.29;1.25;1.22;1.21;1.21;1.2;1.18;1.15;1.14;1.01;0.95;0.82","RENATO TALAMINI;VALTER GATTEI;CARLO LA VECCHIA;LUIGINO DAL MASO;SILVIA FRANCESCHI;DIEGO SERRAINO;DAVIDE ROSSI;GIANLUCA GAÏDANO;FRANCESCO FORCONI;MICHELE SPINA;FRANCESCO BERTONI;UMBERTO TIRELLI;ANTONELLA ZUCCHETTO;GIOVANNI DEL POETA;ROBERTO MARASCA;CRISTINA BOSETTI;JERRY POLESEL;ALESSANDRA VIEL;MICHELE MAIO;PIETRO BULIAN","24;19;17;16;16;16;15;15;13;13;12;12;11;11;11;10;10;9;8;8","RENATO TALAMINI;CARLO LA VECCHIA;DIEGO SERRAINO;SILVIA FRANCESCHI;CHIARA LESTUZZI;ALESSANDRA VIEL;LUIGINO DAL MASO;ANTONELLA ZUCCHETTO;ANNALISA GIACALONE;ANTONINO CARBONE;MICHELE SPINA;UMBERTO TIRELLI;JERRY POLESEL;CRISTINA BOSETTI;VALTER GATTEI;LINO DEL PUP;MASSIMILIANO BERRETTA;RICCARDO DOLCETTI;GIUSEPPE TOFFOLI;ALFONSO COLOMBATTI","2.24;1.88;1.75;1.65;1.51;1.49;1.48;1.34;1.29;1.25;1.22;1.21;1.2;1.18;1.15;1.14;1.01;0.95;0.82;0.79","SILVIA FRANCESCHI;LUIGINO DAL MASO;RENATO TALAMINI;MARIO RONCADIN;SAMUELE MASSARUT;CHRISTOBEL SAUNDERS;DAVID JOSEPH;FREDERIK WENZ;JAYANT S. VAIDYA;JEFFREY TOBIAS;MARC SÜTTERLIN;MAX BULSARA;MICHAEL BAUM;MOHAMMED KESHTGAR;NORMAN WILLIAMS;TAMMY CORICA;UTA KRAUS-TIEFENBACHER;SIRANOUSH MANOUKIAN;CARLO LA VECCHIA;APRIL MATTHEWS","1059;923;921;916;884;877;877;877;877;877;877;877;877;877;877;877;877;841;801;739","MARIO RONCADIN;LUIGINO DAL MASO;SAMUELE MASSARUT;RENATO TALAMINI;ALESSANDRA VIEL;VALTER GATTEI;ANTONELLA ZUCCHETTO;ALFONSO COLOMBATTI;JERRY POLESEL;VINCENZO CANZONIERI;DIEGO SERRAINO;FILIPPO SANTORO;FRANCA PODO;LORENZO PREDA;M CRECCO;SANDRO MORASSUT;VALLÌ DE RE;PIETRO BULIAN;MICHELE MAIO;CHIARA LESTUZZI","916;894;884;798;635;610;412;369;331;329;328;318;318;318;318;318;304;278;272;268","RENATO TALAMINI;VALTER GATTEI;ANTONELLA ZUCCHETTO;DIEGO SERRAINO;LUIGINO DAL MASO;MICHELE SPINA;UMBERTO TIRELLI;JERRY POLESEL;ALESSANDRA VIEL;PIETRO BULIAN;MASSIMILIANO BERRETTA;ANTONINO CARBONE;MICHELE MAIO;ALFONSO COLOMBATTI;CHIARA LESTUZZI;DIANA CRIVELLARI;FRANCESCA MARIA ROSSI;GIOVANNA SARTOR;MICHELE DAL BO;RICCARDO BOMBEN","23;19;16;15;15;12;11;9;8;8;7;6;6;6;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;BUSINESS;PHILOSOPHY;ENVIRONMENTAL SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;ART;GEOGRAPHY;HISTORY","145;78;16;14;12;8;5;4;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;IMMUNOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;SURGERY;ENVIRONMENTAL HEALTH;PATHOLOGY;BIOCHEMISTRY;CELL BIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;GYNECOLOGY;MOLECULAR BIOLOGY;COMPUTATIONAL BIOLOGY;OPTICS;PALEONTOLOGY","112;57;49;38;36;29;27;26;26;22;14;12;10;10;10;9;9;8;8;8","CANCER;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;POPULATION;LYMPHOMA;ODDS RATIO;LEUKEMIA;ANTIBODY;CASE-CONTROL STUDY;DISEASE;RADIATION THERAPY;REGIMEN;EPIDEMIOLOGY;IMMUNE SYSTEM;LOGISTIC REGRESSION;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INCIDENCE (GEOMETRY);TRANSPLANTATION;COHORT;OBESITY;STEM CELL","70;46;30;26;24;20;19;17;12;12;11;11;11;9;9;9;8;8;8;7;7;7","BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;GENE EXPRESSION;HAZARD RATIO;CYCLOPHOSPHAMIDE;GENOTYPE;MICRORNA;ALLELE;MUTATION;NEUTROPENIA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;B CELL;CARCINOGENESIS;CD8;CHEMOTHERAPY REGIMEN;CHROMOSOME;ENDOMETRIAL CANCER;ETOPOSIDE;IMMUNOTHERAPY;PANCREATIC CANCER;PHENOTYPE;RITUXIMAB;T CELL;TOLERABILITY;TRANSCRIPTION FACTOR","20;16;12;10;10;7;7;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","IGHV@;SINGLE-NUCLEOTIDE POLYMORPHISM;DNA METHYLATION;DNA MISMATCH REPAIR;EPIRUBICIN;ESTROGEN RECEPTOR;GENE EXPRESSION PROFILING;GERMLINE MUTATION;PENETRANCE;TAMOXIFEN;ADOPTIVE CELL TRANSFER;ANTIRETROVIRAL THERAPY;CAPECITABINE;CD38;CTL*;GLYCEMIC INDEX;IFOSFAMIDE;INTERNATIONAL PROGNOSTIC INDEX;INTRAOPERATIVE RADIOTHERAPY;KARYOTYPE;MARGINAL ZONE;MASTECTOMY;METASTATIC BREAST CANCER;SELECTED REACTION MONITORING;TRASTUZUMAB;VINCRISTINE","8;6;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MIDDLE AGED;ADULT;BREAST NEOPLASMS;MALE;AGED;;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASMS;FLUOROURACIL;ANTINEOPLASTIC AGENTS;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;CASE-CONTROL STUDIES;AGED, 80 AND OVER;HIV INFECTIONS;RISK FACTORS;BIOMARKERS, TUMOR;MOUTH NEOPLASMS","119;80;65;60;54;54;53;47;45;32;28;26;25;24;23;21;20;20;19;19","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;MOLECULAR RESEARCH ON BREAST CANCER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HEPATITIS C INFECTION AND TREATMENT;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GLIOMAS;IMMUNOBIOLOGY OF DENDRITIC CELLS;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA","19;17;6;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2","REGIMEN;BREAST CANCER;CANCER INCIDENCE;CANCER RISK;IGHV@;RADIOTHERAPY;B-CELL RECEPTOR SIGNALING;CANCER;ETIOLOGY;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE;BRCA1;CANCER SUSCEPTIBILITY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CANCER EPIGENETICS;CHEMOTHERAPY REGIMEN;HEALTHY EATING INDEX;TOLERABILITY;TREATMENT;TUMOR MICROENVIRONMENT;BRCA2","11;10;9;9;8;8;7;7;6;6;5;5;4;4;4;4;4;4;4;3","BREAST CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;STEM CELL;CANCER PATIENTS;CANCER RISK;ACTIVE ANTIRETROVIRAL;CASECONTROL STUDY;HIGHLY ACTIVE;ANTIRETROVIRAL THERAPY;BODY MASS;COLORECTAL CANCER;ENDOMETRIAL CANCER;HIV INFECTION;MASS INDEX;PANCREATIC CANCER;VIRUS INFECTION;AERODIGESTIVE TRACT;AUTOLOGOUS STEM;BRCA-ASSOCIATED BREAST;CASE-CONTROL STUDY;CELL TRANSPLANTATION;COMMON GENETIC;GENETIC VARIANTS;ITALIAN ASSOCIATION;ITALIAN STUDY;MASS SPECTROMETRY;METABOLIC SYNDROME;NON-HODGKINS LYMPHOMAS;PATIENTS TREATED","19;13;11;7;6;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;CANCER RISK;BRCA MUTATION;INTRAOPERATIVE RADIOTHERAPY;ODDS RATIOS;TARGETED INTRAOPERATIVE;EXTERNAL BEAM;MUTATION CARRIERS;BEAM RADIOTHERAPY;CELL LINES;CONFIDENCE INTERVAL;HR CI;CELL CYCLE;COLORECTAL CANCER;CONFIDENCE INTERVALS;HAZARD RATIO;HIV DNA;LUNG CANCER;ASCT COHORT;HIV-POSITIVE WOMEN;ODDS RATIO;STEM CELL;ALLELE HR;CAPSULE ENDOSCOPY;CHEMO COHORT;CI -P;DNA LEVELS;ENDOCRINE THERAPY;EXTRACELLULAR MATRIX;HIGHLY ACTIVE","44;22;15;14;13;13;11;11;10;9;9;9;8;8;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6",25,0.15,6,3,2.5,3.25,1,1,3,0,2,3,0,1,2,0,8,1,1,2,1,0,0,62,62,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,5,0.93,3,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALDINUCCI DONATELLA;DOU Q PING;FORMAGGIO FERNANDO;FREGONA DOLORES;RONCONI LUCA","1;1;1;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITA DEGLI STUDI DI PADOVA;WAYNE STATE UNIVERSITY","1;1;1","34 CHEMICAL SCIENCES;41 ENVIRONMENTAL SCIENCES;3402 INORGANIC CHEMISTRY;4102 ECOLOGICAL APPLICATIONS","2;2;1;1","CANCER","1",NA,NA,"A61K38/05;A61K38/06;A61K38/08;A61P35/00;C07K5/062;C07K5/065;C07K5/083;C07K7/06","1;1;1;1;1;1;1;1","A61K31/555;A61P35/00;C07K5/06026;C07K5/0806","1;1;1;1",15,6.83,742.92,6.82,4,0.27,40.6,0,0,7,0,5,0,0,3,0,10,2,0,0,0,0,0,0,11,4,0,12,3,0,0,0,0,0,0,0,0,"Germany;Italy;United Kingdom","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","15;15;6;3;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;KIDNEY DISEASE;LYMPHOMA;ORPHAN DRUG;PATIENT SAFETY;PREVENTION;STEM CELL RESEARCH;TRANSPLANTATION;AGING;BIOTECHNOLOGY;BREAST CANCER;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;GENETIC TESTING;GENETICS","11;10;10;7;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER","14","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","11;2;2;1;1;1","KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;BREAST CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LIVER CANCER;LUNG CANCER;SARCOMA;STOMACH CANCER","3;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","11;3;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH","3;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;4203 HEALTH SERVICES AND SYSTEMS","7;4;3;3;2;1;1","CANCER;GENETICS;BREAST CANCER;PREVENTION;CHILDHOOD LEUKEMIA;CLINICAL RESEARCH;HEMATOLOGY;HUMAN GENOME;PEDIATRIC;PEDIATRIC CANCER;RARE DISEASES","3;3;2;2;1;1;1;1;1;1;1","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE","3","BREAST CANCER;LEUKEMIA / LEUKAEMIA","2;1",NA,NA
"IRCCS_CRO",2011,178,15.0955056179775,3.03932584269663,0.370786516853933,0.297752808988764,0.466292134831461,2.38325991189427,1.22222222222222,1.51428571428571,1.40677966101695,0.471910112359551,1,109,36,20,6,0.61,0.2,0.11,0.03,45.39,1.06708360886761,NA,0.48876404494382,0.938202247191011,0.495,0.427,0.481,0.423,"RENATO TALAMINI;VALTER GATTEI;GIANLUCA GAÏDANO;DAVIDE ROSSI;CARLO LA VECCHIA;FRANCESCO BERTONI;RICCARDO DOLCETTI;SILVIA FRANCESCHI;FRANCESCO FORCONI;DIEGO SERRAINO;TIZIANA PERIN;JERRY POLESEL;EVA NEGRI;VINCENZO CANZONIERI;ANTONINO CARBONE;ROBERTO MARASCA;MICHELE SPINA;ANTONELLA ZUCCHETTO;GIOVANNI DEL POETA;PIETRO BULIAN","25;21;20;16;16;13;12;12;12;10;10;10;10;9;9;9;9;8;8;8","RENATO TALAMINI;CARLO LA VECCHIA;CHIARA LESTUZZI;ANTONINO CARBONE;DIEGO SERRAINO;SILVIA FRANCESCHI;VALTER GATTEI;RICCARDO DOLCETTI;VINCENZO CANZONIERI;TIZIANA PERIN;GIANLUCA GAÏDANO;EVA NEGRI;VALLÌ DE RE;JERRY POLESEL;SAMUELE MASSARUT;DAVIDE ROSSI;M. TROVÒ;MARIA ANTONIETTA ANNUNZIATA;ALFONSO COLOMBATTI;GIUSEPPE TOFFOLI","2.28;1.5;1.48;1.45;1.31;1.28;1.22;1.18;1.15;1.11;1.09;1.03;1.03;0.93;0.88;0.83;0.79;0.77;0.73;0.72","RENATO TALAMINI;VALTER GATTEI;RICCARDO DOLCETTI;DIEGO SERRAINO;TIZIANA PERIN;JERRY POLESEL;VINCENZO CANZONIERI;ANTONINO CARBONE;MICHELE SPINA;ANTONELLA ZUCCHETTO;PIETRO BULIAN;M. TROVÒ;DIANA CRIVELLARI;VALLÌ DE RE;GIANMARIA MIOLO;SAMUELE MASSARUT;GIOVANNI FRANCHIN;ALFONSO COLOMBATTI;EMANUELA VACCHER;ANTONINO DE PAOLI","25;21;12;10;10;10;9;9;9;8;8;8;8;7;7;7;7;6;6;6","RENATO TALAMINI;CHIARA LESTUZZI;ANTONINO CARBONE;DIEGO SERRAINO;VALTER GATTEI;RICCARDO DOLCETTI;VINCENZO CANZONIERI;TIZIANA PERIN;VALLÌ DE RE;JERRY POLESEL;SAMUELE MASSARUT;M. TROVÒ;MARIA ANTONIETTA ANNUNZIATA;ALFONSO COLOMBATTI;GIUSEPPE TOFFOLI;LAURA CAGGIARI;GIANMARIA MIOLO;GIOVANNI FRANCHIN;MICHELE SPINA;EMANUELA VACCHER","2.28;1.48;1.45;1.31;1.22;1.18;1.15;1.11;1.03;0.93;0.88;0.79;0.77;0.73;0.72;0.7;0.69;0.68;0.66;0.65","GIANLUCA GAÏDANO;VALTER GATTEI;DAVIDE ROSSI;FRANCESCO FORCONI;ROBIN FOÀ;SILVIA RASI;FRANCESCO BERTONI;ROBERTO MARASCA;ANNA GUARINI;LUCA LAURENTI;MARCO FANGAZIO;LAURA PASQUALUCCI;RAÚL RABADÁN;RICCARDO DALLA‐FAVERA;STEFANIA CRESTA;SARA MONTI;VALERIA SPINA;DANIELA CAPELLO;GIULIA FABBRI;RENATO TALAMINI","1979;1959;1921;1921;1830;1784;1542;1512;1483;1467;1437;1407;1406;1406;1406;1387;1240;1085;1028;984","VALTER GATTEI;RENATO TALAMINI;PIERGIORGIO MODENA;ANDREA VERONESI;PIETRO BULIAN;JERRY POLESEL;ALESSANDRA VIEL;ALESSIA COVRE;ELISABETTA FRATTA;FRANCESCA COLIZZI;GIULIA PARISI;LUCA SIGALOTTI;MICHELE MAIO;SANDRA CORAL;DIEGO SERRAINO;HUGUES J. M. NICOLAY;RICCARDO DANIELLI;RICCARDO DOLCETTI;LUIGINO DAL MASO;MARIA PINA SIMULA","1959;978;782;642;557;469;390;371;371;371;371;371;371;371;338;316;316;280;247;236","RENATO TALAMINI;VALTER GATTEI;ANTONELLA ZUCCHETTO;TIZIANA PERIN;JERRY POLESEL;DIEGO SERRAINO;RICCARDO DOLCETTI;VINCENZO CANZONIERI;ANTONINO CARBONE;DIANA CRIVELLARI;PIETRO BULIAN;MICHELE SPINA;VALLÌ DE RE;GIOVANNI FRANCHIN;GIANMARIA MIOLO;ALESSANDRA VIEL;M. TROVÒ;SAMUELE MASSARUT;CHIARA LESTUZZI;ELISA PASINI","25;21;12;10;10;10;10;9;8;8;8;8;7;7;7;6;6;6;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;POLITICAL SCIENCE;MATHEMATICS;GEOGRAPHY;PHILOSOPHY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE","149;74;9;9;7;6;6;5;5;4;3;3;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;IMMUNOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;RADIOLOGY;PALEONTOLOGY;CELL BIOLOGY;GYNECOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;GENERAL SURGERY;UROLOGY;ECOLOGY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;VIROLOGY","119;69;43;43;41;35;28;22;21;16;14;12;11;10;7;7;6;6;5;5;5;5","CANCER;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;LEUKEMIA;LYMPHOMA;ANTIBODY;ODDS RATIO;RADIATION THERAPY;POPULATION;ANTIGEN;CASE-CONTROL STUDY;LOGISTIC REGRESSION;DISEASE;IMMUNE SYSTEM;STAGE (STRATIGRAPHY);RECEPTOR;CLINICAL TRIAL;REGIMEN;MULTIVARIATE ANALYSIS;RISK FACTOR;STEM CELL;TOXICITY","83;40;27;23;22;21;19;19;19;17;11;11;11;10;9;9;8;7;7;6;6;6;6","BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;GENOTYPE;B CELL;HAZARD RATIO;MUTATION;CYCLOPHOSPHAMIDE;PANCREATIC CANCER;DIFFUSE LARGE B-CELL LYMPHOMA;FOLLICULAR LYMPHOMA;HEAD AND NECK CANCER;IMMUNOTHERAPY;UNIVARIATE ANALYSIS;CD34;CD8;CELL CYCLE;CHEMORADIOTHERAPY;CISPLATIN;GENE EXPRESSION;METASTASIS;MICRORNA;MONOCLONAL ANTIBODY;NEUTROPENIA;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;T CELL","33;22;11;10;8;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","SINGLE-NUCLEOTIDE POLYMORPHISM;TRASTUZUMAB;IGHV@;CD38;CTL*;DNA METHYLATION;ESTROGEN RECEPTOR;FLUDARABINE;MASTECTOMY;MISSENSE MUTATION;CAPECITABINE;CARBOPLATIN;CYCLIN D1;EPITHELIAL–MESENCHYMAL TRANSITION;EXTERNAL BEAM RADIOTHERAPY;HAPLOTYPE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HPV INFECTION;MAMMOGRAPHY;MARGINAL ZONE;METASTATIC BREAST CANCER;NATIONAL LUNG SCREENING TRIAL;OXALIPLATIN;PENETRANCE;PROSTATE-SPECIFIC ANTIGEN;TAMOXIFEN;VASOACTIVE INTESTINAL PEPTIDE","7;6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;BREAST NEOPLASMS;MIDDLE AGED;AGED;ADULT;MALE;;ITALY;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;NEOPLASMS;RISK FACTORS;CASE-CONTROL STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;PROGNOSIS;MUTATION;YOUNG ADULT","122;90;75;74;65;63;58;53;43;28;24;23;23;23;20;19;19;18;17;16","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;MOLECULAR RESEARCH ON BREAST CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;IMMUNOBIOLOGY OF DENDRITIC CELLS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;PANCREATIC CANCER RESEARCH AND TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;GLIOMAS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;IMPACT OF HEALTH LITERACY ON HEALTH OUTCOMES;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH","20;10;7;5;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2","BREAST CANCER;RADIOTHERAPY;CANCER RISK;REGIMEN;FOLLICULAR LYMPHOMA;IGHV@;UNIVARIATE ANALYSIS;ANTIGEN PRESENTATION;BRCA1;CANCER INCIDENCE;CANCER SUSCEPTIBILITY;CANCER THERAPY;CHEMORADIOTHERAPY;NEOADJUVANT THERAPY;PANCREATIC CANCER;TP53 MUTATION;TRASTUZUMAB;TREATMENT RESPONSE;B-CELL RECEPTOR SIGNALING;CANCER","15;9;8;7;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3","BREAST CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;CANCER PATIENTS;CANCER RISK;PANCREATIC CANCER;LOCALLY ADVANCED;OVARIAN CANCER;PHASE II;B-CELL LYMPHOMA;CASECONTROL STUDY;PROSTATE CANCER;RICHTER SYNDROME;ADJUVANT CHEMOTHERAPY;II STUDY;ITALIAN EXPERIENCE;LUNG CANCER;NEOADJUVANT CHEMOTHERAPY;RECTAL CANCER;RETROSPECTIVE STUDY;ACCESS LAPAROSCOPIC;ADVANCED BREAST;BRCA MUTATION;BREAST IRRADIATION;CANCER IMPLICATIONS;CANCER INFORMATION;CELIAC DISEASE;CELL LINES;CLINICAL OUTCOME;CLL CELLS","24;13;12;7;7;7;5;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;SITU FL;OVERT FL;CANCER RISK;PANCREATIC CANCER;LYMPH NODE;MUTATION CARRIERS;BRCA MUTATION;HR CI;ODDS RATIOS;CHRONIC LYMPHOCYTIC;DISEASE-FREE SURVIVAL;CLONALLY RELATED;CONFIDENCE INTERVAL;LYMPHOCYTIC LEUKEMIA;MEDIAN FOLLOW-UP;OVERT LYMPHOMA;RECTAL CANCER;CANCER PATIENTS;CONFIDENCE INTERVALS;EMAIL PROTECTED;FOLLICULAR LYMPHOMA;NECK CANCER;NOTCH MUTATIONS;BRCA CARRIERS;CD CD;INDOLENT NHL;ORIGINAL MAGNIFICATION;PUBMED SCOPUS;RATIOS ORS","53;47;22;20;20;19;19;16;13;13;12;11;10;10;10;10;10;10;9;9;9;9;9;9;8;8;8;8;8;8",46,0.26,10.89,4,8,1,1,3,7.25,1,1.25,4,0,1,3,0,1,0,1.25,2,1,0,0,109,104,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,7.89,676.5,5.45,3,0.25,94.83,0,0,7,0,4,0,0,1,0,9,1,0,0,0,0,0,0,12,0,0,10,2,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","12;11;4;3;1;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;HEMATOLOGY;LYMPHOMA;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;LUNG CANCER;AGING;BREAST CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;GENETICS;HIV/AIDS;INFECTIOUS DISEASES;ORPHAN DRUG;PATIENT SAFETY;PEDIATRIC","10;9;8;5;5;4;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","9;2","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","9;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;LIVER CANCER;SARCOMA;STOMACH CANCER","6;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","9;1",1,2979700,1489850,6,2,1,1,40,248308.333333333,0.716850689666745,"CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITY OF UDINE","1;1","EUROPEAN RESEARCH COUNCIL","1","EC & ERC - EUROPEAN UNION","1","ERC-2010-ADG_20100317 (CALL FOR PROPOSAL);ERC-AG - ERC ADVANCED GRANT (FUNDING SCHEME);FP7-IDEAS-ERC - SPECIFIC PROGRAMME: ""IDEAS"" IMPLEMENTING THE SEVENTH FRAMEWORK PROGRAMME OF THE EUROPEAN COMMUNITY FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ACTIVITIES (2007 TO 2013) (PROGRAMME)","1;1;1","34 CHEMICAL SCIENCES;40 ENGINEERING;4018 NANOTECHNOLOGY","1;1;1","BIOENGINEERING;BIOTECHNOLOGY;CANCER;NANOTECHNOLOGY","1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1",NA,NA,"NOT SITE-SPECIFIC CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,17,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","12;5","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3204 IMMUNOLOGY;4202 EPIDEMIOLOGY;49 MATHEMATICAL SCIENCES;4905 STATISTICS","23;14;10;8;6;4;2;1;1;1;1;1;1","CANCER;GENETICS;BREAST CANCER;DIGESTIVE DISEASES;HUMAN GENOME;ALCOHOLISM, ALCOHOL USE AND HEALTH;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;IMMUNIZATION;INFECTIOUS DISEASES;LIVER DISEASE;PREVENTION;RARE DISEASES;STEM CELL RESEARCH;SUBSTANCE MISUSE;VACCINE RELATED","7;6;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;GENERIC HEALTH RELEVANCE","11;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS","4;1;1","BIOMEDICAL","3","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","4;4","BREAST CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;PHARYNGEAL CANCER","8;2;2;1;1;1;1",NA,NA
"IRCCS_CRO",2012,227,11.4625550660793,3.46255506607929,0.449339207048458,0.392070484581498,0.709251101321586,2.07671957671958,1.24390243902439,1.85416666666667,1.64285714285714,0.431718061674009,4,135,29,24,25,0.59,0.13,0.11,0.11,54.26,1.29917358223474,6.1671207992734,0.422907488986784,0.86784140969163,0.521,0.437,0.476,0.454,"GIANLUCA GAÏDANO;RENATO TALAMINI;VALTER GATTEI;UMBERTO TIRELLI;DAVIDE ROSSI;JERRY POLESEL;VINCENZO CANZONIERI;GIOVANNI DEL POETA;RICCARDO DOLCETTI;MASSIMILIANO BERRETTA;VALLÌ DE RE;DIEGO SERRAINO;MICHELE DAL BO;PIETRO BULIAN;MICHELE SPINA;RICCARDO BOMBEN;ANDREA VERONESI;SILVIA FRANCESCHI;GIANMARIA MIOLO;CARLO LA VECCHIA","18;18;17;15;14;13;12;12;12;12;10;10;9;9;9;9;8;8;8;8","MARIA ANTONIETTA ANNUNZIATA;BARBARA MUZZATTI;LINO DEL PUP;MASSIMILIANO BERRETTA;UMBERTO TIRELLI;RENATO TALAMINI;VINCENZO CANZONIERI;DIEGO SERRAINO;JERRY POLESEL;LILIANA MEREU;RICCARDO DOLCETTI;ETTORE BIDOLI;LUCA MENCAGLIA;VALLÌ DE RE;VALTER GATTEI;GIANLUCA GAÏDANO;ANDREA VERONESI;PIERO CAPPELLETTI;ALESSIO FRANCESCHI;GIORGIO PAESANI","2.6;2.5;2.02;1.83;1.68;1.57;1.43;1.37;1.3;1.24;1.19;1.16;1.13;1.09;1.08;1.05;1.05;1;1;1","RENATO TALAMINI;VALTER GATTEI;UMBERTO TIRELLI;JERRY POLESEL;VINCENZO CANZONIERI;RICCARDO DOLCETTI;MASSIMILIANO BERRETTA;VALLÌ DE RE;DIEGO SERRAINO;MICHELE DAL BO;PIETRO BULIAN;MICHELE SPINA;RICCARDO BOMBEN;ANDREA VERONESI;GIANMARIA MIOLO;CARLO LA VECCHIA;MARCO TROVÒ;ALFONSO COLOMBATTI;ANTONELLA ZUCCHETTO;FRANCESCA MARIA ROSSI","18;17;15;13;12;12;12;10;10;9;9;9;9;8;8;8;7;7;7;7","MARIA ANTONIETTA ANNUNZIATA;BARBARA MUZZATTI;LINO DEL PUP;MASSIMILIANO BERRETTA;UMBERTO TIRELLI;RENATO TALAMINI;VINCENZO CANZONIERI;DIEGO SERRAINO;JERRY POLESEL;LILIANA MEREU;RICCARDO DOLCETTI;ETTORE BIDOLI;LUCA MENCAGLIA;VALLÌ DE RE;VALTER GATTEI;ANDREA VERONESI;PIERO CAPPELLETTI;ALESSIO FRANCESCHI;GIORGIO PAESANI;E CAMPAGNUTTA","2.6;2.5;2.02;1.83;1.68;1.57;1.43;1.37;1.3;1.24;1.19;1.16;1.13;1.09;1.08;1.05;1;1;1;0.97","ALESSANDRA BEARZ;MICHÈLE MILELLA;A. VERGNENÈGRE;ALFONSO ILLIANO;AMELIA INSA;ANA DROZDOWSKYJ;BARTOMEU MASSUTÍ;CHRISTIAN ROLFO;CINTA PALLARÉS;CRISTINA QUERALT;DELVYS RODRÍGUEZ‐ABREU;DOLORES ISLA;ENRIC CARCERENY;ENRICO CORTESI;ENRIQUETA FELIP;FILIPPO DE MARINIS;FLAVIA LONGO;G. ROBINET;GIUSEPPE ALTAVILLA;GUILLERMO LÓPEZ-VIVANCO","5238;5165;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141;5141","ALESSANDRA BEARZ;VALTER GATTEI;JERRY POLESEL;MICHELE DAL BO;RENATO TALAMINI;PIETRO BULIAN;FRANCESCA MARIA ROSSI;ANTONELLA ZUCCHETTO;RICCARDO DOLCETTI;MARCELLA MONTICO;DIEGO SERRAINO;S. FRUSTACI;ROBERTO SORIO;S. MAIERO;ANTONINO DE PAOLI;ALFONSO COLOMBATTI;M. LISE;ROBERTA MAESTRO;MASSIMILIANO BERRETTA;ELISA PASINI","5238;1318;684;608;574;539;469;439;438;343;336;336;307;266;254;240;232;216;207;181","RENATO TALAMINI;VALTER GATTEI;JERRY POLESEL;UMBERTO TIRELLI;RICCARDO DOLCETTI;MASSIMILIANO BERRETTA;ANTONELLA ZUCCHETTO;VALLÌ DE RE;VINCENZO CANZONIERI;PIETRO BULIAN;RICCARDO BOMBEN;DIEGO SERRAINO;MICHELE DAL BO;ETTORE BIDOLI;GIUSEPPE TOFFOLI;ANTONINO CARBONE;LUCA MENCAGLIA;MARCO TROVÒ;MARIA ANTONIETTA ANNUNZIATA;ALFONSO COLOMBATTI","17;16;13;13;12;11;11;10;10;9;9;9;9;7;7;7;7;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;MATHEMATICS;SOCIOLOGY;PHILOSOPHY;ECONOMICS;MATERIALS SCIENCE;GEOGRAPHY;POLITICAL SCIENCE;BUSINESS;HISTORY","186;107;22;21;14;10;9;8;8;7;6;5;4;4;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;GENETICS;PATHOLOGY;IMMUNOLOGY;SURGERY;CELL BIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;RADIOLOGY;PALEONTOLOGY;MOLECULAR BIOLOGY;GYNECOLOGY;PHARMACOLOGY;PSYCHIATRY;ENDOCRINOLOGY;OPTICS;BIOINFORMATICS;CLINICAL PSYCHOLOGY;NUCLEAR MEDICINE","153;73;57;54;46;40;40;31;27;24;23;20;16;13;12;12;12;10;10;8;8;8","CANCER;GENE;CHEMOTHERAPY;POPULATION;LYMPHOMA;DISEASE;RADIATION THERAPY;CONFIDENCE INTERVAL;LEUKEMIA;IMMUNOHISTOCHEMISTRY;LUNG CANCER;ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);IN VITRO;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;ANTIBODY;APOPTOSIS;CLINICAL TRIAL;RECEPTOR","98;48;37;22;19;18;18;15;14;11;11;11;11;10;9;9;9;8;8;8;8","BREAST CANCER;COLORECTAL CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;MUTATION;GENE EXPRESSION;HAZARD RATIO;CELL CYCLE;CISPLATIN;CLINICAL ENDPOINT;EPIDERMAL GROWTH FACTOR RECEPTOR;OVARIAN CANCER;CHROMOSOME;GENOTYPE;PROSTATE CANCER;TOMOTHERAPY;ALLELE;EJECTION FRACTION;METASTASIS;SALVAGE THERAPY;ADENOCARCINOMA;B CELL;CANCER CELL;CERVICAL CANCER;CYTOTOXICITY;DIFFUSE LARGE B-CELL LYMPHOMA;DOCETAXEL;FLUOROURACIL;HEPATITIS C VIRUS;PI3K/AKT/MTOR PATHWAY;PLACEBO;PROTEIN KINASE B;RITUXIMAB;SUPPRESSOR","28;25;14;13;11;10;9;9;8;8;8;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","GERMLINE MUTATION;TRASTUZUMAB;DNA METHYLATION;IGHV@;METASTATIC BREAST CANCER;FLUORESCENCE IN SITU HYBRIDIZATION;KRAS;CAPECITABINE;CRYOGLOBULINEMIA;CYCLIN-DEPENDENT KINASE;DNA MISMATCH REPAIR;ERLOTINIB;FAMILIAL ADENOMATOUS POLYPOSIS;FRAMESHIFT MUTATION;GEFITINIB;LASER CAPTURE MICRODISSECTION;MICROARRAY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;THYMIDYLATE SYNTHASE;ADENOMATOUS POLYPOSIS COLI;ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;COLONOSCOPY;CTL*;CYCLIN;E2F;EPITHELIAL–MESENCHYMAL TRANSITION;ESTROGEN RECEPTOR;EXTRAPLEURAL PNEUMONECTOMY;GENOME INSTABILITY;GENOTYPING;INTERNATIONAL PROGNOSTIC INDEX;KARYOTYPE;LYMPHOVASCULAR INVASION;MARGINAL ZONE;MASTECTOMY;MISSENSE MUTATION;ONCOGENE;OXALIPLATIN;PEMETREXED;PHARMACOGENETICS;PIN1;PLEURECTOMY;RETINOBLASTOMA PROTEIN;TAXANE","7;7;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;;MIDDLE AGED;MALE;AGED;ADULT;NEOPLASMS;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;LUNG NEOPLASMS;ANTINEOPLASTIC AGENTS;BIOMARKERS, TUMOR;AGED, 80 AND OVER;CARCINOMA, NON-SMALL-CELL LUNG;COLORECTAL NEOPLASMS;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;CARCINOMA, SQUAMOUS CELL;FLUOROURACIL","136;89;86;75;69;63;62;49;45;36;34;31;28;27;24;24;23;23;19;19","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;HER2 SIGNALING IN BREAST CANCER TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER SURVIVORSHIP AND QUALITY OF LIFE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HEPATITIS C INFECTION AND TREATMENT;SARCOMA RESEARCH AND TREATMENT;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MASS SPECTROMETRY TECHNIQUES WITH PROTEINS;NATURAL KILLER CELLS IN IMMUNITY;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;RADIOTHERAPY PHYSICS AND TECHNOLOGY","15;8;7;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3","BREAST CANCER;CANCER INCIDENCE;CLINICAL ENDPOINT;CANCER RISK;RADIOTHERAPY;REGIMEN;TRASTUZUMAB;TOMOTHERAPY;BIOMARKER ANALYSIS;CONCOMITANT;IGHV@;MUTYH;SALVAGE THERAPY;SOFT TISSUE SARCOMA;TUMOR REGRESSION;B CELL ABNORMALITIES;CANCER REGISTRY DATA;CANCER SURVIVORSHIP;CANCER THERAPY;DNA METHYLATION","10;10;9;8;8;7;7;6;5;5;5;5;5;5;5;4;4;4;4;4","BREAST CANCER;CANCER PATIENTS;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;LUNG CANCER;OVARIAN CANCER;PHASE II;RADIATION THERAPY;COLORECTAL CANCER;CANCER RISK;CELL LUNG;FINAL RESULTS;HEPATOCELLULAR CARCINOMA;II TRIAL;NON-SMALL CELL;PATIENTS PTS;ADJUVANT TRASTUZUMAB;CANCER CELLS;ESOPHAGEAL CARCINOMA;HUMAN LEUKOCYTE;LEUKOCYTE ANTIGEN;LYMPHOMA PATIENTS;MARGINAL ZONE;METASTATIC BREAST;OPERATIVE HYSTEROSCOPY;PROSTATE CANCER;PSYCHOLOGICAL DISTRESS;SALVAGE TREATMENT;SOFT TISSUE;ACTIVATION MAPPING","17;16;11;10;7;6;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2","SALIVARY GLAND;FIDUCIAL MARKERS;PLEOMORPHIC ADENOMA;MM SD;SD MM;GROWTH FACTOR;SALIVARY GLANDS;BREAST CANCER;FACTOR RECEPTOR;NGAL EXPRESSION;BONY LANDMARKS;COLORECTAL CANCER;EPIDERMAL GROWTH;HEPATOCELLULAR CARCINOMA;NORMAL SALIVARY;CANCER CELLS;DPPIV ACTIVITY;CHOI CRITERIA;MM NA;MM RANGE;SHIFTS OBTAINED;STATISTICALLY SIGNIFICANT;SUPERIORINFERIOR LATERAL;CD LYMPHOCYTES;GENETIC LESIONS;INTERCALATED DUCT;NEOPLASTIC CELLS;ONCOGENE HOMOLOG;PARAFFIN EMBEDDED;PLEOMORPHIC ADENOMAS","24;20;20;18;18;16;16;15;14;14;12;12;12;12;12;11;10;9;9;9;9;9;9;8;8;8;8;8;8;8",60,0.26,6.12,4,1.5,1,0,3,4.75,1,1,4.25,0,1,3,1.75,2.25,1,1.5,2,1,0,0,67.5,67.5,4,0,2,1,0,2,0,0,0,0,0,0,3,2,0,1,4.2,2.68,2.4,0,4,4,0,0,2,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALDINUCCI DONATELLA;DE MARCO LUIGINO;DOU Q PING;FORMAGGIO FERNANDO;FREGONA DOLORES;MAZZUCATO MARIO;RONCONI LUCA;STEFFAN AGOSTINO;ALDINUCCI, DONATELLA;DOU, Q. PING","2;2;2;2;2;2;2;2;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITA DEGLI STUDI DI PADOVA;SEDICIDODICI SRL;WAYNE STATE UNIVERSITY;CT DI RIFERIMENTO ONCOLOGICO","4;3;2;2;1","34 CHEMICAL SCIENCES;41 ENVIRONMENTAL SCIENCES;3402 INORGANIC CHEMISTRY;4102 ECOLOGICAL APPLICATIONS;3403 MACROMOLECULAR AND MATERIALS CHEMISTRY;40 ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING","8;6;3;3;1;1;1","CANCER;CARDIOVASCULAR;BRAIN DISORDERS","3;2;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","A61P35/00;A61K31/555;A61K38/03;C07K1/14;C07K4/00;C07K5/083;C07K7/06;G01N33/49;G01N33/86;A61K31/28","3;2;2;2;2;2;2;2;2;1","A61K31/555;A61P35/00;C07K5/06026;C07K5/0806;C07K5/6026;C07K5/806;G01N33/4905","3;2;2;2;1;1;1",14,7.15,350.69,3.97,5,0.36,70.43,0,0,6,0,4,0,1,3,0,13,0,0,0,0,0,0,0,13,1,0,13,1,0,0,0,0,0,0,0,0,"Italy;United States;Belgium","2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","14;12;6;5;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY;DIGESTIVE DISEASES;GENETICS;LUNG;AGING;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;HEALTH SERVICES;HODGKIN'S DISEASE;HUMAN GENOME;INFLAMMATORY BOWEL DISEASE;LIVER CANCER;LIVER DISEASE","13;12;10;10;6;6;3;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL","9;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.2 END OF LIFE CARE","9;3;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;HODGKIN'S DISEASE;LIVER CANCER;OVARIAN CANCER;PANCREATIC CANCER;SARCOMA","6;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.6 END-OF-LIFE CARE","9;2;2;1;1;1;1",1,75000,75000,4,1,1,0,2,267058.333333333,0.850001560208444,"CENTRO DI RIFERIMENTO ONCOLOGICO","1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP7-PEOPLE - SPECIFIC PROGRAMME ""PEOPLE"" IMPLEMENTING THE SEVENTH FRAMEWORK PROGRAMME OF THE EUROPEAN COMMUNITY FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ACTIVITIES (2007 TO 2013) (PROGRAMME);FP7-PEOPLE-2011-CIG (CALL FOR PROPOSAL);MC-CIG - SUPPORT FOR TRAINING AND CAREER DEVELOPMENT OF RESEARCHER (CIG) (FUNDING SCHEME)","1;1;1","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1;1","BIOTECHNOLOGY;CANCER;DIGESTIVE DISEASES;GENETICS","1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","COLON AND RECTAL CANCER","1","1.4 CANCER PROGRESSION AND METASTASIS","1","A01 CLINICAL MEDICINE","1",NA,NA,8,"PUBLIC LIBRARY OF SCIENCE","8","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4202 EPIDEMIOLOGY;3105 GENETICS;3204 IMMUNOLOGY","9;6;4;3;3;2;2","CANCER;PREVENTION;GENETICS;BIOTECHNOLOGY;CLINICAL RESEARCH;RARE DISEASES;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;HEPATITIS;HEPATITIS - C;HIV/AIDS;HUMAN GENOME;INFECTIOUS DISEASES;LIVER DISEASE;LUNG;LUNG CANCER;LYMPHOMA;STEM CELL RESEARCH","6;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","BIOMEDICAL","3","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","2;2","SARCOMA;LUNG CANCER;BLADDER CANCER;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER","3;2;1;1;1",NA,NA
"IRCCS_CRO",2013,195,12.1282051282051,3.02564102564103,0.364102564102564,0.292307692307692,0.435897435897436,2.00680272108844,1.16393442622951,1.29545454545455,1.28787878787879,0.502564102564103,4,112,40,19,16,0.57,0.21,0.1,0.08,38.23,1.09567094221689,6.26345840130507,0.461538461538462,0.882051282051282,0.479,0.442,0.488,0.431,"JERRY POLESEL;RENATO TALAMINI;CARLO LA VECCHIA;DIEGO SERRAINO;VALTER GATTEI;EVA NEGRI;ALESSANDRA BEARZ;SILVIA FRANCESCHI;SAMUELE MASSARUT;DAVIDE ROSSI;ANTONELLA ZUCCHETTO;VINCENZO CANZONIERI;LUIGINO DAL MASO;GIANLUCA GAÏDANO;CRISTINA BOSETTI;MARCO TROVÒ;CHIARA LESTUZZI;TIZIANA PERIN;ALFONSO COLOMBATTI;ANTONELLA ZUCCHETTO","19;19;15;12;12;12;10;10;10;9;9;8;8;8;8;7;7;7;6;6","JERRY POLESEL;RENATO TALAMINI;CARLO LA VECCHIA;GIUSEPPE TOFFOLI;MARIA ANTONIETTA ANNUNZIATA;MASSIMILIANO BERRETTA;ROBERTO BORTOLUS;BARBARA MUZZATTI;DIEGO SERRAINO;ALESSANDRA BEARZ;EVA NEGRI;SAMUELE MASSARUT;ELIANA PIVETTA ALFONSO COLOMBATTI;LINO DEL PUP;ETTORE BIDOLI;ANTONELLA ZUCCHETTO;MARCO TROVÒ;SILVIA FRANCESCHI;CHIARA LESTUZZI;TIZIANA PERIN","1.8;1.75;1.26;1.25;1.22;1.12;1.1;1.09;1.08;1.03;1.03;1.03;1;1;0.92;0.86;0.85;0.84;0.81;0.81","JERRY POLESEL;RENATO TALAMINI;DIEGO SERRAINO;VALTER GATTEI;ALESSANDRA BEARZ;SAMUELE MASSARUT;ANTONELLA ZUCCHETTO;VINCENZO CANZONIERI;LUIGINO DAL MASO;MARCO TROVÒ;CHIARA LESTUZZI;TIZIANA PERIN;ALFONSO COLOMBATTI;ANTONELLA ZUCCHETTO;M. TROVÒ;MARIA ANTONIETTA ANNUNZIATA;MASSIMILIANO BERRETTA;GIORGIO GIORDA;GIOVANNI FRANCHIN;MICHELE MAIO","19;19;12;12;10;10;9;8;8;7;7;7;6;6;6;6;6;6;6;5","JERRY POLESEL;RENATO TALAMINI;GIUSEPPE TOFFOLI;MARIA ANTONIETTA ANNUNZIATA;MASSIMILIANO BERRETTA;ROBERTO BORTOLUS;BARBARA MUZZATTI;DIEGO SERRAINO;ALESSANDRA BEARZ;SAMUELE MASSARUT;ELIANA PIVETTA ALFONSO COLOMBATTI;LINO DEL PUP;ETTORE BIDOLI;ANTONELLA ZUCCHETTO;MARCO TROVÒ;CHIARA LESTUZZI;TIZIANA PERIN;VINCENZO CANZONIERI;M. CIMITAN;M. TROVÒ","1.8;1.75;1.25;1.22;1.12;1.1;1.09;1.08;1.03;1.03;1;1;0.92;0.86;0.85;0.81;0.81;0.78;0.75;0.71","SAMUELE MASSARUT;ALAN S. COATES;ARON GOLDHIRSCH;KAREN N. PRICE;MARCO COLLEONI;MEREDITH M. REGAN;RICHARD D. GELBER;A. RECALCATI;ALBERTO LUINI;BERNARD F. COLE;CAMELIA CHIFU;DAVID R. G. LITTLEJOHN;GIOVANNI MAZZAROL;GIUSEPPE VIALE;HANNE GALATIUS;JANEZ Z̆GAJNAR;JEAN‐REMI GARBAY;MANUELA SARGENTI;MATTIA INTRA;MAURO G. MASTROPASQUA","1903;1152;1152;1152;1152;1152;1152;1099;1099;1099;1099;1099;1099;1099;1099;1099;1099;1099;1099;1099","SAMUELE MASSARUT;RENATO TALAMINI;MARIO RONCADIN;JERRY POLESEL;VALTER GATTEI;VINCENZO CANZONIERI;DIEGO SERRAINO;ANTONELLA ZUCCHETTO;GIORGIO GIORDA;LUIGINO DAL MASO;ALFONSO COLOMBATTI;FRANCESCA MARIA ROSSI;ANTONINO DE PAOLI;GUSTAVO BALDASSARRE;ALESSANDRA VIEL;BARBARA BELLETTI;MAURA SONEGO;ROBERTO SORIO;MICHELE DAL BO;RICCARDO BOMBEN","1903;983;796;766;526;514;478;393;318;303;290;258;253;253;237;227;227;216;192;190","RENATO TALAMINI;JERRY POLESEL;ANTONELLA ZUCCHETTO;VALTER GATTEI;DIEGO SERRAINO;ALESSANDRA BEARZ;SAMUELE MASSARUT;LUIGINO DAL MASO;VINCENZO CANZONIERI;TIZIANA PERIN;MARCO TROVÒ;CHIARA LESTUZZI;GIOVANNI FRANCHIN;M. TROVÒ;GIORGIO GIORDA;ALFONSO COLOMBATTI;MARIA ANTONIETTA PIZZICHETTA;MARIO RONCADIN;ROBERTA MAESTRO;TANJA BARESIC","21;18;12;12;10;10;10;8;8;7;7;7;6;6;6;6;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;ENGINEERING;COMPUTER SCIENCE;MATERIALS SCIENCE;PSYCHOLOGY;ECONOMICS;POLITICAL SCIENCE;GEOGRAPHY;MATHEMATICS;BUSINESS;GEOLOGY;HISTORY;PHILOSOPHY","169;86;18;15;12;6;5;5;5;4;3;2;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GENETICS;IMMUNOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;RADIOLOGY;GASTROENTEROLOGY;CELL BIOLOGY;PALEONTOLOGY;NURSING;PSYCHIATRY;MOLECULAR BIOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;OPTICS;DEMOGRAPHY;GYNECOLOGY","144;58;51;46;43;31;30;28;25;21;20;17;15;13;12;11;10;10;10;9;9","CANCER;GENE;CHEMOTHERAPY;POPULATION;CONFIDENCE INTERVAL;RADIATION THERAPY;DISEASE;LUNG CANCER;ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);MULTIVARIATE ANALYSIS;CASE-CONTROL STUDY;LEUKEMIA;LYMPHOMA;QUALITY OF LIFE (HEALTHCARE);PROPORTIONAL HAZARDS MODEL;INCIDENCE (GEOMETRY);LOGISTIC REGRESSION;RECEPTOR","104;37;28;24;20;20;15;13;13;12;12;11;10;10;10;10;9;8;8;8","BREAST CANCER;COLORECTAL CANCER;PROSTATE CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;GENE EXPRESSION;METASTASIS;MUTATION;CLINICAL ENDPOINT;HAZARD RATIO;OVARIAN CANCER;DOCETAXEL;UNIVARIATE ANALYSIS;CISPLATIN;CYCLOPHOSPHAMIDE;EPIDERMAL GROWTH FACTOR RECEPTOR;PANCREATIC CANCER;ALLELE;CANCER CELL;CELL CYCLE;GENOTYPE;METHYLATION;MULTICENTER STUDY;RITUXIMAB;RNA;TOLERABILITY","37;13;12;10;9;8;8;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4","DNA METHYLATION;MASTECTOMY;AXILLA;SENTINEL NODE;ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;CHROMATIN REMODELING;GERMLINE MUTATION;TRASTUZUMAB;CD38;CHLORAMBUCIL;CORONAVIRUS DISEASE 2019 (COVID-19);DEBULKING;DUCTAL CARCINOMA;EPIDEMIOLOGY OF CANCER;ERLOTINIB;ESTROGEN RECEPTOR;IGHV@;INTERNATIONAL PROGNOSTIC INDEX;KRAS;LYMPHOVASCULAR INVASION;METASTATIC BREAST CANCER;PLEURECTOMY;POINT MUTATION;RELATIVE SURVIVAL;RIBONUCLEASE;RNA INTERFERENCE;SANGER SEQUENCING;SENTINEL LYMPH NODE;SYSTEMIC THERAPY;TAXANE","6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MIDDLE AGED;BREAST NEOPLASMS;MALE;;AGED;ITALY;ADULT;NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;ANTINEOPLASTIC AGENTS;SKIN NEOPLASMS;BIOMARKERS, TUMOR;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;LUNG NEOPLASMS;RISK FACTORS;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CASE-CONTROL STUDIES","128;89;68;66;65;63;60;51;50;50;33;26;24;21;21;21;21;20;20;20","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR RESEARCH ON BREAST CANCER;CANCER SURVIVORSHIP AND QUALITY OF LIFE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;MELANOMA;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHROMATIN REMODELING IN CANCER AND DEVELOPMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER","11;8;6;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;CANCER;CLINICAL ENDPOINT;RADIOTHERAPY;REGIMEN;CANCER RISK;UNIVARIATE ANALYSIS;CANCER INCIDENCE;MELANOMA;TREATMENT;TUMOR STAGING;AXILLA;B-CELL RECEPTOR SIGNALING;DNA METHYLATION;NON-SMALL CELL LUNG CANCER;NUTRITIONAL EPIDEMIOLOGY;PROSTATE CANCER;RECURRENT PERICARDITIS;TUMOR MODELS;BREAST-CONSERVING SURGERY","9;7;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3","BREAST CANCER;CANCER PATIENTS;LUNG CANCER;CANCER RISK;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;OVARIAN CANCER;PROSTATE CANCER;COLORECTAL CANCER;III STUDY;PANCREATIC CANCER;PHASE III;RADIATION THERAPY;CASE-CONTROL STUDY;MULTICENTER STUDY;NEOPLASTIC PERICARDIAL;RETROSPECTIVE STUDY;CELL LUNG;CHEMOTHERAPY CT;FAMILY HISTORY;FINAL RESULTS;IMMUNOMODULATORY ACTIVITY;ITALIAN CANCER;LONG-TERM FOLLOW-UP;NON-SMALL CELL;PERICARDIAL EFFUSION;PHASE II;STEM CELL;ADVANCED OVARIAN;ANTI-CD NANOPARTICLES","18;10;10;8;8;8;8;7;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2","BREAST CANCER;AXILLARY DISSECTION;RADIATION THERAPY;CANCER PATIENTS;CANCER RISK;LUNG CANCER;MEDIAN FOLLOW-UP;INCREASED RISK;CANCER CELLS;EPITHELIOID SARCOMA;IL- IL-;LOGISTIC REGRESSION;SERIES II;CELL LINES;MPM PATIENTS;ODDS RATIOS;RATIOS ORS;STATISTICALLY SIGNIFICANT;SYSTEMIC CT;MONTHS NA;PANCREATIC CANCER;RESEARCH FUNDING;SENTINEL NODE;BONE METASTASES;DISEASE-FREE SURVIVAL;FERRARA FERRARA;FERRARA ITALY;LOCAL CT;LOCALLY ADVANCED;MEDITERRANEAN DIET","59;28;14;12;12;12;12;11;9;9;9;9;9;8;8;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6",61,0.31,7.65,5,3.5,1.25,2,15.25,5.75,1,1,7,1,1,5.25,1,3,1,2.5,6,3.5,0,0,80,80,2,2,0,0,0,0,0,1,0,0,0,0,2,1,0,4,3,1.53,2.33333333333333,0,3,2,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MAIO MICHELE;SIGALOTTI LUCA;ALDINUCCI DONATELLA;DOU Q PING;FORMAGGIO FERNANDO;FREGONA DOLORES;RONCONI LUCA","2;2;1;1;1;1;1","AZIENDA OSPEDALIERA UNIVERSITARIA SENESE;CENTRO DI RIFERIMENTO ONCOLOGICO;CENTRO DI RIFERIMENTO ONCOLOGICO ISTITUTO NAZ TUMORI AVIANO;UNIVERSITA DEGLI STUDI DI PADOVA;WAYNE STATE UNIVERSITY","2;2;1;1;1","31 BIOLOGICAL SCIENCES;3105 GENETICS;34 CHEMICAL SCIENCES;41 ENVIRONMENTAL SCIENCES;3402 INORGANIC CHEMISTRY;4102 ECOLOGICAL APPLICATIONS","4;2;2;2;1;1","CANCER;GENETICS;PATIENT SAFETY","3;2;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2","A61K38/04;C12N15/10;C12Q1/68","1;1;1","C12N15/1072;C12Q1/6886;C12Q2600/112;C12Q2600/118;C12Q2600/154;C12Q2600/158;A61K31/555;A61P35/00;C07K5/06026;C07K5/0806","2;2;2;2;2;2;1;1;1;1",18,6.61,438.06,6.32,14,0.78,93.44,0,1,5,2,8,0,0,2,0,17,1,0,0,0,0,0,0,14,4,0,18,0,0,0,0,0,0,0,0,0,"United States;Germany;Italy;United Kingdom","5;2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","18;17;7;5;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;BREAST CANCER;AGING;LUNG;LUNG CANCER;PATIENT SAFETY;ORPHAN DRUG;OVARIAN CANCER;BIOMEDICAL IMAGING;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;REHABILITATION;STEM CELL RESEARCH;TRANSPLANTATION","17;17;12;11;8;8;4;3;3;3;3;2;2;1;1;1;1;1;1;1","CANCER","15","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","16;6;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;LEUKEMIA / LEUKAEMIA;OVARIAN CANCER;HODGKIN'S DISEASE","8;4;4;2;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","15;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,"PUBLIC LIBRARY OF SCIENCE;THE CAMBRIDGE STRUCTURAL DATABASE","31;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;34 CHEMICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3107 MICROBIOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3215 REPRODUCTIVE MEDICINE;3401 ANALYTICAL CHEMISTRY;3406 PHYSICAL CHEMISTRY;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;40 ENGINEERING","43;14;14;13;6;4;4;2;2;2;1;1;1;1;1;1;1;1;1;1","RARE DISEASES;CANCER;GENETICS;CLINICAL RESEARCH;HEMATOLOGY;BREAST CANCER;OVARIAN CANCER;PREVENTION;HUMAN GENOME;LYMPHOMA;ORPHAN DRUG;AGING;AUTOIMMUNE DISEASE;BIOENGINEERING;BIOTECHNOLOGY;BRAIN CANCER;BRAIN DISORDERS;DIGESTIVE DISEASES;GENETIC TESTING;NANOTECHNOLOGY","9;8;6;5;5;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","12;3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","7;1;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","3;3;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","9;8;3","OVARIAN CANCER;BREAST CANCER;MELANOMA;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER;STOMACH CANCER;BRAIN TUMOR;GENITAL SYSTEM, FEMALE;GENITAL SYSTEM, MALE;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER","6;5;4;3;2;2;1;1;1;1;1",NA,NA
"IRCCS_CRO",2014,205,14.809756097561,2.99512195121951,0.307317073170732,0.278048780487805,0.546341463414634,2.35249042145594,1.26,1.58333333333333,1.67164179104478,0.478048780487805,2,118,38,15,18,0.58,0.19,0.07,0.09,45.87,1.21371336510435,6.25190258751904,0.44390243902439,0.926829268292683,0.474,0.401,0.416,0.412,"VALTER GATTEI;DIEGO SERRAINO;GIANLUCA GAÏDANO;RENATO TALAMINI;VINCENZO CANZONIERI;ALFONSO COLOMBATTI;DAVIDE ROSSI;GIOVANNI DEL POETA;M. TROVÒ;PIETRO BULIAN;RICCARDO DOLCETTI;CARLO FURLAN;GIUSEPPE TOFFOLI;CARLO LA VECCHIA;MICHELE SPINA;EMILIO MINATEL;LUIGINO DAL MASO;CRISTINA BOSETTI;MASSIMILIANO BERRETTA;MAURIZIO MASCARIN","18;14;13;13;11;11;11;11;11;10;9;9;9;9;9;8;8;8;8;8","ANTONINO CARBONE;ALFONSO COLOMBATTI;VALTER GATTEI;RENATO TALAMINI;DIEGO SERRAINO;VINCENZO CANZONIERI;M. TROVÒ;CARLO FURLAN;GIUSEPPE TOFFOLI;MASSIMILIANO BERRETTA;MARIA ANTONIETTA ANNUNZIATA;LINO DEL PUP;BARBARA MUZZATTI;MAURIZIO MASCARIN;RICCARDO DOLCETTI;CARLO LA VECCHIA;EMILIO MINATEL;GIANLUCA GAÏDANO;ANNUNZIATA GLOGHINI;PIETRO BULIAN","2.03;1.33;1.25;1.24;1.24;1.17;1.1;1.08;1.07;1.04;1;1;1;0.93;0.88;0.88;0.87;0.8;0.79;0.77","VALTER GATTEI;DIEGO SERRAINO;GIANLUCA GAÏDANO;RENATO TALAMINI;VINCENZO CANZONIERI;ALFONSO COLOMBATTI;DAVIDE ROSSI;GIOVANNI DEL POETA;M. TROVÒ;PIETRO BULIAN;RICCARDO DOLCETTI;CARLO FURLAN;GIUSEPPE TOFFOLI;MICHELE SPINA;EMILIO MINATEL;LUIGINO DAL MASO;MASSIMILIANO BERRETTA;MAURIZIO MASCARIN;JERRY POLESEL;UMBERTO TIRELLI","18;14;13;13;11;11;11;11;11;10;9;9;9;9;8;8;8;8;8;8","ANTONINO CARBONE;ALFONSO COLOMBATTI;VALTER GATTEI;RENATO TALAMINI;DIEGO SERRAINO;VINCENZO CANZONIERI;M. TROVÒ;CARLO FURLAN;GIUSEPPE TOFFOLI;MASSIMILIANO BERRETTA;MARIA ANTONIETTA ANNUNZIATA;LINO DEL PUP;BARBARA MUZZATTI;MAURIZIO MASCARIN;RICCARDO DOLCETTI;EMILIO MINATEL;GIANLUCA GAÏDANO;PIETRO BULIAN;JERRY POLESEL;UMBERTO TIRELLI","2.03;1.33;1.25;1.24;1.24;1.17;1.1;1.08;1.07;1.04;1;1;1;0.93;0.88;0.87;0.8;0.77;0.75;0.74","ANGELA BUONADONNA;ALBERTO ZANIBONI;DIEGO SERRAINO;VITTORINA ZAGONEL;SARA LONARDI;ALFREDO FALCONE;C. BONI;CHIARA CARLOMAGNO;CHIARA CREMOLINI;D. AMOROSO;ENRICO CORTESI;FOTIOS LOUPAKIS;GIACOMO ALLEGRINI;GIANLUCA MASI;GIANLUCA TOMASELLO;GIUSEPPE TONINI;LISA SALVATORE;LUCA BONI;MONICA RONZONI;ROSELLA SPADI","1143;1021;1018;960;939;919;919;919;919;919;919;919;919;919;919;919;919;919;919;919","ANGELA BUONADONNA;DIEGO SERRAINO;VALTER GATTEI;DIANA CRIVELLARI;ANTONELLA ZUCCHETTO;RENATO TALAMINI;EMANUELE ANGELUCCI;ROBERTA MAESTRO;ROBERTO SORIO;D BARONCIANI;ANTONINO DE PAOLI;LUIGINO DAL MASO;ALESSANDRA BEARZ;ALESSANDRA VIEL;CARLO BIAGINI;VINCENZO CANZONIERI;L. CIONINI;MARIANNA COPPOLA;SILVIA CERVO;RENATO CANNIZZARO","1069;933;779;721;576;489;455;399;368;349;309;279;273;269;262;259;254;254;217;214","VALTER GATTEI;DIEGO SERRAINO;ANTONELLA ZUCCHETTO;RENATO TALAMINI;VINCENZO CANZONIERI;M. TROVÒ;PIETRO BULIAN;RICCARDO DOLCETTI;CARLO FURLAN;EMILIO MINATEL;JERRY POLESEL;MAURIZIO MASCARIN;MICHELE SPINA;ALFONSO COLOMBATTI;LUIGINO DAL MASO;PAOLO DE PAOLI;GIOVANNI FRANCHIN;GIUSEPPE TOFFOLI;UMBERTO TIRELLI;ALESSANDRA VIEL","18;13;12;11;11;11;10;9;9;8;8;8;8;7;7;7;7;7;7;6","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;PHILOSOPHY;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE;BUSINESS;ENGINEERING;GEOGRAPHY;HISTORY;ART;ENVIRONMENTAL SCIENCE","178;78;21;21;10;9;8;7;6;6;5;5;2;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;PATHOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;PALEONTOLOGY;NUCLEAR MEDICINE;OPTICS;PHARMACOLOGY;GYNECOLOGY;NURSING;CELL BIOLOGY;INTENSIVE CARE MEDICINE;ORGANIC CHEMISTRY;UROLOGY","149;76;45;44;37;36;36;30;24;21;20;19;15;11;11;9;9;8;8;8;8","CANCER;CHEMOTHERAPY;GENE;LYMPHOMA;RADIATION THERAPY;POPULATION;CONFIDENCE INTERVAL;LEUKEMIA;LUNG CANCER;STAGE (STRATIGRAPHY);ODDS RATIO;CLINICAL TRIAL;ANTIBODY;LOGISTIC REGRESSION;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;TOXICITY;TRANSPLANTATION;COHORT;IMMUNE SYSTEM;INCIDENCE (GEOMETRY)","96;41;35;30;23;20;16;13;13;13;11;10;9;9;9;8;8;8;7;7;7","COLORECTAL CANCER;BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;MUTATION;CLINICAL ENDPOINT;PROSTATE CANCER;NEUTROPENIA;RITUXIMAB;CYCLOPHOSPHAMIDE;DOCETAXEL;OVARIAN CANCER;CISPLATIN;GENOTYPE;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;BEVACIZUMAB;CERVICAL CANCER;HEAD AND NECK CANCER;PACLITAXEL;SALVAGE THERAPY;SOMATIC EVOLUTION IN CANCER","23;22;13;13;12;11;9;9;8;8;8;6;6;6;6;6;5;5;5;5;5;5","ANDROGEN DEPRIVATION THERAPY;KRAS;BENDAMUSTINE;FLUDARABINE;IGHV@;IRINOTECAN;DNA MISMATCH REPAIR;OXALIPLATIN;PROSTATECTOMY;SANGER SEQUENCING;ANDROGEN RECEPTOR;BUSULFAN;CAPECITABINE;CARBOPLATIN;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHEMOIMMUNOTHERAPY;DEEP SEQUENCING;FRAMESHIFT MUTATION;GERMLINE MUTATION;INTERNATIONAL PROGNOSTIC INDEX;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;ONCOGENE;PEMETREXED;PHARMACOGENETICS;POINT MUTATION;RELATIVE SURVIVAL;TRABECTEDIN;TRASTUZUMAB;VINCRISTINE","5;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;;MIDDLE AGED;MALE;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;ANTINEOPLASTIC AGENTS;COLORECTAL NEOPLASMS;BREAST NEOPLASMS;AGED, 80 AND OVER;TREATMENT OUTCOME;YOUNG ADULT;OVARIAN NEOPLASMS;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;LUNG NEOPLASMS;CELL PROLIFERATION;NEOPLASM RECURRENCE, LOCAL","123;80;77;66;65;56;55;41;39;30;30;29;25;22;22;21;20;20;19;19","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;ACUTE MYELOID LEUKEMIA;GYNECOLOGIC ONCOLOGY;MELANOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ANALYSIS OF GENE INTERACTION NETWORKS;CANCER IMMUNOTHERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF SJÖGREN'S SYNDROME","15;9;9;7;6;5;5;5;4;4;4;3;3;3;3;3;2;2;2;2","CLINICAL ENDPOINT;RADIOTHERAPY;BREAST CANCER;HEALTHY EATING INDEX;REGIMEN;CANCER INCIDENCE;CANCER SUSCEPTIBILITY;CANCER THERAPY;DIETARY PATTERNS;IMAGE-GUIDED RADIOTHERAPY;INTENSITY-MODULATED RADIOTHERAPY;REFRACTORY (PLANETARY SCIENCE);SALVAGE THERAPY;BENDAMUSTINE;BRCA1;CANCER GENOMICS;FOLFIRI;IGHV@;METASTATIC COLORECTAL CANCER;NEOADJUVANT THERAPY","12;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4","BREAST CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;PROSTATE CANCER;LUNG CANCER;RADIATION THERAPY;CANCER PATIENTS;HODGKIN LYMPHOMA;OVARIAN CANCER;CANCER RISK;PATIENTS PTS;PHASE II;B-CELL LYMPHOMA;CASECONTROL STUDY;CELL TRANSPLANTATION;CLINICAL OUTCOME;II TRIAL;METASTATIC COLORECTAL;NECK CANCER;PHASE TRIAL;STEM CELL;ADVANCED OVARIAN;CANCER CELLS;CASTRATION-RESISTANT PROSTATE;CELL LUNG;DIETARY PATTERNS;ENDOMETRIAL CANCER;FIRST-LINE CHEMOTHERAPY;II STUDY","14;13;12;10;10;9;9;8;8;8;7;7;7;6;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","CELL LINES;CROSSREF PUBMED;PUBMED SCOPUS;BREAST CANCER;PRIMARY EFFUSION;PEL CELL;REGGIO EMILIA;BRCA MUTATION;CANCER INSTITUTE;MEC- CELLS;MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML;NATIONAL CANCER;OVARIAN CANCER;PHASE II;ACUTE GRADE;CLL CELLS;NOTCH MUTATIONS;XMLNSMMLHTTPWWWWORGMATHMATHML IDMMMLMIPMMLMIMMLMOLTMMLMOMMLMN;ARCISPEDALE SANTA;CANCER CELLS;CANCER PATIENTS;CANCER UNIT;CHRONIC LYMPHOCYTIC;EFFUSION LYMPHOMA;IDMMMLMIPMMLMIMMLMOLTMMLMOMMLMN FONTSTYLEITALICMMLMNMMLMATH;MARIA NUOVA-IRCCS;NUOVA-IRCCS REGGIO;PROSTATE CANCER;SANTA MARIA;SKIN CANCER","48;37;36;31;20;18;18;15;14;14;14;14;14;14;13;13;13;13;12;12;12;12;12;12;12;12;12;12;12;12",69,0.34,8.08,6,2,3.5,1,6.5,3,1,1,7,0,1,6,0,1.5,1,3,4,2,0,0,84,84,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,5,0.81,3,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALDINUCCI DONATELLA;DOU Q PING;FORMAGGIO FERNANDO;FREGONA DOLORES;RONCONI LUCA","1;1;1;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITA DEGLI STUDI DI PADOVA;WAYNE STATE UNIVERSITY","1;1;1","34 CHEMICAL SCIENCES;3402 INORGANIC CHEMISTRY","2;1",NA,NA,NA,NA,"A61K31/555;A61P35/00;C07K5/062;C07K5/083","1;1;1;1","A61K31/555;A61P35/00;C07K5/06026;C07K5/0806","1;1;1;1",17,6.82,472,7.14,13,0.76,90.65,0,1,6,1,7,0,0,2,0,16,1,0,0,0,0,0,0,11,3,3,17,0,0,0,0,0,0,0,0,0,"Italy;United States","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","17;14;4;4;2;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;RARE DISEASES;AGING;HEMATOLOGY;LYMPHOMA;PROSTATE CANCER;UROLOGIC DISEASES;DIGESTIVE DISEASES;ORPHAN DRUG;PATIENT SAFETY;REGENERATIVE MEDICINE;STEM CELL RESEARCH;TRANSPLANTATION;CHRONIC PAIN;CONTRACEPTION/REPRODUCTION;IMMUNIZATION;LUNG","14;14;13;5;4;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;REPRODUCTIVE HEALTH AND CHILDBIRTH","14;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","15;3;1;1;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER;CERVICAL CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA","5;4;3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.2 SURVEILLANCE","15;2;1;1;1",1,601790,85970,4,7,5,1,6,288550.833333333,0.710446743930157,"CARDIFF UNIVERSITY;CENTRO DI RIFERIMENTO ONCOLOGICO;FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA;KING'S COLLEGE LONDON;NATIONAL INSTITUTES OF HEALTH;UNIVERSITY OF BIRMINGHAM;UNIVERSITY OF TORONTO","1;1;1;1;1;1;1","MEDICAL RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","RESEARCH GRANT (PROJECT CATEGORY)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY","1;1","AUTOIMMUNE DISEASE;CROHN'S DISEASE;DIGESTIVE DISEASES;INFECTIOUS DISEASES;INFLAMMATORY BOWEL DISEASE;PREVENTION","1;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL","1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","COLON AND RECTAL CANCER","1","1.1 NORMAL FUNCTIONING","1","A01 CLINICAL MEDICINE","1",NA,NA,10,"PUBLIC LIBRARY OF SCIENCE","10","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3105 GENETICS;3202 CLINICAL SCIENCES","20;6;5;4;2;2;1;1","CANCER;RARE DISEASES;BREAST CANCER;CLINICAL RESEARCH;GENETIC TESTING;GENETICS;HEMATOLOGY;HIV/AIDS;LYMPHOMA;OVARIAN CANCER;PREVENTION;TRANSPLANTATION","2;2;1;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM","5;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;6.4 SURGERY","4;1;1;1","BIOMEDICAL","2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","4;2","NOT SITE-SPECIFIC CANCER;BREAST CANCER;OVARIAN CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA","3;2;2;1;1",NA,NA
"IRCCS_CRO",2015,222,15.3198198198198,3.23423423423423,0.369369369369369,0.333333333333333,0.563063063063063,2.61678832116788,1.28125,1.76190476190476,1.52439024390244,0.576576576576577,7,127,49,19,13,0.57,0.22,0.09,0.06,29.58,0.793614135555439,6.31096681096682,0.387387387387387,0.878378378378378,0.542,0.471,0.446,0.439,"DIEGO SERRAINO;PAOLO DE PAOLI;CARLO LA VECCHIA;JERRY POLESEL;VALTER GATTEI;LUIGINO DAL MASO;CRISTINA BOSETTI;MASSIMO LIBRA;ANTONELLA ZUCCHETTO;ANGELA BUONADONNA;VINCENZO CANZONIERI;MICHELE DAL BO;GIUSEPPE TOFFOLI;UMBERTO TIRELLI;LUCIA FRATINO;GIOVANNI DEL POETA;MASSIMILIANO BERRETTA;SIMON SPAZZAPAN;RICCARDO BOMBEN;ANTONELLA ZUCCHETTO","30;20;18;18;16;12;12;11;11;11;10;10;10;10;9;9;9;9;9;8","SAMUELE MASSARUT;DIEGO SERRAINO;PAOLO DE PAOLI;VINCENZO CANZONIERI;JERRY POLESEL;CARLO LA VECCHIA;MASSIMILIANO BERRETTA;ANTONELLA ZUCCHETTO;MASSIMO LIBRA;VALTER GATTEI;LUIGINO DAL MASO;GIUSEPPE TOFFOLI;CRISTINA BOSETTI;MAX DAHELE;UMBERTO TIRELLI;LUCIA FRATINO;GUSTAVO BALDASSARRE;AGOSTINO STEFFAN;ETTORE BIDOLI;ROBERTA MAESTRO","5.38;3.34;2.59;1.9;1.7;1.67;1.42;1.19;1.18;1.18;1.1;1.02;1;1;0.92;0.9;0.78;0.77;0.75;0.73","DIEGO SERRAINO;PAOLO DE PAOLI;JERRY POLESEL;VALTER GATTEI;LUIGINO DAL MASO;ANTONELLA ZUCCHETTO;ANGELA BUONADONNA;VINCENZO CANZONIERI;MICHELE DAL BO;GIUSEPPE TOFFOLI;UMBERTO TIRELLI;LUCIA FRATINO;MASSIMILIANO BERRETTA;SIMON SPAZZAPAN;RICCARDO BOMBEN;ANTONELLA ZUCCHETTO;ROBERTA MAESTRO;ALESSANDRA BEARZ;RICCARDO DOLCETTI;MATTEO DI MASO","30;20;18;16;12;11;11;10;10;10;10;9;9;9;9;8;8;8;8;8","SAMUELE MASSARUT;DIEGO SERRAINO;PAOLO DE PAOLI;VINCENZO CANZONIERI;JERRY POLESEL;MASSIMILIANO BERRETTA;ANTONELLA ZUCCHETTO;VALTER GATTEI;LUIGINO DAL MASO;GIUSEPPE TOFFOLI;MAX DAHELE;UMBERTO TIRELLI;LUCIA FRATINO;GUSTAVO BALDASSARRE;AGOSTINO STEFFAN;ETTORE BIDOLI;ROBERTA MAESTRO;MATTEO DI MASO;ALFONSO COLOMBATTI;ALESSANDRA BEARZ","5.38;3.34;2.59;1.9;1.7;1.42;1.19;1.18;1.1;1.02;1;0.92;0.9;0.78;0.77;0.75;0.73;0.71;0.69;0.68","DIEGO SERRAINO;CARLO LA VECCHIA;LUIGINO DAL MASO;RICCARDO DOLCETTI;JERRY POLESEL;ANTONELLA ZUCCHETTO;SIRANOUSH MANOUKIAN;PAOLO RADICE;VALERIA PENSOTTI;BERNARDO BONANNI;ANA OSÓRIO;BERNARD PEISSEL;JAVIER BENÍTEZ;MAURIZIO GENUARDI;SILVIA FRANCESCHI;GILLIAN MITCHELL;HANS EHRENCRONA;LORIS BERNARD;OLGA M. SINILNIKOVA;SYLVIE MAZOYER","1084;820;777;760;686;629;603;595;572;570;539;539;539;530;518;507;507;507;507;507","DIEGO SERRAINO;LUIGINO DAL MASO;RICCARDO DOLCETTI;ANTONELLA ZUCCHETTO;JERRY POLESEL;VALTER GATTEI;ROBERTA MAESTRO;GIUSEPPE TOFFOLI;RICCARDO SPIZZO;PAOLO DE PAOLI;PIETRO BULIAN;SIMON SPAZZAPAN;ALFONSO COLOMBATTI;RENATO TALAMINI;RENATO CANNIZZARO;AGOSTINO STEFFAN;LUIGI DE MARCO;ANDREA GINI;MATTEO DI MASO;SILVIA CERVO","1023;683;675;629;588;487;455;381;300;292;291;258;250;220;213;209;208;202;199;194","DIEGO SERRAINO;ANTONELLA ZUCCHETTO;JERRY POLESEL;PAOLO DE PAOLI;VALTER GATTEI;LUIGINO DAL MASO;ANGELA BUONADONNA;MICHELE DAL BO;VINCENZO CANZONIERI;UMBERTO TIRELLI;MASSIMILIANO BERRETTA;GIUSEPPE TOFFOLI;LUCIA FRATINO;SIMON SPAZZAPAN;RICCARDO BOMBEN;ROBERTA MAESTRO;SAMUELE MASSARUT;MATTEO DI MASO;RICCARDO DOLCETTI;ALESSANDRA BEARZ","28;19;17;17;16;11;10;10;10;10;9;9;9;9;9;8;8;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;SOCIOLOGY;BUSINESS;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY;PSYCHOLOGY;HISTORY","198;80;21;19;13;11;11;7;6;5;4;4;4;3;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;IMMUNOLOGY;GENETICS;CANCER RESEARCH;ENVIRONMENTAL HEALTH;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;CELL BIOLOGY;RADIOLOGY;PALEONTOLOGY;NUCLEAR MEDICINE;OPTICS;DEMOGRAPHY;GYNECOLOGY;NURSING;PHARMACOLOGY;VIROLOGY","167;93;52;43;42;40;33;30;27;24;17;16;13;12;12;11;11;11;11;11","CANCER;GENE;CHEMOTHERAPY;POPULATION;RADIATION THERAPY;CONFIDENCE INTERVAL;LYMPHOMA;ODDS RATIO;LEUKEMIA;CASE-CONTROL STUDY;INCIDENCE (GEOMETRY);REGIMEN;DISEASE;LOGISTIC REGRESSION;STAGE (STRATIGRAPHY);ANTIBODY;COHORT;ANTIGEN;LUNG CANCER;TRANSPLANTATION","117;41;38;28;19;18;15;13;12;11;11;11;10;10;10;9;9;8;8;8","BREAST CANCER;COLORECTAL CANCER;PROSTATE CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;GENOTYPE;HEAD AND NECK CANCER;HAZARD RATIO;MUTATION;CELL CYCLE;CISPLATIN;DOCETAXEL;METASTASIS;PANCREATIC CANCER;CYCLOPHOSPHAMIDE;GENE EXPRESSION;PROSTATE;TRANSCRIPTION FACTOR;BEVACIZUMAB;CLINICAL ENDPOINT;GEMCITABINE;SALVAGE THERAPY","25;19;14;12;12;9;8;8;7;7;7;7;7;6;6;6;6;5;5;5;5","IGHV@;ANDROGEN DEPRIVATION THERAPY;IRINOTECAN;SINGLE-NUCLEOTIDE POLYMORPHISM;ANDROGEN RECEPTOR;DNA METHYLATION;PHARMACOGENETICS;CERVICAL INTRAEPITHELIAL NEOPLASIA;CYCLIN-DEPENDENT KINASE;GENOTYPING;HAPLOTYPE;METASTATIC BREAST CANCER;RELATIVE SURVIVAL;TAXANE;TRASTUZUMAB;CARBOPLATIN;EXTRAPLEURAL PNEUMONECTOMY;FLUDARABINE;GERMLINE MUTATION;GONADOTROPIN-RELEASING HORMONE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HERPESVIRIDAE;IBRUTINIB;IMATINIB MESYLATE;MEGAKARYOCYTE;MHC CLASS I;MOLECULAR MEDICINE;ONCOGENE;PDGFRA;PEMETREXED;PLEURECTOMY;TAMOXIFEN;THYMIDYLATE SYNTHASE;UNTRANSLATED REGION;VINORELBINE","6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;;MIDDLE AGED;MALE;AGED;ADULT;ITALY;NEOPLASMS;AGED, 80 AND OVER;BREAST NEOPLASMS;CARCINOMA, SQUAMOUS CELL;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;COLORECTAL NEOPLASMS;HEAD AND NECK NEOPLASMS;CASE-CONTROL STUDIES;HIV INFECTIONS;LUNG NEOPLASMS;RISK FACTORS","131;89;85;80;75;68;62;51;40;35;33;27;26;26;26;26;25;25;23;23","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;LYMPHOID NEOPLASMS;GASTRIC CANCER RESEARCH AND TREATMENT;IMMUNOLOGICAL MECHANISMS IN PREGNANCY AND FETAL-MATERNAL INTERFACE;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES","12;10;8;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3","CANCER RISK;REGIMEN;BREAST CANCER;TREATMENT;CANCER INCIDENCE;CANCER SUSCEPTIBILITY;HEALTHY EATING INDEX;HEMATOLOGY;IGHV@;ABIRATERONE ACETATE;ADJUVANT THERAPY;CLINICAL ENDPOINT;IMAGE-GUIDED RADIOTHERAPY;INTENSITY-MODULATED RADIOTHERAPY;METASTATIC PROSTATE CANCER;SALVAGE THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;DPYD;HIV;MICRORNAS","11;11;9;9;7;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4","CANCER PATIENTS;BREAST CANCER;PROSTATE CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;CANCER RISK;COLORECTAL CANCER;NECK CANCER;CASECONTROL STUDY;CASTRATION-RESISTANT PROSTATE;PANCREATIC CANCER;PATIENTS PTS;PEER REVIEW;PHASE II;PROGNOSTIC FACTORS;RADIATION THERAPY;REVIEW REPORT;CANCER PROGNOSTIC;COHORT STUDY;HIGH-DOSE CHEMOTHERAPY;ITALIAN CANCER;LOCALLY ADVANCED;LUNG CANCER;METASTATIC CASTRATION-RESISTANT;OVARIAN CANCER;POOLED ANALYSIS;SQUAMOUS CELL;STEM CELL;ALLEANZA CONTRO;B-CELL RECEPTOR","14;12;12;10;10;9;8;8;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3","CANCER PATIENTS;BREAST CANCER;HR CI;CANCER RISK;CD CD;PATIENTS TREATED;PERIPHERAL BLOOD;SYSTEMIC THERAPY;ADJUVANT SYSTEMIC;MULTIVARIATE ANALYSIS;RICERCHE SPA;DPYD-RS DPYD-RS;INCREASED RISK;LOGISTIC REGRESSION;SPA EMPLOYMENT;SURVIVAL OS;CONFIDENCE INTERVAL;PANCREATIC CANCER;REGRESSION MODELS;ADVERSE EVENTS;AVIANO ITALY;BLADDER CANCER;BRCA MUTATION;HIV INFECTION;HIV- RESERVOIR;ITALY DEPARTMENT;LIFE EXPECTANCY;MEDIAN AGE;PROGRESSION-FREE SURVIVAL;RISK FACTORS","30;27;24;16;14;14;13;13;12;12;12;11;11;11;11;10;9;9;9;8;8;8;8;8;8;8;8;8;8;8",102,0.46,6.19,5,1,2,0,2,2.75,0,1,6,1,0,4,0,2,1.5,2,3,2,0,0,77.75,78,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,6,0.84,2,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"AFFANNI ANTONIO;COZZI MARIA RITA;DE MARCO LUIGINO;MAZZUCATO MARIO;SPECOGNA RUBEN;TREVISAN FRANCESCO","1;1;1;1;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITA DEGLI STUDI DI UDINE","1;1","40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","2;1",NA,NA,NA,NA,"G01N33/49","1","G01N33/4905","1",12,6.1,1490.11,4.62,5,0.42,76.25,1,0,5,0,4,0,0,2,0,8,2,0,0,0,0,0,0,9,3,0,10,2,0,0,0,0,0,0,0,0,"United States;Australia","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","11;10;3;2;2;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;LUNG CANCER;BREAST CANCER;DIGESTIVE DISEASES;OVARIAN CANCER;PATIENT SAFETY;RARE DISEASES;BIOTECHNOLOGY;COLO-RECTAL CANCER;GENETICS;IMMUNIZATION;NEURODEGENERATIVE;ORPHAN DRUG;VACCINE RELATED","10;9;7;3;3;2;2;2;2;2;1;1;1;1;1;1;1","CANCER","10","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","9;3;2;1;1","LUNG CANCER;BREAST CANCER;MELANOMA;OVARIAN CANCER;COLON AND RECTAL CANCER","3;2;2;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","9;3",1,4654333,581791.62,6,8,5,1,18,385516.104166667,0.575851430330975,"CENTRO DI RIFERIMENTO ONCOLOGICO;EUROPEAN RESEARCH SERVICES;ISTITUTO NEUROLOGICO CARLO BESTA;ISTITUTO TUMORI BARI;LIONIX (NETHERLANDS);UNIVERSITY COLLEGE LONDON;UNIVERSITY OF MÜNSTER;ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE","1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2014-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY","1;1;1","BIOENGINEERING;BIOTECHNOLOGY;NANOTECHNOLOGY;ORPHAN DRUG;RARE DISEASES","1;1;1;1;1",NA,NA,"5.1 PHARMACEUTICALS","1","NOT SITE-SPECIFIC CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,24,"PUBLIC LIBRARY OF SCIENCE;THE CAMBRIDGE STRUCTURAL DATABASE;TAYLOR & FRANCIS GROUP","21;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3105 GENETICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3004 CROP AND PASTURE PRODUCTION;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;4205 NURSING","37;13;5;4;2;1;1;1;1;1;1;1;1","CANCER;HEMATOLOGY;GENETICS;CLINICAL RESEARCH;RARE DISEASES;BIOTECHNOLOGY;DIGESTIVE DISEASES;HIV/AIDS;HUMAN GENOME;INFECTIOUS DISEASES;LYMPHOMA;ORPHAN DRUG;OVARIAN CANCER;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION","9;8;7;3;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION","10;3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","7;1;1;1","CLINICAL;BIOMEDICAL","3;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","14;3","NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;NON-HODGKIN'S LYMPHOMA;KAPOSI'S SARCOMA;LUNG CANCER;OVARIAN CANCER","8;2;2;2;1;1;1",NA,NA
"IRCCS_CRO",2016,230,15.7521739130435,3.29565217391304,0.352173913043478,0.330434782608696,0.560869565217391,2.56081081081081,1.22727272727273,1.49019607843137,1.53571428571429,0.569565217391304,2,131,54,19,13,0.57,0.23,0.08,0.06,29.62,0.911914844596922,5.87373396353816,0.48695652173913,0.939130434782609,0.517,0.468,0.451,0.454,"DIEGO SERRAINO;VINCENZO CANZONIERI;JERRY POLESEL;ANGELA BUONADONNA;CARLO LA VECCHIA;VALTER GATTEI;ANTONINO DE PAOLI;GIUSEPPE TOFFOLI;LUIGINO DAL MASO;PAOLO DE PAOLI;ROBERTA MAESTRO;ALESSANDRA BEARZ;RENATO CANNIZZARO;RICCARDO DOLCETTI;SANDRO PIGNATA;CLAUDIO BELLUCO;ANTONELLA ZUCCHETTO;ANGELO PAOLO DEI TOS;GIOVANNI DEL POETA;MICHELE DAL BO","26;25;18;17;15;13;12;12;11;11;10;10;10;9;9;9;8;8;8;8","DIEGO SERRAINO;VINCENZO CANZONIERI;CARLO LA VECCHIA;PAOLO DE PAOLI;JERRY POLESEL;IVANA TRUCCOLO;GUSTAVO BALDASSARRE;GIUSEPPE TOFFOLI;ANGELA BUONADONNA;LUIGINO DAL MASO;LINO DEL PUP;MARIA ANTONIETTA ANNUNZIATA;FRANCESCO SOPRACORDEVOLE;BARBARA BELLETTI;MICHELE AVANZO;NITIN SHIVAPPA;JAMES R. HÉBERT;ANTONINO DE PAOLI;BARBARA MUZZATTI;MAURIZIO MONTELLA","2.7;2.26;1.55;1.38;1.33;1.32;1.23;1.21;1.16;1.13;1.1;0.95;0.9;0.88;0.87;0.86;0.86;0.85;0.85;0.83","DIEGO SERRAINO;VINCENZO CANZONIERI;JERRY POLESEL;ANGELA BUONADONNA;CARLO LA VECCHIA;VALTER GATTEI;ANTONINO DE PAOLI;GIUSEPPE TOFFOLI;LUIGINO DAL MASO;PAOLO DE PAOLI;ROBERTA MAESTRO;ALESSANDRA BEARZ;RENATO CANNIZZARO;RICCARDO DOLCETTI;CLAUDIO BELLUCO;ANTONELLA ZUCCHETTO;MICHELE DAL BO;PIETRO BULIAN;MASSIMILIANO BERRETTA;ERIKA CECCHIN","26;25;18;17;15;13;12;12;11;11;10;10;10;9;9;8;8;8;8;8","DIEGO SERRAINO;VINCENZO CANZONIERI;CARLO LA VECCHIA;PAOLO DE PAOLI;JERRY POLESEL;IVANA TRUCCOLO;GUSTAVO BALDASSARRE;GIUSEPPE TOFFOLI;ANGELA BUONADONNA;LUIGINO DAL MASO;LINO DEL PUP;MARIA ANTONIETTA ANNUNZIATA;FRANCESCO SOPRACORDEVOLE;BARBARA BELLETTI;MICHELE AVANZO;ANTONINO DE PAOLI;BARBARA MUZZATTI;RENATO CANNIZZARO;VALTER GATTEI;ETTORE BIDOLI","2.7;2.26;1.55;1.38;1.33;1.32;1.23;1.21;1.16;1.13;1.1;0.95;0.9;0.88;0.87;0.85;0.85;0.82;0.82;0.81","LUIGINO DAL MASO;SILVIA FRANCESCHI;JERRY POLESEL;CHRISTOPHER P. WILD;FREDDIE BRAY;MARTYN PLUMMER;SALVATORE VACCARELLA;DIEGO SERRAINO;CARLO LA VECCHIA;GIUSEPPE TOFFOLI;ANGELA BUONADONNA;ΠΑΓΏΝΑ ΛΆΓΙΟΥ;IVANA HOLCÁTOVÁ;CRISTINA CANOVA;ERIKA CECCHIN;ALESSANDRO COMANDONE;VINCENZO CANZONIERI;RENATO CANNIZZARO;JAMES MCKAY;MARTA VILENSKY","1281;1208;1008;962;962;962;962;842;559;507;469;463;447;436;428;412;393;363;354;354","LUIGINO DAL MASO;JERRY POLESEL;DIEGO SERRAINO;GIUSEPPE TOFFOLI;ERIKA CECCHIN;VINCENZO CANZONIERI;RENATO CANNIZZARO;ROBERTO BORTOLUSSI;ANTONELLA ZUCCHETTO;RICCARDO DOLCETTI;MARTINA TABORELLI;MARCO TROVÒ;S. MAIERO;ROBERTA MAESTRO;LINO DEL PUP;MILENA S. NICOLOSO;PAOLO DE PAOLI;GIORGIO GIORDA;ANTONINO DE PAOLI;GUSTAVO BALDASSARRE","1281;1008;842;507;428;383;363;332;262;259;257;248;243;241;236;223;219;207;202;190","DIEGO SERRAINO;VINCENZO CANZONIERI;JERRY POLESEL;ANTONELLA ZUCCHETTO;VALTER GATTEI;ANGELA BUONADONNA;ANTONINO DE PAOLI;GIUSEPPE TOFFOLI;LUIGINO DAL MASO;PAOLO DE PAOLI;RENATO CANNIZZARO;ROBERTA MAESTRO;CLAUDIO BELLUCO;ALESSANDRA BEARZ;RICCARDO DOLCETTI;MAURIZIO MASCARIN;MICHELE DAL BO;PIETRO BULIAN;RICCARDO BOMBEN;GUSTAVO BALDASSARRE","26;24;18;15;13;13;12;12;11;10;10;10;9;9;9;8;8;8;8;8","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;ART;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;HISTORY","206;77;21;19;15;8;8;7;7;6;5;5;5;3;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;NUCLEAR MEDICINE;RADIOLOGY;CELL BIOLOGY;PHARMACOLOGY;OPTICS;PALEONTOLOGY;ENDOCRINOLOGY;NURSING;UROLOGY","173;88;51;43;43;41;29;26;26;23;17;16;15;14;13;12;12;11;10;10","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;POPULATION;ODDS RATIO;LOGISTIC REGRESSION;LEUKEMIA;LUNG CANCER;LYMPHOMA;PROPORTIONAL HAZARDS MODEL;CASE-CONTROL STUDY;CLINICAL TRIAL;ADVERSE EFFECT;COHORT;DISEASE;RECEPTOR;STAGE (STRATIGRAPHY)","126;39;35;34;24;20;19;16;13;12;12;12;12;11;11;10;9;9;9;9","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;PROSTATE CANCER;METASTASIS;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;MUTATION;HAZARD RATIO;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;DOCETAXEL;GENOTYPE;QUARTILE;MICRORNA;MULTICENTER STUDY;CARCINOGENESIS;CHEMORADIOTHERAPY;RANDOMIZATION;SUNITINIB","26;24;14;14;12;11;11;11;10;10;9;8;8;8;7;7;6;6;6;6","OXALIPLATIN;ANDROGEN RECEPTOR;ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;IGHV@;SINGLE-NUCLEOTIDE POLYMORPHISM;CERVICAL INTRAEPITHELIAL NEOPLASIA;GERMLINE MUTATION;MISSENSE MUTATION;COLPOSCOPY;CRIZOTINIB;IRINOTECAN;LASER CAPTURE MICRODISSECTION;MASTECTOMY;MULTICENTER TRIAL;NEOADJUVANT THERAPY;TOTAL MESORECTAL EXCISION;ANAPLASTIC LYMPHOMA KINASE;ANTIRETROVIRAL THERAPY;CAPECITABINE;CIRCULATING TUMOR CELL;CYCLIN-DEPENDENT KINASE;DEBULKING;EPIRUBICIN;FRAMESHIFT MUTATION;HBSAG;IBRUTINIB;IFOSFAMIDE;INTRAOPERATIVE RADIOTHERAPY;METASTASECTOMY;METASTATIC BREAST CANCER;NON-SMALL CELL LUNG CANCER (NSCLC);PAZOPANIB;PDGFRA;PEMETREXED;PRENATAL DIAGNOSIS","7;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MIDDLE AGED;AGED;MALE;ADULT;ITALY;NEOPLASMS;AGED, 80 AND OVER;COLORECTAL NEOPLASMS;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;OVARIAN NEOPLASMS;LIVER NEOPLASMS;RISK FACTORS;YOUNG ADULT;CASE-CONTROL STUDIES","124;104;93;80;71;71;68;60;37;35;32;28;28;25;24;24;23;22;22;21","ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER RESEARCH AND TREATMENT;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;RENAL CELL CARCINOMA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN LUNG CANCER RESEARCH;LYMPHOID NEOPLASMS;SARCOMA RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GLIOMAS;ROLE OF AMP-ACTIVATED PROTEIN KINASE IN CELLULAR METABOLISM;CANCER IMMUNOTHERAPY;EXPANDING ACCESS TO RADIOTHERAPY GLOBALLY;GASTRIC CANCER RESEARCH AND TREATMENT;HERBAL MEDICINE USE AND SAFETY MONITORING","11;10;9;8;7;6;6;6;6;5;5;5;4;4;4;4;3;3;3;3","CLINICAL ENDPOINT;HEALTHY EATING INDEX;BREAST CANCER;PROGRESSION-FREE SURVIVAL;METASTATIC COLORECTAL CANCER;QUARTILE;TREATMENT;CHEMORADIOTHERAPY;CONCOMITANT;RADIOTHERAPY;REGIMEN;CANCER INCIDENCE;CANCER RISK;CANCER SURVIVORSHIP;INTENSITY-MODULATED RADIOTHERAPY;SOFT TISSUE SARCOMA;CABAZITAXEL;CARBOPLATIN;CHILDHOOD CANCER SURVIVOR STUDY;DIETARY PATTERNS","14;10;9;9;8;8;8;7;7;7;7;6;6;6;6;6;5;5;5;5","BREAST CANCER;OVARIAN CANCER;PROSTATE CANCER;CHRONIC LYMPHOCYTIC;LOCALLY ADVANCED;LYMPHOCYTIC LEUKEMIA;RECTAL CANCER;CANCER RISK;LUNG CANCER;PATIENTS PTS;PHASE III;CASECONTROL STUDY;COLORECTAL CANCER;ADVANCED RECTAL;CANCER PATIENTS;CANCER MCRPC;CELL CARCINOMA;III TRIAL;ITALIAN CASECONTROL;ADJUVANT CHEMOTHERAPY;CASTRATION-RESISTANT PROSTATE;CHEMOTHERAPY CT;METASTATIC CASTRATION-RESISTANT;PRELIMINARY RESULTS;AGENTS NAS;CELL LUNG;CLINICAL TRIAL;CLINICAL TRIALS;DIETARY INFLAMMATORY;GASTRIC CANCER","12;12;12;10;10;10;10;9;9;9;9;8;8;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4","BREAST CANCER;NOTCH MUTATIONS;OVARIAN CANCER;COLORECTAL CANCER;ITALY DEPARTMENT;HR CI;CANCER RISK;MONTHS NA;PATIENTS TREATED;CONFIDENCE INTERVAL;DII SCORES;LOGISTIC REGRESSION;LUNG CANCER;MEDIAN AGE;MEDIAN OS;MONTHS CI;DS DS;STATISTICALLY SIGNIFICANT;SURVIVAL OS;CELL LINES;CONFIDENCE INTERVALS;ODDS RATIOS;RESPONSE RATE;TUMOR CELLS;CANCER PATIENTS;MEDIAN FOLLOW-UP;PROGRESSION-FREE SURVIVAL;RECTAL CANCER;EXPRESSION LEVELS;LOCALLY ADVANCED","39;24;22;20;20;19;18;17;16;15;15;15;15;15;15;15;13;13;13;12;12;12;12;12;11;11;11;11;10;10",93,0.4,8,6,3,2.25,4,2,2,0,1,8,1,1,5.25,2.75,2.5,1.25,3,5,2,0,0,66,66,2,1,0,0,0,0,1,0,1,0,0,0,2,1,0,1,6,2.37,2.33333333333333,0,3,2,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"AFFANNI ANTONIO;MAZZUCATO MARIO;SPECOGNA RUBEN;TREVISAN FRANCESCO;BATTISTON MONICA;DE MARCO LUIGINO;COZZI MARIA RITA;MARCO LUIGINO DE","3;3;3;3;2;2;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITA DEGLI STUDI DI UDINE;CT DI RIFERIMENTO ONCOLOGICO","3;3;1","40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;34 CHEMICAL SCIENCES","4;2;1;1;1",NA,NA,NA,NA,"G01N33/49;G01N27/02;G01N27/12;G01N33/86","2;1;1;1","B01L2300/0877;B01L3/502715;G01N27/023;G01N27/128;G01N2800/224;G01N2800/226;G01N33/4915;G01N33/86;G01N33/4905","2;2;2;2;2;2;2;2;1",16,6.12,358.12,5.71,9,0.56,94.75,0,0,3,0,10,0,0,3,0,13,3,0,0,0,0,0,0,14,2,0,16,0,0,0,0,0,0,0,0,0,"United States;Italy","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;50 PHILOSOPHY AND RELIGIOUS STUDIES;5002 HISTORY AND PHILOSOPHY OF SPECIFIC FIELDS","16;13;7;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;LUNG;LUNG CANCER;BREAST CANCER;PATIENT SAFETY;DIGESTIVE DISEASES;GENETICS;HEMATOLOGY;KIDNEY DISEASE;LYMPHOMA;ORPHAN DRUG;PREVENTION;AGING;BIOTECHNOLOGY;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;COLO-RECTAL CANCER","16;15;12;5;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;INFECTION","11;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.7 PHYSICAL;8.1 ORGANISATION AND DELIVERY OF SERVICES","12;2;1;1;1","LUNG CANCER;BREAST CANCER;KIDNEY CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;SARCOMA;STOMACH CANCER","4;3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","10;1;1;1;1;1",2,10465741,714649.37,6,14,7.5,1,150,604982.559722222,0.380176248560958,"CENTRO DI RIFERIMENTO ONCOLOGICO;KAROLINSKA INSTITUTET;AB ANALITICA (ITALY);ANDALUSIAN HEALTH SERVICE;DÉLÉGATION PARIS 11;FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES;GOLDEN HELIX FOUNDATION;INSTITUT PASTEUR;ISTITUTO SUPERIORE DI SANITÀ;LEIDEN UNIVERSITY MEDICAL CENTER;LIVERPOOL UNIVERSITY HOSPITALS NHS FOUNDATION TRUST;MEDICAL UNIVERSITY OF VIENNA;PAUL SABATIER UNIVERSITY;ROBERT BOSCH (GERMANY);ST. ANTONIUS ZIEKENHUIS;UNIVERSITY MEDICAL CENTER UTRECHT;UNIVERSITY OF CAMBRIDGE;UNIVERSITY OF HELSINKI;UNIVERSITY OF LIVERPOOL;UNIVERSITY OF LJUBLJANA","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2015-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","2;1;1;1;1","GENETICS;BIOTECHNOLOGY;CANCER;CLINICAL RESEARCH;HUMAN GENOME;ORPHAN DRUG;OVARIAN CANCER;PATIENT SAFETY;RARE DISEASES","2;1;1;1;1;1;1;1;1","CANCER","1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)","2;2;1;1;1;1","OVARIAN CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CRO",2017,201,16.0845771144279,3.26865671641791,0.348258706467662,0.298507462686567,0.407960199004975,2.78389830508475,1.27272727272727,1.66666666666667,1.32258064516129,0.651741293532338,3,115,47,13,8,0.57,0.23,0.06,0.04,25.75,0.873663107907549,5.71011793916822,0.432835820895522,0.935323383084577,0.482,0.409,0.449,0.426,"DIEGO SERRAINO;JERRY POLESEL;ALESSANDRA BEARZ;VINCENZO CANZONIERI;VALTER GATTEI;ANGELA BUONADONNA;GIUSEPPE TOFFOLI;UGO DE GIORGI;CARLO LA VECCHIA;ERIKA CECCHIN;RICCARDO DOLCETTI;LUCA GALLI;RENATO CANNIZZARO;RICCARDO BOMBEN;LUCIA FRATINO;MASSIMO LIBRA;DAVIDE ROSSI;CARLO FURLAN;FRANCESCO ZAJA;GIANLUCA GAÏDANO","27;24;17;16;13;12;11;11;11;10;9;9;9;9;8;8;8;8;8;8","JERRY POLESEL;DIEGO SERRAINO;SAMUELE MASSARUT;ERIKA CECCHIN;VINCENZO CANZONIERI;ANNUNZIATA GLOGHINI;ANTONINO CARBONE;GIUSEPPE TOFFOLI;ANGELA BUONADONNA;CARLO LA VECCHIA;ALESSANDRA BEARZ;RICCARDO DOLCETTI;ANTONINO DE PAOLI;RENATO CANNIZZARO;LARA ALESSANDRINI;VALLÌ DE RE;MASSIMO LIBRA;VALTER GATTEI;ELENA DE MATTIA;ANDREA CIAVATTINI","2.34;2.32;2.1;1.92;1.36;1.13;1.13;1.08;1.04;1.01;1;0.83;0.81;0.81;0.72;0.69;0.69;0.63;0.62;0.62","DIEGO SERRAINO;JERRY POLESEL;ALESSANDRA BEARZ;VINCENZO CANZONIERI;VALTER GATTEI;ANGELA BUONADONNA;GIUSEPPE TOFFOLI;ERIKA CECCHIN;RICCARDO DOLCETTI;RENATO CANNIZZARO;RICCARDO BOMBEN;LUCIA FRATINO;CARLO FURLAN;ANTONINO DE PAOLI;VALLÌ DE RE;LARA ALESSANDRINI;GIOVANNI LO RE;MASSIMILIANO BERRETTA;ALFONSO COLOMBATTI;ELENA DE MATTIA","27;24;17;16;13;12;11;10;9;9;9;8;8;8;7;7;7;7;6;6","JERRY POLESEL;DIEGO SERRAINO;SAMUELE MASSARUT;ERIKA CECCHIN;VINCENZO CANZONIERI;ANTONINO CARBONE;GIUSEPPE TOFFOLI;ANGELA BUONADONNA;ALESSANDRA BEARZ;RICCARDO DOLCETTI;ANTONINO DE PAOLI;RENATO CANNIZZARO;LARA ALESSANDRINI;VALLÌ DE RE;VALTER GATTEI;ELENA DE MATTIA;ANDREA CIAVATTINI;FRANCESCO SOPRACORDEVOLE;MASSIMILIANO BERRETTA;ALFONSO COLOMBATTI","2.34;2.32;2.1;1.92;1.36;1.13;1.08;1.04;1;0.83;0.81;0.81;0.72;0.69;0.63;0.62;0.62;0.62;0.6;0.6","ALESSANDRA BEARZ;DIEGO SERRAINO;JERRY POLESEL;VINCENZO CANZONIERI;SILVIA NOVELLO;GEOFFREY LIU;ALICE T. SHAW;CESARE GRIDELLI;CHENG ZHENG;CRISTIAN MASSACESI;DAVID R. SPIGEL;ENRIQUETA FELIP;GIORGIO V. SCAGLIOTTI;KALYANEE VIRASWAMI-APPANNA;KATSUYUKI KIURA;LUCIO CRINÓ;MAKOTO NISHIO;OLIVER GAUTSCHI;PATRICK URBAN;SERAFINO PANTANO","962;958;864;605;535;507;503;503;503;503;503;503;503;503;503;503;503;503;503;503","ALESSANDRA BEARZ;DIEGO SERRAINO;JERRY POLESEL;VINCENZO CANZONIERI;ANTONELLA ZUCCHETTO;ROBERTA MAESTRO;DEBORA MARTORELLI;LOREDANA MILITELLO;SIMON SPAZZAPAN;VALTER GATTEI;ELENA MURARO;MASSIMILIANO BERRETTA;ANGELA BUONADONNA;MARA FORNASARIG;EMANUELA VACCHER;LUIGINO DAL MASO;ANTONINO DE PAOLI;AGOSTINO STEFFAN;FRANCESCA MARIA ROSSI;ALESSANDRA VIEL","962;958;854;604;301;296;290;269;263;257;241;240;235;225;209;209;203;200;194;186","DIEGO SERRAINO;JERRY POLESEL;ALESSANDRA BEARZ;VINCENZO CANZONIERI;VALTER GATTEI;ANGELA BUONADONNA;GIUSEPPE TOFFOLI;ERIKA CECCHIN;ANTONELLA ZUCCHETTO;RENATO CANNIZZARO;LUCIA FRATINO;RICCARDO BOMBEN;ANTONINO DE PAOLI;VALLÌ DE RE;CARLO FURLAN;LARA ALESSANDRINI;MASSIMILIANO BERRETTA;GIORGIO GIORDA;ALFONSO COLOMBATTI;DEBORA MARTORELLI","27;23;17;15;12;12;11;10;9;9;8;8;8;7;7;7;7;6;6;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;MATERIALS SCIENCE;SOCIOLOGY;ENGINEERING;PSYCHOLOGY;PHILOSOPHY;HISTORY;MATHEMATICS;ART;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;POLITICAL SCIENCE","179;76;22;18;14;8;6;6;5;4;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GENETICS;GASTROENTEROLOGY;PATHOLOGY;PALEONTOLOGY;IMMUNOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;OPTICS;RADIOLOGY;GYNECOLOGY;UROLOGY;MEDICAL PHYSICS;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;DEMOGRAPHY;NURSING","159;93;45;42;35;34;32;24;23;22;22;17;13;13;10;10;8;8;8;6;6","CANCER;GENE;CHEMOTHERAPY;RADIATION THERAPY;CONFIDENCE INTERVAL;POPULATION;ADVERSE EFFECT;CLINICAL TRIAL;LUNG CANCER;LYMPHOMA;CASE-CONTROL STUDY;ODDS RATIO;STAGE (STRATIGRAPHY);CONTEXT (ARCHAEOLOGY);RANDOMIZED CONTROLLED TRIAL;REGIMEN;DISEASE;INCIDENCE (GEOMETRY);LEUKEMIA;LOGISTIC REGRESSION;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION","99;38;33;23;22;21;15;15;14;14;11;11;11;10;10;10;9;9;9;9;9;9","BREAST CANCER;COLORECTAL CANCER;PROSTATE CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;HAZARD RATIO;MUTATION;HEAD AND NECK CANCER;GENE EXPRESSION;OVARIAN CANCER;CYCLOPHOSPHAMIDE;DOCETAXEL;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;GENOTYPE;PHASES OF CLINICAL RESEARCH;BLADDER CANCER;CANCER REGISTRY;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;IMMUNOTHERAPY;MALIGNANT PLEURAL EFFUSION","24;18;14;13;13;12;10;9;8;8;7;7;6;6;6;6;5;5;5;5;5;5","ANDROGEN RECEPTOR;METASTATIC BREAST CANCER;ANDROGEN DEPRIVATION THERAPY;CRIZOTINIB;ANAPLASTIC LYMPHOMA KINASE;CERVICAL INTRAEPITHELIAL NEOPLASIA;COLPOSCOPY;IRINOTECAN;KRAS;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA METHYLATION;FEBRILE NEUTROPENIA;GERMLINE MUTATION;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IBRUTINIB;NIVOLUMAB;PAZOPANIB;CAPECITABINE;CDH1;CETUXIMAB;CHEMOIMMUNOTHERAPY;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;EPIRUBICIN;EPITHELIAL OVARIAN CANCER;HAPLOTYPE;IGHV@;KARYOTYPE;MILAN CRITERIA;NEOADJUVANT THERAPY;OXALIPLATIN;PHARMACOGENETICS;PROMOTER;TRABECTEDIN;VAGINAL CANCER;VINCRISTINE;VINORELBINE","8;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MIDDLE AGED;MALE;ADULT;AGED;ITALY;BREAST NEOPLASMS;ANTINEOPLASTIC AGENTS;NEOPLASM RECURRENCE, LOCAL;NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;YOUNG ADULT;CARCINOMA, SQUAMOUS CELL;MEMBRANE GLYCOPROTEINS;RISK FACTORS;AGED, 80 AND OVER;LUNG NEOPLASMS;BIOMARKERS, TUMOR","108;92;76;64;62;49;49;37;29;23;23;23;22;21;20;20;20;18;18;17","ADVANCEMENTS IN LUNG CANCER RESEARCH;LYMPHOID NEOPLASMS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;CANCER IMMUNOTHERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;INTEGRIN SIGNALING IN INFLAMMATION AND CANCER;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;RENAL CELL CARCINOMA;SARCOMA RESEARCH AND TREATMENT;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MOLECULAR RESEARCH ON BREAST CANCER","10;10;9;8;7;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;REGIMEN;HEALTHY EATING INDEX;DIET QUALITY;ENZALUTAMIDE;ABIRATERONE ACETATE;CABAZITAXEL;CANCER RISK;CHEMOTHERAPY REGIMEN;DIETARY PATTERNS;METASTATIC PROSTATE CANCER;RADIOTHERAPY;TREATMENT;ALK INHIBITOR;ALK INHIBITORS;BREAST CANCER;CERITINIB;CYTOLOGY SCREENING;EXPANDED ACCESS","13;13;10;8;7;7;5;5;5;5;5;5;5;5;4;4;4;4;4;4","BREAST CANCER;CELL CARCINOMA;PROSTATE CANCER;NECK CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;OVARIAN CANCER;RENAL CELL;COLORECTAL CANCER;METASTATIC RENAL;PHASE II;CANCER MCRPC;CANCER RISK;CASTRATION-RESISTANT PROSTATE;LUNG CANCER;METASTATIC CASTRATION-RESISTANT;PATIENTS PTS;SQUAMOUS CELL;CANCER CELLS;CANCER PATIENTS;CASECONTROL STUDY;CELL TRANSPLANTATION;EPITHELIAL OVARIAN;EXPANDED ACCESS;HEPATOCELLULAR CARCINOMA;HODGKIN LYMPHOMA;ITALIAN STUDY;MATRIX PROTEIN;MULTICENTER ITALIAN;PATIENTS TREATED","13;13;10;8;7;7;7;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","CANCER INSTITUTE;INSTITUTE AVIANO;NATIONAL CANCER;CRO AVIANO;AVIANO ITALY;ITALY SEARCH;AVIANO IRCCS;IRCCS NATIONAL;MDAH CELLS;HR CI;ONCOLOGY CRO;BREAST CANCER;MOLECULAR ONCOLOGY;ISTITUTO NAZIONALE;MEDIAN FOLLOW-UP;ADVERSE EVENTS;CELL LINES;RISK FACTORS;CELL DEATH;DATA REPRESENT;MEDIAN PFS;PATIENTS TREATED;PROGRESSION-FREE SURVIVAL;CELLS TREATED;DISEASE CONTROL;RESPONSE RATE;SURVIVAL OS;WESTERN BLOT;CANCER PATIENTS;CELL CYCLE","39;38;38;37;36;36;32;32;29;28;23;21;21;16;15;14;14;14;13;13;13;13;13;12;12;12;12;12;11;11",82,0.41,6.08,6,2,1,1,2.5,3.25,0,1.5,7,2,1,6,0,1,1,2,4,2,0,0,61.75,61.75,2,1,0,1,0,0,0,0,0,0,0,0,2,0,0,0,5.5,1.67,2,0,2,2,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"COLOMBATTI ALFONSO;DOLCETTI RICCARDO;DOLIANA ROBERTO;FAE' DAMIANA ANTONIA;GLISIC SANJA;MARTORELLI DEBORA;PEROVIC VLADIMIR;ROSATO ANTONIO;TURRINI RICCARDO;VELJKOVIC NEVENA","1;1;1;1;1;1;1;1;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;CENTRO DI RIFERIMENTO ONCOLOGICO - CRO-IRCCS AVIANO;ST ONCOLOGICO VENETO IOV-IRCCS;VINCA INSTITUTE OF NUCLEAR SCIENCES","1;1;1;1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","2;1",NA,NA,"1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","1","A61K38/16;A61K39/245;A61K39/39;A61K39/395;A61K45/06;A61P35/00;C07K14/05;C07K14/255;C07K16/08;C07K16/12","1;1;1;1;1;1;1;1;1;1","A61K2039/55516;A61K2039/585;A61K2039/6081;A61K38/164;A61K39/12;A61K39/39;A61K39/395;A61K39/39558;A61K45/06;A61K47/48507","1;1;1;1;1;1;1;1;1;1",18,6.18,771.59,8,9,0.5,54.72,2,1,6,1,4,0,1,3,0,15,2,0,0,0,0,0,0,14,3,1,17,1,0,0,0,0,0,0,0,0,"United States;Germany;Sweden;Austria;Greece;Italy;Netherlands;Slovenia;United Kingdom","4;2;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","18;13;9;5;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;LYMPHOMA;BREAST CANCER;GENETICS;HUMAN GENOME;LUNG;LUNG CANCER;ORPHAN DRUG;BIOMEDICAL IMAGING;BIOTECHNOLOGY;CARDIOVASCULAR;HEALTH SERVICES;NEUROSCIENCES;PEDIATRIC;PREVENTION","17;14;11;8;6;6;5;3;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","13;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","15;4;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HODGKIN'S DISEASE;PROSTATE CANCER;SMALL INTESTINE CANCER;STOMACH CANCER","5;3;2;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","13;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,"SPRINGER NATURE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;PUBLIC LIBRARY OF SCIENCE;TAYLOR & FRANCIS GROUP","11;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;44 HUMAN SOCIETY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES","15;11;10;4;1;1;1;1;1;1","CANCER;GENETICS;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;HIV/AIDS;INFECTIOUS DISEASES;LYMPHOMA;RARE DISEASES","2;2;1;1;1;1;1;1","CANCER;INFECTION","13;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT","1;1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","6;2","COLON AND RECTAL CANCER;HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;BLOOD CANCER;HODGKIN'S DISEASE;KAPOSI'S SARCOMA;LARYNGEAL CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;SARCOMA","11;2;2;2;2;1;1;1;1;1;1;1",NA,NA
"IRCCS_CRO",2018,260,15.4384615384615,3.11923076923077,0.292307692307692,0.330769230769231,0.673076923076923,2.74915254237288,1.2258064516129,1.8695652173913,1.75,0.607692307692308,0,158,53,18,14,0.61,0.2,0.07,0.05,32.82,1.07562315162105,5.45049794961922,0.396153846153846,0.965384615384615,0.496,0.406,0.434,0.435,"DIEGO SERRAINO;VALTER GATTEI;ANGELA BUONADONNA;FABIO PUGLISI;GIUSEPPE TOFFOLI;JERRY POLESEL;RICCARDO BOMBEN;ANTONELLA ZUCCHETTO;GIOVANNI DEL POETA;SILVIA FRANCESCHI;ANTONINO DE PAOLI;ETTORE BIDOLI;GABRIELE POZZATO;GIANPIERO FASOLA;LORENZO GERRATANA;MAURIZIO MASCARIN;VINCENZO CANZONIERI;AGOSTINO STEFFAN;ANGELO PAOLO DEI TOS;PAOLO G. CASALI","22;21;20;18;15;14;13;12;12;12;11;11;11;10;10;10;9;9;9;9","SILVIA FRANCESCHI;GIUSEPPE TOFFOLI;DIEGO SERRAINO;VALTER GATTEI;FABIO PUGLISI;GUSTAVO BALDASSARRE;VINCENZO CANZONIERI;PAOLO BALDO;GIULIA FORNASIER;SARA FRANCESCON;ANGELA BUONADONNA;ETTORE BIDOLI;JERRY POLESEL;MAURIZIO MASCARIN;GIANPIERO FASOLA;AGOSTINO STEFFAN;BARBARA BELLETTI;GARY M. CLIFFORD;RENATO CANNIZZARO;ILENIA SEGATTO","1.75;1.57;1.55;1.42;1.22;1.1;1.08;1.06;1.06;1.06;1.05;1.04;1.02;1.01;0.94;0.94;0.94;0.91;0.88;0.85","DIEGO SERRAINO;VALTER GATTEI;ANGELA BUONADONNA;FABIO PUGLISI;GIUSEPPE TOFFOLI;JERRY POLESEL;RICCARDO BOMBEN;ANTONELLA ZUCCHETTO;SILVIA FRANCESCHI;ANTONINO DE PAOLI;ETTORE BIDOLI;MAURIZIO MASCARIN;VINCENZO CANZONIERI;AGOSTINO STEFFAN;RENATO CANNIZZARO;GIANMARIA MIOLO;LUCIA FRATINO;ERIKA TISSINO;GIACOMO PELIZZARI;GUSTAVO BALDASSARRE","22;21;20;18;15;14;13;12;12;11;11;10;9;9;9;9;8;8;8;8","SILVIA FRANCESCHI;GIUSEPPE TOFFOLI;DIEGO SERRAINO;VALTER GATTEI;FABIO PUGLISI;GUSTAVO BALDASSARRE;VINCENZO CANZONIERI;PAOLO BALDO;GIULIA FORNASIER;SARA FRANCESCON;ANGELA BUONADONNA;ETTORE BIDOLI;JERRY POLESEL;MAURIZIO MASCARIN;AGOSTINO STEFFAN;BARBARA BELLETTI;RENATO CANNIZZARO;ILENIA SEGATTO;ANTONINO DE PAOLI;GIANMARIA MIOLO","1.75;1.57;1.55;1.42;1.22;1.1;1.08;1.06;1.06;1.06;1.05;1.04;1.02;1.01;0.94;0.94;0.88;0.85;0.82;0.8","ANGELA BUONADONNA;PAOLO G. CASALI;ALESSANDRO GRONCHI;GIOVANNI GRIGNANI;ANGELO PAOLO DEI TOS;SILVIA STACCHIOTTI;ANTONIO LÓPEZ–POUSA;JAVIER MARTÍN‐BROTO;PIERO PICCI;ANDREA FERRARI;MARIA A. PANTALEO;A. BASSIM HASSAN;AKMAL SAFWAT;ANNA MARIA FREZZA;AXEL LE CESNE;BERND KASPER;DAGMAR ADÁMKOVÁ KRÁKOROVÁ;ENRIQUE DE ÁLAVA;EVA WARDELMANN;FRITS VAN COEVORDEN","2839;2611;2608;2606;2602;2594;2589;2589;2589;2532;2530;2525;2525;2525;2525;2525;2525;2525;2525;2525","ANGELA BUONADONNA;ALESSANDRA BEARZ;DIEGO SERRAINO;SAMUELE MASSARUT;JERRY POLESEL;GIUSEPPE TOFFOLI;SILVIA FRANCESCHI;LUIGINO DAL MASO;VALTER GATTEI;ALFONSO COLOMBATTI;ANTONELLA ZUCCHETTO;MAURIZIO MONGIAT;AGOSTINO STEFFAN;FABIO PUGLISI;GIULIA FORNASIER;PAOLO BALDO;SARA FRANCESCON;ROBERTO DOLIANA;ANTONINO DE PAOLI;CHIARA PANATO","2833;850;578;555;404;374;286;268;216;196;192;180;174;173;168;168;168;159;156;134","DIEGO SERRAINO;VALTER GATTEI;ANGELA BUONADONNA;ANTONELLA ZUCCHETTO;GIUSEPPE TOFFOLI;JERRY POLESEL;FABIO PUGLISI;RICCARDO BOMBEN;ANTONINO DE PAOLI;SILVIA FRANCESCHI;ETTORE BIDOLI;MAURIZIO MASCARIN;AGOSTINO STEFFAN;VINCENZO CANZONIERI;RENATO CANNIZZARO;ERIKA TISSINO;GUSTAVO BALDASSARRE;LUCIA FRATINO;GIANMARIA MIOLO;PIETRO BULIAN","22;21;19;16;14;14;13;13;11;11;11;10;9;9;9;8;8;8;8;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;PSYCHOLOGY;MATHEMATICS;ECONOMICS;MATERIALS SCIENCE;BUSINESS;PHILOSOPHY;ENGINEERING;GEOGRAPHY;POLITICAL SCIENCE;HISTORY;ART;GEOLOGY","232;105;28;23;22;15;11;10;9;7;6;6;4;4;4;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GENETICS;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;BIOCHEMISTRY;PALEONTOLOGY;CELL BIOLOGY;GYNECOLOGY;RADIOLOGY;OPTICS;PHARMACOLOGY;PSYCHIATRY;NURSING;MOLECULAR BIOLOGY;ENDOCRINOLOGY;FAMILY MEDICINE;PEDIATRICS","188;102;52;50;49;48;43;38;35;34;25;20;17;16;15;15;15;13;11;10;10;10","CANCER;GENE;POPULATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;RADIATION THERAPY;LYMPHOMA;LEUKEMIA;PROPORTIONAL HAZARDS MODEL;ADVERSE EFFECT;COHORT;LUNG CANCER;MULTIVARIATE ANALYSIS;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;STAGE (STRATIGRAPHY);CLINICAL TRIAL;INCIDENCE (GEOMETRY);CONTEXT (ARCHAEOLOGY);EPIDEMIOLOGY;ODDS RATIO","136;48;37;31;29;21;19;16;16;15;14;14;14;13;13;13;12;12;10;10;10","BREAST CANCER;COLORECTAL CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;HAZARD RATIO;MUTATION;CLINICAL ENDPOINT;DOCETAXEL;UNIVARIATE ANALYSIS;METASTASIS;PROSTATE CANCER;GENE EXPRESSION;PROGRESSION-FREE SURVIVAL;CISPLATIN;GENOTYPE;TUMOR MICROENVIRONMENT;TYROSINE KINASE;CERVICAL CANCER;HEAD AND NECK CANCER;TOLERABILITY;HODGKIN LYMPHOMA;IMMUNOTHERAPY;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;POLYMERASE CHAIN REACTION;THYROID CANCER;TRANSCRIPTION FACTOR","38;33;14;14;12;11;10;10;9;9;8;8;7;7;7;7;6;6;6;5;5;5;5;5;5;5","IRINOTECAN;METASTATIC BREAST CANCER;KRAS;GERMLINE MUTATION;IBRUTINIB;BRUTON'S TYROSINE KINASE;METASTASECTOMY;NEOADJUVANT THERAPY;VINORELBINE;ANDROGEN DEPRIVATION THERAPY;IGHV@;ANDROGEN RECEPTOR;CRIZOTINIB;CYSTECTOMY;MAMMARY GLAND;MICROSATELLITE;NIVOLUMAB;OXALIPLATIN;PHARMACOGENETICS;PRIMARY TUMOR;TRIPLE-NEGATIVE BREAST CANCER","9;9;7;6;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;;MIDDLE AGED;MALE;AGED;ADULT;ITALY;BREAST NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;YOUNG ADULT;ADOLESCENT;TREATMENT OUTCOME;LUNG NEOPLASMS;PROGNOSIS;HODGKIN DISEASE;NEOPLASMS","146;112;110;86;80;77;71;64;55;40;33;29;26;26;25;24;23;23;22;22","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;SARCOMA RESEARCH AND TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN LUNG CANCER RESEARCH;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MOLECULAR RESEARCH ON BREAST CANCER;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;CANCER IMMUNOTHERAPY;CANCER STEM CELLS AND TUMOR METASTASIS;COLORECTAL CANCER RESEARCH AND TREATMENT;GLIOMAS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE","15;10;10;9;7;7;7;7;6;6;6;5;5;5;4;4;4;4;4;3","BREAST CANCER;CLINICAL ENDPOINT;UNIVARIATE ANALYSIS;CANCER INCIDENCE;METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;RADIOTHERAPY;CANCER THERAPY;METASTATIC BREAST CANCER;TREATMENT;CANCER RISK;NEOADJUVANT THERAPY;SOFT TISSUE SARCOMA;SURGICAL ONCOLOGY;TOLERABILITY;FOLFIRI;IBRUTINIB;METASTASECTOMY;VINORELBINE;ALPHA PARTICLE THERAPY","13;12;10;8;8;8;8;7;7;7;6;6;6;6;6;5;5;5;5;4","BREAST CANCER;COLORECTAL CANCER;CANCER PATIENTS;METASTATIC COLORECTAL;LUNG CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;PROSTATE CANCER;RADIATION THERAPY;CLINICAL PRACTICE;GASTRIC CANCER;HODGKIN LYMPHOMA;METASTATIC BREAST;RECTAL CANCER;CANCER RISK;CELL LUNG;ELDERLY PATIENTS;LOCALLY ADVANCED;MULTICENTER STUDY;OVARIAN CANCER;PHASE II;ADMINISTRATIVE HEALTHCARE;ANTICANCER DRUG;BLADDER CANCER;CANCER MCRPC;CASTRATION-RESISTANT PROSTATE;DRUG MONITORING;HEALTHCARE DATABASES;ICD--CM CODES;NECK CANCER","23;18;16;12;11;10;10;8;7;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","PUBMED SCOPUS;CROSSREF PUBMED;BREAST CANCER;RESEARCH FUNDING;GASTROINTESTINAL STROMAL;HR CI;ONCOL -CROSSREF;HONORARIA RESEARCH;CLIN ONCOL;CONSULTANCY HONORARIA;SOFT TISSUE;ONCOL -ABSTRACT;CLL CELLS;COLORECTAL CANCER;SURVIVAL OS;PATIENTS TREATED;PROGRESSION-FREE SURVIVAL;LOCALLY ADVANCED;PROGNOSTIC FACTORS;ADVERSE EVENTS;MEDIAN AGE;MULTIVARIATE ANALYSIS;BAXBCL- RATIO;GROWTH FACTOR;STANDARD TREATMENT;CANCER PATIENTS;STROMAL TUMORS;SURVIVAL PFS;BONE SARCOMAS;FREE SURVIVAL","107;73;38;38;34;32;31;27;26;23;23;21;19;19;19;18;18;16;16;15;15;15;14;14;14;13;13;13;12;12",122,0.47,6.53,8,2,2,1,6.5,2,1,1,9.75,1,1,7.25,1,1,1,3,5.75,4,0,0,60.75,60.75,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,6,0.74,2,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BONIFACIO ALOIS;CERVO SILVIA;COLOMBATTI ALFONSO;DALLA MARTA SILVIA;SERGO VALTER;SPIZZO RICCARDO","1;1;1;1;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITA DEGLI STUDI DI TRIESTE","1;1","34 CHEMICAL SCIENCES;3402 INORGANIC CHEMISTRY;40 ENGINEERING","1;1;1",NA,NA,NA,NA,"B82Y40/00;G01N21/65","1;1","B82Y40/00;G01N21/658","1;1",22,6.14,507.38,7.94,12,0.55,108.86,0,0,8,0,9,0,1,4,0,18,3,0,0,0,0,0,0,19,3,0,21,1,0,0,0,0,0,0,0,0,"United States;Japan;United Kingdom;Switzerland;Germany;Italy","12;5;3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS","22;21;7;4;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;HEMATOLOGY;RARE DISEASES;DIGESTIVE DISEASES;LYMPHOMA;BRAIN DISORDERS;EMERGING INFECTIOUS DISEASES;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);LUNG;LUNG CANCER;PATIENT SAFETY;PREVENTION;AGING;DOWN SYNDROME;ESTROGEN;HEALTH SERVICES;LIVER DISEASE","20;19;15;6;5;5;3;3;2;2;2;2;2;2;2;1;1;1;1;1","CANCER","15","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","20;5;1;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;LUNG CANCER;BLADDER CANCER;CERVICAL CANCER;HODGKIN'S DISEASE;LIVER CANCER;OVARIAN CANCER;STOMACH CANCER","6;5;3;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","15;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS","15;7;6","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;31 BIOLOGICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;3105 GENETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;41 ENVIRONMENTAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3107 MICROBIOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3405 ORGANIC CHEMISTRY;3406 PHYSICAL CHEMISTRY;40 ENGINEERING;4105 POLLUTION AND CONTAMINATION;46 INFORMATION AND COMPUTING SCIENCES","40;12;10;6;5;4;4;3;2;1;1;1;1;1;1;1;1;1;1","CANCER;GENETICS;CLINICAL RESEARCH;DIGESTIVE DISEASES;COLO-RECTAL CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;DENTAL/ORAL AND CRANIOFACIAL DISEASE;BREAST CANCER;BIOTECHNOLOGY;GENETIC TESTING;HUMAN GENOME;INFECTIOUS DISEASES;OVARIAN CANCER;PREVENTION;PROSTATE CANCER;SEXUALLY TRANSMITTED INFECTIONS;UROLOGIC DISEASES","10;8;6;6;5;4;4;4;3;2;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","13;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","5;2;1;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","5;2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","11;8;1","NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;BREAST CANCER;CERVICAL CANCER;NASAL CAVITY AND PARANASAL SINUS CANCER;OVARIAN CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER","7;5;3;2;2;2;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_CRO",2019,287,18.184668989547,3.97909407665505,0.310104529616725,0.320557491289199,0.435540069686411,2.79901960784314,1.25352112676056,1.84,1.34408602150538,0.609756097560976,0,145,68,24,14,0.51,0.24,0.08,0.05,18.59,0.764585298216038,5.41256830601092,0.400696864111498,0.993031358885017,0.498,0.405,0.466,0.429,"ANGELA BUONADONNA;VINCENZO CANZONIERI;FABIO PUGLISI;VALTER GATTEI;DIEGO SERRAINO;GIUSEPPE TOFFOLI;ANTONINO DE PAOLI;DEBORA BASILE;JERRY POLESEL;RENATO CANNIZZARO;GIACOMO PELIZZARI;ERIKA CECCHIN;GUSTAVO BALDASSARRE;MICHELE BARTOLETTI;GIANMARIA MIOLO;LORENZO GERRATANA;ALESSANDRO DEL CONTE;C. LISANTI;ANTONELLA ZUCCHETTO;DAVIDE ROSSI","23;22;20;20;19;16;14;14;14;13;13;13;12;11;11;11;11;10;10;10","VINCENZO CANZONIERI;ANGELA BUONADONNA;GIUSEPPE TOFFOLI;DIEGO SERRAINO;GUSTAVO BALDASSARRE;ERIKA CECCHIN;FABIO PUGLISI;VALTER GATTEI;RENATO CANNIZZARO;DEBORA BASILE;ANTONINO DE PAOLI;FLAVIO RIZZOLIO;JERRY POLESEL;SAMUELE MASSARUT;GIAN LUCA RAMPIONI VINCIGUERRA;GIANMARIA MIOLO;SILVANA SARACCHINI;LUCIA CADORIN;ALESSANDRO DEL CONTE;BARBARA BELLETTI","1.91;1.42;1.29;1.26;1.13;1.11;1.07;1.03;0.93;0.9;0.89;0.86;0.85;0.81;0.8;0.76;0.75;0.75;0.74;0.74","ANGELA BUONADONNA;VINCENZO CANZONIERI;FABIO PUGLISI;VALTER GATTEI;DIEGO SERRAINO;GIUSEPPE TOFFOLI;ANTONINO DE PAOLI;DEBORA BASILE;JERRY POLESEL;RENATO CANNIZZARO;GIACOMO PELIZZARI;ERIKA CECCHIN;GUSTAVO BALDASSARRE;MICHELE BARTOLETTI;GIANMARIA MIOLO;LORENZO GERRATANA;ALESSANDRO DEL CONTE;C. LISANTI;ANTONELLA ZUCCHETTO;GIORGIO GIORDA","23;22;20;20;19;16;14;14;14;13;13;13;12;11;11;11;11;10;10;10","VINCENZO CANZONIERI;ANGELA BUONADONNA;GIUSEPPE TOFFOLI;DIEGO SERRAINO;GUSTAVO BALDASSARRE;ERIKA CECCHIN;FABIO PUGLISI;VALTER GATTEI;RENATO CANNIZZARO;DEBORA BASILE;ANTONINO DE PAOLI;FLAVIO RIZZOLIO;JERRY POLESEL;SAMUELE MASSARUT;GIAN LUCA RAMPIONI VINCIGUERRA;GIANMARIA MIOLO;SILVANA SARACCHINI;LUCIA CADORIN;ALESSANDRO DEL CONTE;BARBARA BELLETTI","1.91;1.42;1.29;1.26;1.13;1.11;1.07;1.03;0.93;0.9;0.89;0.86;0.85;0.81;0.8;0.76;0.75;0.75;0.74;0.74","DOMENICA LORUSSO;PAOLO MARCHETTI;GIORGIO GIORDA;GIOVANNI SCAMBIA;FRANCESCO RASPAGLIESI;SEBASTIANO BUTI;ALEXANDER BURGES;ALEXANDER MUSTEA;ALEXANDER REUß;ANDREAS DU BOIS;ANNETTE HASENBURG;BARBARA SCHMALFELDT;BJÖRN LAMPE;CARMEN SCHADE‐BRITTINGER;CHRISTIAN MARTH;DAVID CIBULA;FELIX HILPERT;GIOVANNI ALETTI;IGNACE VERGOTE;INGO B. RUNNEBAUM","547;528;518;513;474;460;431;431;431;431;431;431;431;431;431;431;431;431;431;431","GIORGIO GIORDA;DIEGO SERRAINO;VINCENZO CANZONIERI;GIUSEPPE TOFFOLI;MARIANNA TUDINI;ROSA RITA SILVA;ALESSANDRA BEARZ;ETTORE BIDOLI;FABIO PUGLISI;BARBARA BELLETTI;GUSTAVO BALDASSARRE;FLAVIO RIZZOLIO;RENATO CANNIZZARO;VALTER GATTEI;GIAN LUCA RAMPIONI VINCIGUERRA;ERIKA CECCHIN;BARBARA MUZZATTI;CRISTIANA FLAIBAN;KATIUSCIA MARIA GIPPONI;MARIA ANTONIETTA ANNUNZIATA","518;318;318;308;307;307;305;265;264;237;233;228;228;219;202;191;186;186;186;186","ANGELA BUONADONNA;VINCENZO CANZONIERI;VALTER GATTEI;DIEGO SERRAINO;FABIO PUGLISI;GIUSEPPE TOFFOLI;JERRY POLESEL;ANTONINO DE PAOLI;RENATO CANNIZZARO;ERIKA CECCHIN;GUSTAVO BALDASSARRE;DEBORA BASILE;GIANMARIA MIOLO;GIORGIO GIORDA;ALESSANDRO DEL CONTE;ANTONELLA ZUCCHETTO;GIACOMO PELIZZARI;MICHELE BARTOLETTI;RICCARDO BOMBEN;ROBERTO SORIO","23;22;20;19;19;16;15;14;13;13;12;11;11;10;10;10;10;10;10;10","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHILOSOPHY;ECONOMICS;PSYCHOLOGY;ENGINEERING;MATERIALS SCIENCE;POLITICAL SCIENCE;BUSINESS","264;108;30;28;19;17;13;10;9;9;8;8;4;3","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;RADIOLOGY;PALEONTOLOGY;CELL BIOLOGY;OPTICS;NUCLEAR MEDICINE;FAMILY MEDICINE;NURSING;GYNECOLOGY;UROLOGY;DEMOGRAPHY;PHARMACOLOGY;STATISTICS","231;129;64;53;49;46;34;33;32;31;28;24;16;16;15;14;14;13;12;11;11;11","CANCER;CHEMOTHERAPY;GENE;RADIATION THERAPY;CONFIDENCE INTERVAL;POPULATION;LYMPHOMA;ADVERSE EFFECT;CLINICAL TRIAL;LEUKEMIA;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;COHORT;DISEASE;INCIDENCE (GEOMETRY);RETROSPECTIVE COHORT STUDY;CONTEXT (ARCHAEOLOGY);IMMUNE SYSTEM;ODDS RATIO;RECEPTOR","165;58;48;29;27;27;23;20;19;16;16;16;15;15;15;15;14;14;10;10","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;CHRONIC LYMPHOCYTIC LEUKEMIA;OVARIAN CANCER;PROSTATE CANCER;HAZARD RATIO;IMMUNOTHERAPY;MUTATION;PROGRESSION-FREE SURVIVAL;RITUXIMAB;BEVACIZUMAB;GENOTYPE;CISPLATIN;HEAD AND NECK CANCER;NEUTROPENIA;CERVICAL CANCER;METASTASIS;CANCER REGISTRY;TOLERABILITY","37;35;18;16;16;16;14;14;14;12;12;10;10;9;9;9;8;8;7;7","IBRUTINIB;GERMLINE MUTATION;IRINOTECAN;METASTATIC BREAST CANCER;TRASTUZUMAB;BRUTON'S TYROSINE KINASE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;NIVOLUMAB;PROSTATECTOMY;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN RECEPTOR;CAPECITABINE;CARBOPLATIN;GENOTYPING;KRAS;SINGLE-NUCLEOTIDE POLYMORPHISM;BENDAMUSTINE;BRENTUXIMAB VEDOTIN;CANCER IMMUNOTHERAPY;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHEMOIMMUNOTHERAPY;COLPOSCOPY;CRIZOTINIB;CYCLIC VOLTAMMETRY;GEFITINIB;INTRAOPERATIVE RADIOTHERAPY;IPILIMUMAB;MASTECTOMY;OXALIPLATIN;PHARMACOGENETICS;RNA SPLICING;TAXANE;TRANSCRIPTOME","9;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;OVARIAN NEOPLASMS;NEOPLASMS;RETROSPECTIVE STUDIES;CARCINOMA, NON-SMALL-CELL LUNG;YOUNG ADULT;PROGNOSIS;ANTINEOPLASTIC AGENTS;COLORECTAL NEOPLASMS","144;142;110;90;89;80;72;47;43;43;42;41;36;30;30;29;28;26;24;21","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;CANCER IMMUNOTHERAPY;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;CANCER SURVIVORSHIP AND QUALITY OF LIFE;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DNA NANOTECHNOLOGY AND BIOANALYTICAL APPLICATIONS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HER2 SIGNALING IN BREAST CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DRUG METABOLISM AND PHARMACOGENOMICS;GASTRIC CANCER RESEARCH AND TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK","18;15;14;12;11;8;6;6;6;5;4;4;4;4;4;4;3;3;3;3","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;BREAST CANCER;CANCER RISK;METASTATIC COLORECTAL CANCER;TOLERABILITY;BIOMARKERS FOR IMMUNOTHERAPY;CANCER INCIDENCE;REGIMEN;CANCER SURVIVORSHIP;MANTLE CELL LYMPHOMA;RADIOTHERAPY;CANCER TREATMENT;EGFR MUTATIONS;FOLLICULAR LYMPHOMA;IBRUTINIB;REFRACTORY (PLANETARY SCIENCE);TREATMENT;TUMOR MODELS;AUTOLOGOUS STEM-CELL TRANSPLANTATION","19;13;12;10;9;9;8;8;8;7;7;7;6;6;6;6;6;6;6;5","BREAST CANCER;CANCER PATIENTS;COLORECTAL CANCER;OVARIAN CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;METASTATIC COLORECTAL;PHASE II;LUNG CANCER;PROSTATE CANCER;CANCER RISK;POOLED ANALYSIS;FONDAZIONE ITALIANA;GASTRIC CANCER;ITALIANA LINFOMI;LOCALLY ADVANCED;PATIENTS PTS;RANDOMIZED TRIAL;CELL CARCINOMA;COHORT STUDY;FIRST-LINE CHEMOTHERAPY;NECK CANCER;NECK SQUAMOUS;PATIENTS TREATED;PHASE TRIAL;SQUAMOUS CELL;ADVANCED GASTRIC;ADVANCED OVARIAN;CANCER INCIDENCE;CASTRATION-RESISTANT PROSTATE","22;17;16;16;12;11;11;10;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4","ADVISORY CONSULTANCY;BUREAU EXPERT;EXPERT TESTIMONY;SPEAKER BUREAU;CONSULTANCY SPEAKER;SPEAKERS BUREAU;ACCOMMODATION EXPENSES;TRAVEL ACCOMMODATION;ADVISORY COMMITTEES;ENTITYS BOARD;BREAST CANCER;HR CI;GRANT FUNDING;RESEARCH GRANT;FUNDING INSTITUTION;COMMITTEES SPEAKERS;RESEARCH FUNDING;MEDIAN AGE;PATIENTS TREATED;BOEHRINGER INGELHEIM;SURVIVAL OS;TESTIMONY TRAVEL;CONSULTANCY MEMBERSHIP;ADVISORY BOARD;CANCER PATIENTS;CONSULTANCY RESEARCH;NOVARTIS HONORARIA;CLINICAL TRIAL;ELI LILLY;ROCHE HONORARIA","183;100;100;100;75;65;64;64;61;61;55;53;51;51;41;35;32;28;26;25;24;23;22;21;20;20;19;18;18;18",137,0.48,8,8,2,1,0,2,2,1,1,9,1,1,7,1,1,1,4,6,4,0,0,52,52,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5.46,346.58,7.28,11,0.42,67.85,1,0,8,0,7,0,1,9,0,18,8,0,0,0,0,0,0,19,6,1,26,0,0,0,0,0,0,0,0,0,"United States;Japan;Switzerland","8;5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","26;23;12;5;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;BREAST CANCER;PATIENT SAFETY;LUNG;LUNG CANCER;PREVENTION;AGING;BRAIN DISORDERS;ESTROGEN;GENETICS;ORPHAN DRUG;OVARIAN CANCER;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN CANCER","24;23;17;11;8;8;6;6;4;4;4;2;2;2;2;2;2;1;1;1","CANCER;CARDIOVASCULAR;SKIN","19;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","19;5;4;3;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;BLADDER CANCER;PROSTATE CANCER;SKIN CANCER","6;5;4;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","16;2;1;1;1;1",1,44263,14754.33,2,3,1,1,1,342558.893055556,0.837812142140052,"CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITY OF TRIESTE;UNIVERSITY OF UDINE","1;1;1","SARCOMA FOUNDATION OF AMERICA","1","HRA - HEALTH RESEARCH ALLIANCE","1","THE LAST MILE SARCOMA RESEARCH GRANT (FUNDING PROGRAM)","1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1;1","CANCER;GENETICS","1;1","GENERIC HEALTH RELEVANCE","1","5.1 PHARMACEUTICALS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,13,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;THE CAMBRIDGE STRUCTURAL DATABASE","5;5;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;37 EARTH SCIENCES;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3202 CLINICAL SCIENCES;3703 GEOCHEMISTRY;38 ECONOMICS;3801 APPLIED ECONOMICS;40 ENGINEERING;50 PHILOSOPHY AND RELIGIOUS STUDIES;51 PHYSICAL SCIENCES","12;5;5;2;2;2;1;1;1;1;1;1;1","CANCER;DIGESTIVE DISEASES;GENETICS;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER CANCER;LIVER DISEASE;LYMPHOMA;RARE DISEASES","5;5;5;4;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;INFECTION","4;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE","6","COLON AND RECTAL CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA","4;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_CRO",2020,296,18.1554054054054,3.375,0.283783783783784,0.283783783783784,0.449324324324324,3.24350649350649,1.21739130434783,2,1.37113402061856,0.635135135135135,4,165,57,33,12,0.56,0.19,0.11,0.04,22.82,0.905778679373636,6.31861042183623,0.405405405405405,0.97972972972973,0.522,0.472,0.48,0.493,"FABIO PUGLISI;DIEGO SERRAINO;DEBORA BASILE;GIUSEPPE TOFFOLI;JERRY POLESEL;ANGELA BUONADONNA;MAURIZIO MASCARIN;LORENZO GERRATANA;VINCENZO CANZONIERI;AGOSTINO STEFFAN;RENATO CANNIZZARO;VALTER GATTEI;GIUSEPPE APRILE;RICCARDO BOMBEN;GIANPIERO FASOLA;ELENA ONGARO;ANTONINO DE PAOLI;C. LISANTI;GIACOMO PELIZZARI;CARLO LA VECCHIA","32;26;21;20;20;19;18;16;15;13;12;12;12;12;11;11;11;10;10;10","ANTONINO CARBONE;DIEGO SERRAINO;FABIO PUGLISI;GIUSEPPE TOFFOLI;MAURIZIO MASCARIN;JERRY POLESEL;DEBORA BASILE;AGOSTINO STEFFAN;FLAVIO RIZZOLIO;ANGELA BUONADONNA;VINCENZO CANZONIERI;DONATELLA ALDINUCCI;PAOLA SPESSOTTO;GIANMARIA MIOLO;RENATO CANNIZZARO;GIUSEPPE CORONA;LORENZO GERRATANA;ELIANA PIVETTA;CARLO LA VECCHIA;FRANCESCA DAL MAS","3.1;3.1;2.06;1.78;1.4;1.33;1.24;1.17;1.03;1.02;0.96;0.95;0.94;0.93;0.93;0.86;0.86;0.79;0.78;0.78","FABIO PUGLISI;DIEGO SERRAINO;DEBORA BASILE;GIUSEPPE TOFFOLI;JERRY POLESEL;ANGELA BUONADONNA;MAURIZIO MASCARIN;LORENZO GERRATANA;VINCENZO CANZONIERI;AGOSTINO STEFFAN;RENATO CANNIZZARO;VALTER GATTEI;RICCARDO BOMBEN;ELENA ONGARO;ANTONINO DE PAOLI;C. LISANTI;GIACOMO PELIZZARI;FRANCESCO SOPRACORDEVOLE;FRANCESCO CORTIULA;FLAVIO RIZZOLIO","32;26;21;20;20;19;18;16;15;13;12;12;12;11;11;10;10;9;9;9","ANTONINO CARBONE;DIEGO SERRAINO;FABIO PUGLISI;GIUSEPPE TOFFOLI;MAURIZIO MASCARIN;JERRY POLESEL;DEBORA BASILE;AGOSTINO STEFFAN;FLAVIO RIZZOLIO;ANGELA BUONADONNA;VINCENZO CANZONIERI;DONATELLA ALDINUCCI;PAOLA SPESSOTTO;GIANMARIA MIOLO;RENATO CANNIZZARO;GIUSEPPE CORONA;LORENZO GERRATANA;ELIANA PIVETTA;FRANCESCO CORTIULA;MASSIMILIANO BERRETTA","3.1;3.1;2.06;1.78;1.4;1.33;1.24;1.17;1.03;1.02;0.96;0.95;0.94;0.93;0.93;0.86;0.86;0.79;0.77;0.74","JERRY POLESEL;PAOLO BOSCOLO‐RIZZO;GIACOMO SPINATO;DANIELE BORSETTO;CLAIRE HOPKINS;CRISTOFORO FABBRIS;DIEGO CAZZADOR;DANIELE SANTINI;ALFREDO FALCONE;ANGELA BUONADONNA;GIUSEPPE APRILE;DIEGO SERRAINO;SARA LONARDI;ALBERTO ZANIBONI;GIANLUCA TOMASELLO;EMILIANO TAMBURINI;ROBERTO BORDONARO;ANDREA MAMBRINI;CHIARA CARLOMAGNO;CRISTINA GRANETTO","1350;1080;1058;1028;1006;1006;893;769;708;629;583;555;554;522;516;509;509;488;488;488","JERRY POLESEL;ANGELA BUONADONNA;DIEGO SERRAINO;SAMUELE MASSARUT;ANTONINO DE PAOLI;VINCENZO CANZONIERI;LORENZO VINANTE;FLAVIO RIZZOLIO;FABIO PUGLISI;ANTONELLA ZUCCHETTO;SILVIA FRANCESCHI;FRANCESCO SOPRACORDEVOLE;GIUSEPPE TOFFOLI;ELENA ONGARO;LUIGINO DAL MASO;MARIANNA TUDINI;AGOSTINO STEFFAN;RICCARDO BOMBEN;STEFANO PALAZZOLO;MARCELLA MONTICO","1350;629;553;488;455;370;329;306;293;286;273;267;258;252;236;235;230;223;217;205","FABIO PUGLISI;DIEGO SERRAINO;JERRY POLESEL;GIUSEPPE TOFFOLI;ANGELA BUONADONNA;MAURIZIO MASCARIN;DEBORA BASILE;VINCENZO CANZONIERI;AGOSTINO STEFFAN;LORENZO GERRATANA;RENATO CANNIZZARO;VALTER GATTEI;RICCARDO BOMBEN;ANTONINO DE PAOLI;ANTONELLA ZUCCHETTO;ELENA ONGARO;FLAVIO RIZZOLIO;FRANCESCO SOPRACORDEVOLE;GIANMARIA MIOLO;GIORGIO GIORDA","30;25;21;19;19;18;15;15;13;12;12;12;12;11;11;11;9;9;9;9","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;PSYCHOLOGY;POLITICAL SCIENCE;ECONOMICS;MATHEMATICS;PHILOSOPHY;BUSINESS;ENGINEERING;MATERIALS SCIENCE;GEOGRAPHY;HISTORY;ENVIRONMENTAL SCIENCE;GEOLOGY","272;101;33;22;21;19;16;11;10;9;8;6;5;4;3;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GENETICS;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;FAMILY MEDICINE;OPTICS;DEMOGRAPHY;PALEONTOLOGY;CELL BIOLOGY;RADIOLOGY;PHARMACOLOGY;VIROLOGY;LAW","228;122;60;56;55;48;44;35;34;31;18;17;17;16;16;14;14;13;13;11","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;DISEASE;POPULATION;COHORT;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY;LYMPHOMA;INCIDENCE (GEOMETRY);PROPORTIONAL HAZARDS MODEL;LUNG CANCER;MULTIVARIATE ANALYSIS;ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;RECEPTOR;IMMUNE SYSTEM;OUTBREAK","161;48;47;40;33;29;27;21;21;20;15;15;14;14;13;13;12;12;11;11","BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;IMMUNOTHERAPY;PROGRESSION-FREE SURVIVAL;HODGKIN LYMPHOMA;OVARIAN CANCER;CISPLATIN;MUTATION;PROSTATE CANCER;BEVACIZUMAB;CANCER CELL;CHRONIC LYMPHOCYTIC LEUKEMIA;UNIVARIATE ANALYSIS;CYCLOPHOSPHAMIDE;GENOTYPE;HEAD AND NECK CANCER;2019-20 CORONAVIRUS OUTBREAK;CANCER REGISTRY;CERVICAL CANCER;GENOME;NEUTROPENIA;PACLITAXEL","51;33;21;20;16;16;14;11;11;10;10;9;8;8;8;8;7;7;7;6;6;6;6;6;6","CORONAVIRUS DISEASE 2019 (COVID-19);METASTATIC BREAST CANCER;OXALIPLATIN;IRINOTECAN;NIVOLUMAB;HORMONE RECEPTOR;NEOADJUVANT THERAPY;ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;GERMLINE MUTATION;PEMBROLIZUMAB;TRABECTEDIN;TRASTUZUMAB;AROMATASE;BENDAMUSTINE;BRENTUXIMAB VEDOTIN;CERVICAL INTRAEPITHELIAL NEOPLASIA;COPY-NUMBER VARIATION;ESTROGEN RECEPTOR;EXTERNAL BEAM RADIOTHERAPY;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IPILIMUMAB;KRAS;PDGFRA;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN;TAXANE","20;15;10;9;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;BREAST NEOPLASMS;MIDDLE AGED;MALE;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;RETROSPECTIVE STUDIES;COLORECTAL NEOPLASMS;AGED, 80 AND OVER;PROGNOSIS;CORONAVIRUS INFECTIONS;OVARIAN NEOPLASMS;PNEUMONIA, VIRAL;YOUNG ADULT;ADOLESCENT;CISPLATIN","181;115;76;60;53;52;47;42;35;30;27;21;20;20;18;18;18;18;17;17","IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;LYMPHOID NEOPLASMS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;CANCER IMMUNOTHERAPY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MOLECULAR RESEARCH ON BREAST CANCER;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER SURVIVORSHIP AND QUALITY OF LIFE;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GLIOMAS;N-HETEROCYCLIC CARBENES IN CATALYSIS AND MATERIALS CHEMISTRY;OLFACTORY DYSFUNCTION IN HEALTH AND DISEASE","13;12;9;8;8;8;8;7;7;7;6;6;5;4;4;4;4;4;4;4","CLINICAL ENDPOINT;PANDEMIC;PROGRESSION-FREE SURVIVAL;BREAST CANCER;HEALTHY EATING INDEX;BIOMARKERS FOR IMMUNOTHERAPY;CANCER RISK;REGIMEN;UNIVARIATE ANALYSIS;CANCER GENOMICS;CANCER SURVIVORSHIP;FOLFIRI;HEMATOLOGY;METASTATIC COLORECTAL CANCER;TREATMENT;TUMOR MICROENVIRONMENT;2019-20 CORONAVIRUS OUTBREAK;CANCER IMAGING;CANCER IMMUNOEDITING;CANCER INCIDENCE","16;14;14;11;9;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6","BREAST CANCER;CANCER PATIENTS;COLORECTAL CANCER;CELL CARCINOMA;HODGKIN LYMPHOMA;METASTATIC COLORECTAL;PATIENTS TREATED;OVARIAN CANCER;COHORT STUDY;METASTATIC BREAST;LUNG CANCER;PROSTATE CANCER;CELL LUNG;CHRONIC LYMPHOCYTIC;FIRST-LINE THERAPY;GASTRIC CANCER;ITALIAN ASSOCIATION;RENAL CELL;CLINICAL OUTCOMES;LYMPHOCYTIC LEUKEMIA;METASTATIC RENAL;NON-SMALL CELL;POOLED ANALYSIS;PROGNOSTIC ROLE;RETROPERITONEAL SARCOMA;SQUAMOUS CELL;ABSTRACT P--;ADVANCED BREAST;BLADDER CANCER;CANCER RISK","37;21;15;10;10;10;10;9;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4","BREAST CANCER;CANCER PATIENTS;HR CI;SURVIVAL OS;DISEASE PROGRESSION;MEDIAN AGE;PATIENTS TREATED;SARS-COV- INFECTION;MEDIAN FOLLOW-UP;ADVERSE EVENTS;PROGRESSION-FREE SURVIVAL;TRIESTE TRIESTE;OVARIAN CANCER;SURVIVAL PFS;CELL LINES;DERMATOLOGY MAGGIORE;HAZARD RATIO;MAGGIORE HOSPITAL;MD DEPARTMENT;MDS PATIENTS;TRIESTE ITALYSEARCH;TRIESTE UNIVERSITY;CANCER RISK;CONFIDENCE INTERVAL;COLORECTAL CANCER;PRIMARY ENDPOINT;RESEARCH FUNDING;MEDIAN PFS;MULTIVARIATE ANALYSIS;PATIENTS UNDERGOING","93;47;34;27;26;24;24;24;21;20;20;18;17;17;16;16;16;16;16;16;16;16;15;15;14;14;14;13;13;13",157,0.53,7,8,2,2,0,6,1.75,1,1.5,9,1,1,7.5,2,1.5,2,4,5,5,0,0,48,48,3,0,0,5,0,0,0,0,0,0,0,0,2,0,3,0,4.4,2.2,1.8,0,4,2,0,0,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BONAZZA GREGORIO;DANIELE SALVATORE;POLO FEDERICO;TARTAGGIA STEFANO;TOFFOLI GIUSEPPE;BALDASSARRE GUSTAVO;SONEGO MAURA","4;4;4;4;4;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;UNIV CA FOSCARI;CENTRO DI RIFERIMENTO ONCOLOGICO ISTITUTO NAZ TUMORI AVIANO","4;4;1","34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY","4;2","CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEMATOLOGY;RARE DISEASES","2;1;1;1;1",NA,NA,"G01N27/48;G01N30/00;G01N33/487","2;2;2","G01N27/48;G01N33/48714;G01N2030/884;G01N30/06;C12Q1/6886;C12Q2600/106;C12Q2600/158","3;3;2;2;1;1;1",29,4.97,430.31,9.73,21,0.72,107.9,0,0,6,3,12,0,3,5,0,24,5,0,0,0,0,0,0,25,2,2,29,0,0,0,0,0,0,0,0,0,"United States;Germany;Japan;Switzerland;United Kingdom;Italy","6;2;2;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","29;25;20;4;2;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA;PATIENT SAFETY;BREAST CANCER;DIGESTIVE DISEASES;GENETICS;ORPHAN DRUG;UROLOGIC DISEASES;AGING;BIOMEDICAL IMAGING;INFECTIOUS DISEASES;PREVENTION;PROSTATE CANCER;CERVICAL CANCER","29;27;23;10;9;7;7;7;7;4;4;4;3;3;2;2;2;2;2;1","CANCER","22","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","24;4;3;2;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;PROSTATE CANCER;SARCOMA;BLADDER CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","7;7;6;2;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.2 SURVEILLANCE","19;3;1;1;1",5,0,0,5,1,1,0,8.75,342558.893055556,0.864084996771622,"CENTRO DI RIFERIMENTO ONCOLOGICO","5","ITALIAN ASSOCIATION FOR CANCER RESEARCH","5","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","5",NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","4;4;1;1","CANCER;RARE DISEASES;CLINICAL RESEARCH;BIOTECHNOLOGY;GENETICS;BREAST CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;HUMAN GENOME;LYMPHOMA;ORPHAN DRUG;OVARIAN CANCER;PEDIATRIC;PREVENTION","5;4;3;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","5;1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION","4;3;2;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;SARCOMA","1;1;1;1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.4 CANCER PROGRESSION AND METASTASIS;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;6.2 SURVEILLANCE","3;2;1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","4;1","3 GOOD HEALTH AND WELL BEING","2",30,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;THE CAMBRIDGE STRUCTURAL DATABASE","18;11;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;44 HUMAN SOCIETY;40 ENGINEERING;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4014 MANUFACTURING ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS;3210 NUTRITION AND DIETETICS;3401 ANALYTICAL CHEMISTRY;37 EARTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","25;14;8;7;6;4;4;3;2;2;2;2;2;2;2;2;1;1;1;1","CANCER;GENETICS;BIOTECHNOLOGY;BREAST CANCER;CLINICAL RESEARCH;RARE DISEASES;DIGESTIVE DISEASES;ESTROGEN;PATIENT SAFETY;BEHAVIORAL AND SOCIAL SCIENCE;HUMAN GENOME;NUTRITION","12;7;5;5;4;4;3;2;2;1;1;1","CANCER;ORAL AND GASTROINTESTINAL","10;3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;7.1 INDIVIDUAL CARE NEEDS;5.1 PHARMACEUTICALS","3;3;2","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","4;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","12;3;1","BREAST CANCER;SARCOMA;COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER;STOMACH CANCER","5;4;3;1;1","3 GOOD HEALTH AND WELL BEING","3"
"IRCCS_CRO",2021,278,21.1978417266187,3.2841726618705,0.258992805755396,0.248201438848921,0.348920863309353,2.70118343195266,1.26315789473684,1.76923076923077,1.40579710144928,0.715827338129496,1,123,83,26,8,0.44,0.3,0.09,0.03,18.79,1.21857976217453,6.25057155921353,0.435251798561151,0.989208633093525,0.538,0.367,0.363,0.445,"FABIO PUGLISI;VINCENZO CANZONIERI;JERRY POLESEL;DIEGO SERRAINO;LORENZO GERRATANA;VALTER GATTEI;GIUSEPPE TOFFOLI;MICHELE SPINA;FLAVIO RIZZOLIO;MICHELE MERLI;ALESSANDRO RE;DAVIDE ROSSI;MONICA TANI;GUIDO GINI;FRANCESCA RE;ANGELA BUONADONNA;VITTORIO RUGGERO ZILIOLI;FRANCESCO MERLI;GERARDO MUSURACA;AGOSTINO STEFFAN","30;22;19;18;16;16;15;15;14;14;13;12;12;12;12;12;11;11;11;10","VINCENZO CANZONIERI;FLAVIO RIZZOLIO;FABIO PUGLISI;DIEGO SERRAINO;GIUSEPPE TOFFOLI;ANTONINO CARBONE;CESARE MAZZARO;JERRY POLESEL;LORENZO GERRATANA;MAURIZIO MONGIAT;EMANUELA VACCHER;LUCIA FRATINO;AGOSTINO STEFFAN;LUIGINO DAL MASO;MAURIZIO MASCARIN;MAURIZIO POLANO;ISABELLA CALIGIURI;MUHAMMAD ADEEL;MICHELE AVANZO;ALESSANDRA BEARZ","2.48;2.01;1.82;1.72;1.49;1.31;1.24;1.11;1.11;1.05;0.87;0.87;0.86;0.81;0.8;0.78;0.77;0.7;0.7;0.69","FABIO PUGLISI;VINCENZO CANZONIERI;JERRY POLESEL;DIEGO SERRAINO;LORENZO GERRATANA;VALTER GATTEI;GIUSEPPE TOFFOLI;MICHELE SPINA;FLAVIO RIZZOLIO;ANGELA BUONADONNA;AGOSTINO STEFFAN;LUIGINO DAL MASO;GUSTAVO BALDASSARRE;MAURIZIO MASCARIN;ANTONELLA ZUCCHETTO;ALESSANDRA BEARZ;LUCIA FRATINO;ROBERTA MAESTRO;EUGENIO BORSATTI;MICHELE AVANZO","30;22;19;18;16;16;15;15;14;12;10;10;10;10;9;9;8;8;8;8","VINCENZO CANZONIERI;FLAVIO RIZZOLIO;FABIO PUGLISI;DIEGO SERRAINO;GIUSEPPE TOFFOLI;ANTONINO CARBONE;CESARE MAZZARO;JERRY POLESEL;LORENZO GERRATANA;MAURIZIO MONGIAT;EMANUELA VACCHER;LUCIA FRATINO;AGOSTINO STEFFAN;LUIGINO DAL MASO;MAURIZIO MASCARIN;MAURIZIO POLANO;ISABELLA CALIGIURI;MUHAMMAD ADEEL;MICHELE AVANZO;ALESSANDRA BEARZ","2.48;2.01;1.82;1.72;1.49;1.31;1.24;1.11;1.11;1.05;0.87;0.87;0.86;0.81;0.8;0.78;0.77;0.7;0.7;0.69","ALESSANDRO GRONCHI;D. STRAUß;JEAN‐YVES BLAY;PIOTR RUTKOWSKI;WINAN J. VAN HOUDT;ANGELO PAOLO DEI TOS;MARTA SBARAGLIA;AKIRA KAWAI;ANNA MARIA FREZZA;ANNALISA TRAMA;AXEL LE CESNE;BERND KASPER;HANS GELDERBLOM;JAVIER MARTÍN‐BROTO;JUDITH V.M.G. BOVÉE;KIRSTEN SUNDBY HALL;MIKAEL ERIKSSON;OLIVIER MIR;PAOLO G. CASALI;PETER HOHENBERGER","1285;1285;1285;1285;1285;1249;1240;1233;1233;1233;1233;1233;1233;1233;1233;1233;1233;1233;1233;1233","ANGELA BUONADONNA;SILVIA FRANCESCHI;JERRY POLESEL;LUIGINO DAL MASO;VINCENZO CANZONIERI;FABIO PUGLISI;MICHELE AVANZO;FLAVIO RIZZOLIO;ROBERTA MAESTRO;DIEGO SERRAINO;MICHELE SPINA;GIUSEPPE TOFFOLI;LORENZO GERRATANA;MUHAMMAD ADEEL;AGOSTINO STEFFAN;KANWAL ASIF;FRANCESCO SOPRACORDEVOLE;LUCIA FRATINO;ARBEN LLESHI;EMANUELA CHIMIENTI","1210;628;567;556;316;299;240;239;178;159;156;141;140;134;125;123;108;107;102;98","FABIO PUGLISI;VINCENZO CANZONIERI;JERRY POLESEL;DIEGO SERRAINO;MICHELE SPINA;VALTER GATTEI;FLAVIO RIZZOLIO;GIUSEPPE TOFFOLI;ANTONELLA ZUCCHETTO;ANGELA BUONADONNA;AGOSTINO STEFFAN;MAURIZIO MASCARIN;GUSTAVO BALDASSARRE;ALESSANDRA BEARZ;LORENZO GERRATANA;LUIGINO DAL MASO;MICHELE AVANZO;ERIKA CECCHIN;EUGENIO BORSATTI;LUCIA FRATINO","29;21;19;18;16;16;14;14;12;12;10;10;10;9;9;9;8;8;8;8","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;ENGINEERING;MATERIALS SCIENCE;PSYCHOLOGY;MATHEMATICS;BUSINESS;ART;PHILOSOPHY","248;98;32;27;19;11;11;11;9;6;6;5;3;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;BIOCHEMISTRY;GENETICS;ENVIRONMENTAL HEALTH;IMMUNOLOGY;GASTROENTEROLOGY;PALEONTOLOGY;FAMILY MEDICINE;GYNECOLOGY;CELL BIOLOGY;OPTICS;PHARMACOLOGY;RADIOLOGY;LAW;MEDICAL PHYSICS;ORGANIC CHEMISTRY","215;130;51;48;43;40;39;34;34;33;24;20;18;17;17;15;14;11;11;11","CANCER;CHEMOTHERAPY;GENE;LYMPHOMA;POPULATION;DISEASE;CONFIDENCE INTERVAL;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY;COHORT;CLINICAL TRIAL;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);LEUKEMIA;PROSPECTIVE COHORT STUDY;LUNG CANCER;PROPORTIONAL HAZARDS MODEL;TRANSPLANTATION;ADVERSE EFFECT","138;43;42;36;32;28;26;25;25;23;17;17;16;16;15;14;13;13;11;10","BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;CHRONIC LYMPHOCYTIC LEUKEMIA;OVARIAN CANCER;PROSTATE CANCER;IMMUNOTHERAPY;CISPLATIN;CYCLOPHOSPHAMIDE;RITUXIMAB;GENOTYPE;METASTASIS;MUTATION;PROGRESSION-FREE SURVIVAL;CHEMORADIOTHERAPY;DIFFUSE LARGE B-CELL LYMPHOMA;HEAD AND NECK CANCER;CERVICAL CANCER;CYTOTOXICITY;DOCETAXEL;EPIGENETICS;FOLLICULAR LYMPHOMA;GENE EXPRESSION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;LIQUID BIOPSY;MAPK/ERK PATHWAY;NEUTROPENIA;PHASES OF CLINICAL RESEARCH;SALVAGE THERAPY;THERAPEUTIC DRUG MONITORING;THYROID CANCER;TYROSINE KINASE","45;22;17;17;15;12;12;11;10;9;9;9;8;8;8;8;7;7;7;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);METASTATIC BREAST CANCER;IBRUTINIB;NIVOLUMAB;IRINOTECAN;NEOADJUVANT THERAPY;PEMBROLIZUMAB;VINCRISTINE;BRUTON'S TYROSINE KINASE;CIRCULATING TUMOR CELL;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IGHV@;TAXANE;ADJUVANT CHEMOTHERAPY;ANTHRACYCLINE;ATROPHIC GASTRITIS;BRCA MUTATION;CARBOPLATIN;CETUXIMAB;GENETIC HETEROGENEITY;GERMLINE MUTATION;HORMONE RECEPTOR;INTERNATIONAL PROGNOSTIC INDEX;IPILIMUMAB;PHARMACOGENETICS;SPLENIC MARGINAL ZONE LYMPHOMA;TAMOXIFEN;TRASTUZUMAB","17;15;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;ITALY;RETROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED;BREAST NEOPLASMS;NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;ADULT;OVARIAN NEOPLASMS;ANTINEOPLASTIC AGENTS;LUNG NEOPLASMS;SARCOMA;COVID-19;HODGKIN DISEASE;AGED, 80 AND OVER","138;137;59;41;38;36;36;35;34;31;31;29;28;23;20;20;18;17;17;16","LYMPHOID NEOPLASMS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ADVANCEMENTS IN LUNG CANCER RESEARCH;SARCOMA RESEARCH AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;HEPATITIS C INFECTION AND TREATMENT;RADIOMICS IN MEDICAL IMAGING ANALYSIS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;CANCER STEM CELLS AND TUMOR METASTASIS;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLIOMAS","22;10;10;10;9;9;6;6;6;5;5;5;5;4;4;4;4;4;4;4","CLINICAL ENDPOINT;BREAST CANCER;PANDEMIC;PROGRESSION-FREE SURVIVAL;CANCER;MANTLE CELL LYMPHOMA;REGIMEN;TREATMENT;CANCER INCIDENCE;CANCER RISK;CHEMORADIOTHERAPY;MOLECULAR PROFILING;CANCER GENOMICS;MELANOMA;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE;SURGICAL ONCOLOGY;ADJUVANT THERAPY;BIOMARKERS FOR IMMUNOTHERAPY;FOLLICULAR LYMPHOMA;IBRUTINIB","16;12;10;9;8;8;8;8;7;7;7;7;6;6;6;6;5;5;5;5","BREAST CANCER;CANCER PATIENTS;FONDAZIONE ITALIANA;ITALIANA LINFOMI;HODGKIN LYMPHOMA;METASTATIC BREAST;PHASE II;CIRCULATING TUMOR;PROSTATE CANCER;LUNG CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;OVARIAN CANCER;PATIENTS TREATED;CELL CARCINOMA;COLORECTAL CANCER;ITALIAN ASSOCIATION;LINFOMI FIL;LOCALLY ADVANCED;MULTICENTER STUDY;SQUAMOUS CELL;TUMOR DNA;CANCER MBC;CELL LUNG;CLASSICAL HODGKIN;CLINICAL ONCOLOGY;GASTRIC CANCER;NON-SMALL CELL;RADIATION THERAPY;RECTAL CANCER","25;18;15;15;13;12;10;9;9;8;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;RESEARCH FUNDING;HR CI;CONSULTANCY HONORARIA;PUBMED SCOPUS;ACCOMODATIONS EXPENSES;TRAVEL ACCOMODATIONS;CANCER PATIENTS;MEDIAN AGE;SURVIVAL OS;MEDIAN FOLLOW-UP;PROGRESSION-FREE SURVIVAL;BREAST CANCER;ADVISORY ROLE;GASTRIC CANCER;CLINICAL PRACTICE;SURVIVAL PFS;JANSSEN CONSULTANCY;PYLORI INFECTION;COMMITTEES SPEAKERS;COMPLETE RESPONSE;GILEAD SCIENCES;HONORARIA RESEARCH;ADVISORY BOARD;CROSSREF PUBMED;ONCOL -ABSTRACT;PATIENTS TREATED;CLINICAL TRIALS","143;143;87;67;54;41;40;32;32;29;28;27;25;25;23;22;22;20;20;19;19;18;18;18;18;17;17;17;17;16",156,0.56,7.51,9,1,1,0,5,1,0,1,10.25,1,0,9,1.75,1.75,1.75,4.5,6,3,0,0,33,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,5.33,400.06,5.66,13,0.72,99.83,1,1,4,0,7,0,0,5,0,13,4,0,0,0,1,0,0,17,0,1,17,0,0,0,0,1,0,0,0,0,"United States;Japan;Belgium;Germany","4;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY","18;17;10;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;LUNG;LUNG CANCER;ORPHAN DRUG;PEDIATRIC;BREAST CANCER;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEMATOLOGY;LYMPHOMA;ASSISTIVE TECHNOLOGY;BIOENGINEERING;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;NUTRITION;PEDIATRIC CANCER","17;17;16;8;7;4;4;4;4;2;2;2;2;1;1;1;1;1;1;1","CANCER;INFECTION","15;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;7.3 MANAGEMENT AND DECISION MAKING","14;3;1;1;1","LUNG CANCER;SARCOMA;NON-HODGKIN'S LYMPHOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BREAST CANCER;BLADDER CANCER;HEAD AND NECK CANCER;HODGKIN'S DISEASE;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER","4;4;3;2;2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","12;2;1;1",1,0,0,4,1,1,0,1,238216.455555556,1.1670058617557,"CENTRO DI RIFERIMENTO ONCOLOGICO","1","ITALIAN ASSOCIATION FOR CANCER RESEARCH","1","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","1",NA,NA,"31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1;1","CANCER;GENETICS;OVARIAN CANCER;RARE DISEASES","1;1;1;1","CANCER","1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1;1","OVARIAN CANCER","1","1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1","A01 CLINICAL MEDICINE","1",NA,NA,25,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;THE CAMBRIDGE STRUCTURAL DATABASE;ZENODO;SPRINGER NATURE","13;6;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;3401 ANALYTICAL CHEMISTRY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;40 ENGINEERING;4014 MANUFACTURING ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;4403 DEMOGRAPHY;46 INFORMATION AND COMPUTING SCIENCES;50 PHILOSOPHY AND RELIGIOUS STUDIES;51 PHYSICAL SCIENCES","35;15;12;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;GENETICS;PATIENT SAFETY;RARE DISEASES;LUNG;LUNG CANCER;ORPHAN DRUG;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIGESTIVE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;HEMATOLOGY;PREVENTION","15;14;11;10;9;8;8;8;3;3;2;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;NEUROLOGICAL","15;2;1","6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","10;2;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","14;1;1","CLINICAL MEDICINE AND SCIENCE","17","LUNG CANCER;HEAD AND NECK CANCER;NOT SITE-SPECIFIC CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;BREAST CANCER;COLON AND RECTAL CANCER;ORAL CAVITY AND LIP CANCER","8;2;2;2;2;1;1;1","3 GOOD HEALTH AND WELL BEING","3"
"IRCCS_CRO",2022,281,19.3807829181495,2.65836298932384,0.213523131672598,0.213523131672598,0.256227758007117,2.57586206896552,1.22448979591837,1.53846153846154,1.44,0.772241992882562,0,131,70,13,13,0.47,0.25,0.05,0.05,8.01,0.897372917515766,5.92816717457555,0.459074733096085,0.99288256227758,0.507,0.483,0.472,0.489,"FABIO PUGLISI;DIEGO SERRAINO;VINCENZO CANZONIERI;GIOVANNI SCAMBIA;JERRY POLESEL;FLAVIO RIZZOLIO;LORENZO GERRATANA;VALTER GATTEI;SANDRO PIGNATA;LUIGINO DAL MASO;DOMENICA LORUSSO;MARTINA TABORELLI;ANGELA BUONADONNA;UGO DE GIORGI;CARLO LA VECCHIA;MAURIZIO MASCARIN;LUCIA MUSACCHIO;MICHELE BARTOLETTI;GIUSEPPE FORNARINI;RICCARDO BOMBEN","26;26;17;16;15;14;14;14;14;13;12;11;11;11;11;11;10;10;10;10","DIEGO SERRAINO;FABIO PUGLISI;FLAVIO RIZZOLIO;VINCENZO CANZONIERI;JERRY POLESEL;LORENZO GERRATANA;LUCA MICELI;CARLO LA VECCHIA;MARTINA TABORELLI;ANGELA BUONADONNA;FEDERICA TOFFOLUTTI;EVA NEGRI;LUIGINO DAL MASO;AGOSTINO STEFFAN;SANDRO PIGNATA;ANTONINO CARBONE;DOMENICA LORUSSO;FRANCESCA DAL MAS;HELENA BIANCUZZI;ETTORE BIDOLI","2.28;1.82;1.62;1.35;1.24;1.08;1.05;0.98;0.93;0.86;0.84;0.81;0.81;0.78;0.78;0.75;0.71;0.7;0.7;0.69","FABIO PUGLISI;DIEGO SERRAINO;VINCENZO CANZONIERI;JERRY POLESEL;FLAVIO RIZZOLIO;LORENZO GERRATANA;VALTER GATTEI;LUIGINO DAL MASO;MARTINA TABORELLI;ANGELA BUONADONNA;MAURIZIO MASCARIN;MICHELE BARTOLETTI;RICCARDO BOMBEN;AGOSTINO STEFFAN;LUCIA FRATINO;ANTONELLA ZUCCHETTO;RENATO CANNIZZARO;MICHELE SPINA;FEDERICA TOFFOLUTTI;FRANCESCO SOPRACORDEVOLE","26;26;17;15;14;14;14;13;11;11;11;10;10;9;9;9;9;9;8;7","DIEGO SERRAINO;FABIO PUGLISI;FLAVIO RIZZOLIO;VINCENZO CANZONIERI;JERRY POLESEL;LORENZO GERRATANA;LUCA MICELI;MARTINA TABORELLI;ANGELA BUONADONNA;FEDERICA TOFFOLUTTI;LUIGINO DAL MASO;AGOSTINO STEFFAN;ANTONINO CARBONE;HELENA BIANCUZZI;ETTORE BIDOLI;MICHELE BARTOLETTI;GIUSEPPE TOFFOLI;VALTER GATTEI;MAURIZIO MASCARIN;MICHELE SPINA","2.28;1.82;1.62;1.35;1.24;1.08;1.05;0.93;0.86;0.84;0.81;0.78;0.75;0.7;0.69;0.67;0.65;0.65;0.62;0.55","JERRY POLESEL;FABIO PUGLISI;FLAVIO RIZZOLIO;DIEGO SERRAINO;VINCENZO CANZONIERI;GIOVANNI SCAMBIA;LUIGINO DAL MASO;LUCA BONI;GEMMA GATTA;GIORGIO BOGANI;PAOLO BOSCOLO‐RIZZO;ALESSANDRA BEARZ;BRIGITTE LACOUR;CLAUDIA SPIX;DEIRDRE M. MURRAY;FRIEDERIKE ERDMANN;KAIRE INNOS;LAURA BOTTA;RICCARDO CAPOCACCIA;SILVIA ROSSI","263;256;215;202;201;190;159;147;146;146;145;144;144;144;144;144;144;144;144;144","JERRY POLESEL;FABIO PUGLISI;FLAVIO RIZZOLIO;VINCENZO CANZONIERI;LUIGINO DAL MASO;ALESSANDRA BEARZ;DIEGO SERRAINO;FRANCESCO SOPRACORDEVOLE;ERIKA CECCHIN;RENATO CANNIZZARO;GIUSEPPE TOFFOLI;MICHELE SPINA;MAURIZIO MASCARIN;ANTONELLA ZUCCHETTO;ROSSANA RONCATO;ANGELA BUONADONNA;SIMON SPAZZAPAN;ISABELLA CALIGIURI;VALTER GATTEI;MICHELE AVANZO","263;256;215;190;159;144;130;114;113;104;93;88;87;84;82;80;78;74;73;72","FABIO PUGLISI;DIEGO SERRAINO;JERRY POLESEL;VINCENZO CANZONIERI;VALTER GATTEI;ANTONELLA ZUCCHETTO;LORENZO GERRATANA;FLAVIO RIZZOLIO;LUIGINO DAL MASO;ANGELA BUONADONNA;MAURIZIO MASCARIN;RICCARDO BOMBEN;MICHELE SPINA;MARTINA TABORELLI;RENATO CANNIZZARO;AGOSTINO STEFFAN;MICHELE BARTOLETTI;LUCIA FRATINO;FEDERICA TOFFOLUTTI;FRANCESCO SOPRACORDEVOLE","26;25;16;16;14;13;13;13;13;11;11;10;10;10;9;9;9;9;8;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;ECONOMICS;ENGINEERING;PHILOSOPHY;BUSINESS;ART;GEOGRAPHY;HISTORY;MATERIALS SCIENCE;GEOLOGY","254;96;32;26;20;17;10;9;9;6;6;6;4;3;3;3;3;1","INTERNAL MEDICINE;ONCOLOGY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;GENETICS;SURGERY;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;GYNECOLOGY;PHARMACOLOGY;RADIOLOGY;FAMILY MEDICINE;CELL BIOLOGY;OPTICS;BIOINFORMATICS;DEMOGRAPHY;PALEONTOLOGY;INTENSIVE CARE MEDICINE","218;126;54;45;45;45;42;42;38;37;18;18;17;16;15;15;13;13;12;11","CANCER;GENE;POPULATION;CHEMOTHERAPY;DISEASE;COHORT;CONFIDENCE INTERVAL;LYMPHOMA;CLINICAL TRIAL;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;LUNG CANCER;IMMUNE SYSTEM;LEUKEMIA;PROSPECTIVE COHORT STUDY;PROPORTIONAL HAZARDS MODEL;TRANSPLANTATION;LOGISTIC REGRESSION;RADIATION THERAPY","154;50;49;43;34;26;25;24;23;18;18;15;13;12;11;11;11;10;10;9;9","BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;OVARIAN CANCER;CISPLATIN;IMMUNOTHERAPY;PROGRESSION-FREE SURVIVAL;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CHRONIC LYMPHOCYTIC LEUKEMIA;CANCER REGISTRY;HAZARD RATIO;PROSTATE CANCER;ALLELE;BEVACIZUMAB;CERVICAL CANCER;PHASES OF CLINICAL RESEARCH;GENOTYPE;METASTASIS;PACLITAXEL;POLYMERASE;RITUXIMAB","45;29;18;17;15;14;14;13;11;9;9;8;7;7;7;7;6;6;6;6;6","CORONAVIRUS DISEASE 2019 (COVID-19);METASTATIC BREAST CANCER;NIVOLUMAB;CARBOPLATIN;KRAS;POLY ADP RIBOSE POLYMERASE;CAPECITABINE;CRIZOTINIB;DNA MISMATCH REPAIR;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRASTUZUMAB;CETUXIMAB;CIRCULATING TUMOR CELL;IBRUTINIB;IPILIMUMAB;IRINOTECAN;MICROSATELLITE;OXALIPLATIN;PEMBROLIZUMAB;BENDAMUSTINE;CERVICAL INTRAEPITHELIAL NEOPLASIA;IGHV@;PHARMACOGENETICS;RELATIVE SURVIVAL;TAMOXIFEN;TRABECTEDIN;VINORELBINE","13;13;10;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;RETROSPECTIVE STUDIES;COVID-19;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;BREAST NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;NEOPLASMS;OVARIAN NEOPLASMS;COLORECTAL NEOPLASMS;MALE;PROSPECTIVE STUDIES;PROGNOSIS;UTERINE CERVICAL NEOPLASMS;AGED;ADULT;BRAIN NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG","144;128;36;32;30;29;27;25;25;21;20;19;19;18;15;15;13;12;12;12","LYMPHOID NEOPLASMS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;MELANOMA;CANCER SURVIVORSHIP AND QUALITY OF LIFE;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;COLORECTAL CANCER RESEARCH AND TREATMENT;GYNECOLOGIC ONCOLOGY;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;RADIOMICS IN MEDICAL IMAGING ANALYSIS;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT","15;12;10;9;8;8;7;6;6;5;5;4;4;4;4;4;4;3;3;3","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;METASTATIC BREAST CANCER;CANCER;PANDEMIC;CANCER THERAPY;INTRATUMOR HETEROGENEITY;REGIMEN;BREAST CANCER;CANCER IMAGING;CARBOPLATIN;MELANOMA;RENAL CELL CARCINOMA;TREATMENT;TUMOR MICROENVIRONMENT;CANCER GENOMICS;CANCER SURVIVORSHIP;CONCOMITANT;FOLFIRI;NEOADJUVANT THERAPY","18;14;12;11;9;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5","BREAST CANCER;OVARIAN CANCER;CIRCULATING TUMOR;COLORECTAL CANCER;METASTATIC BREAST;PHASE III;CANCER PATIENTS;CELL CARCINOMA;RENAL CELL;METASTATIC RENAL;PHASE II;HODGKIN LYMPHOMA;METASTATIC COLORECTAL;PROSTATE CANCER;TUMOR DNA;CHRONIC LYMPHOCYTIC;CANCER MBC;CANCER RISK;ENDOMETRIAL CANCER;FONDAZIONE ITALIANA;III RANDOMIZED;ITALIANA LINFOMI;LUNG CANCER;LYMPHOCYTIC LEUKEMIA;POPULATION-BASED STUDY;B-CELL LYMPHOMA;CELL LUNG;COVID- VACCINATION;DNA CTDNA;ELDERLY PATIENTS","29;12;11;11;10;10;9;9;9;8;8;7;7;7;7;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4","PROGRESSION-FREE SURVIVAL;BREAST CANCER;SURVIVAL OS;ADVERSE EVENTS;CANCER PATIENTS;MEDIAN FOLLOW-UP;MEDIAN AGE;COLORECTAL CANCER;PATIENTS TREATED;SURVIVAL PFS;CANCER RISK;MONTHS CI;OVARIAN CANCER;TP MUTATIONS;CELL LINES;MEET-URO SCORE;RESPONSE RATE;PATIENTS RECEIVED;STATISTICALLY SIGNIFICANT;B-CELL LYMPHOMA;BONE MARROW;CONFIDENCE INTERVAL;MEDIAN TIME;NEWLY DIAGNOSED;PATIENTS RECEIVING;PRIMARY ENDPOINT;VIEW LARGEDOWNLOAD;BLADDER CANCER;CELL CARCINOMA;INCREASED RISK","36;33;30;29;29;27;26;22;21;21;20;20;19;17;16;16;15;13;13;12;12;12;12;12;12;12;12;11;11;11",164,0.58,6.76,7,1,1,0,2.25,0,1,1,9,1,1,6.25,0,1,1,4,4,4.25,0,0,16.25,17,2,0,0,2,1,0,0,0,0,0,0,0,2,0,1,0,4.33333333333333,1.74,1.33333333333333,0,1,3,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"AGOSTINI FRANCESCO;DURANTE CRISTINA;MAZZUCATO MARIO;VICINANZA CARLA;BONAZZA GREGORIO;DANIELE SALVATORE;POLO FEDERICO;TARTAGGIA STEFANO;TOFFOLI GIUSEPPE","2;2;2;2;1;1;1;1;1","CENTRO DI RIFERIMENTO ONCOLOGICO;UNIVERSITA' CA' FOSCARI","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;40 ENGINEERING","4;2;2;1;1","HEMATOLOGY;BIOTECHNOLOGY;CANCER;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","2;1;1;1;1;1;1","5.2 CELLULAR AND GENE THERAPIES","1","A61K;A61K35/28;C12N5/0775;G01N27/48;G01N30/00;G01N33/487","1;1;1;1;1;1","A61K35/28;C12N13/00;C12N2501/135;C12N2509/00;C12N2533/30;C12N5/0663;C12N5/0664;C12N5/0667;C12N5/0668;G01N27/48","2;2;2;2;2;2;2;2;2;1",10,5.3,531.8,3.57,5,0.5,61.9,0,1,2,0,3,0,0,4,0,6,4,0,0,0,0,0,0,9,1,0,10,0,0,0,0,0,0,0,0,0,"United States;Australia;Belgium;Finland;Italy;Japan;Spain;Switzerland","5;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","10;9;5;2;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;BREAST CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEMATOLOGY;LUNG;LUNG CANCER;AGING;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;LYMPHOMA;NEUROSCIENCES;NUTRITION;OBESITY;ORPHAN DRUG;PREVENTION","10;9;8;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;STROKE","9;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;7.1 INDIVIDUAL CARE NEEDS","7;2;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;LUNG CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;RESPIRATORY SYSTEM","2;2;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","5;1;1;1;1;1",1,0,0,3,1,1,0,1,0,0,"CENTRO DI RIFERIMENTO ONCOLOGICO","1","ITALIAN ASSOCIATION FOR CANCER RESEARCH","1","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","1",NA,NA,"31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1;1","CANCER;CLINICAL RESEARCH;GENETICS;ORPHAN DRUG;OVARIAN CANCER;RARE DISEASES","1;1;1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1;1","OVARIAN CANCER","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1","A01 CLINICAL MEDICINE","1",NA,NA,33,"FRONTIERS;THE CAMBRIDGE STRUCTURAL DATABASE;ZENODO;PUBLIC LIBRARY OF SCIENCE;AMERICAN CHEMICAL SOCIETY;KARGER PUBLISHERS;SPRINGER NATURE","16;4;4;3;2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4202 EPIDEMIOLOGY;41 ENVIRONMENTAL SCIENCES;4205 NURSING;4609 INFORMATION SYSTEMS;4610 LIBRARY AND INFORMATION STUDIES;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","40;20;15;6;6;5;5;3;3;3;2;2;2;1;1;1;1;1;1","CANCER;RARE DISEASES;CLINICAL RESEARCH;GENETICS;DIGESTIVE DISEASES;BREAST CANCER;PREVENTION;BIOTECHNOLOGY;KIDNEY DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COLO-RECTAL CANCER;GENETIC TESTING;HEMATOLOGY;LUNG;LYMPHOMA;NEUROSCIENCES;ORPHAN DRUG;PANCREATIC CANCER;PATIENT SAFETY;PEDIATRIC","20;12;9;9;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;MENTAL HEALTH","19;1;1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;3;2;1;1","BIOMEDICAL;CLINICAL","11;6","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","11;5;3","BREAST CANCER;KIDNEY CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;SARCOMA;ENDOMETRIAL CANCER;LIVER CANCER;OVARIAN CANCER;PHARYNGEAL CANCER","4;3;2;2;2;2;2;1;1;1;1",NA,NA
"IRCCS_CRO",2023,282,19.758865248227,2.88652482269503,0.25531914893617,0.234042553191489,0.315602836879433,2.90714285714286,1.24137931034483,1.73684210526316,1.53448275862069,0.74113475177305,1,143,63,11,10,0.51,0.22,0.04,0.04,4.37,0.996738577918957,5.54598908021839,0.50709219858156,0.975177304964539,0.525,0.452,0.461,0.453,"FABIO PUGLISI;VALTER GATTEI;LORENZO GERRATANA;MICHELE SPINA;JERRY POLESEL;RICCARDO BOMBEN;ANTONELLA ZUCCHETTO;TAMARA BITTOLO;LUIGINO DAL MASO;GIUSEPPE TOFFOLI;DAVIDE ROSSI;LUCIA FRATINO;MASSIMO CRISTOFANILLI;ANNALISA CHIARENZA;MICHELE BARTOLETTI;DIEGO SERRAINO;CAROLINA REDUZZI;MARILENA DI NAPOLI;SEBASTIANO BUTI;MARCO MARUZZO","27;25;22;18;18;17;15;15;15;14;13;12;12;12;12;12;12;11;11;11","FABIO PUGLISI;ANTONINO CARBONE;LORENZO GERRATANA;LUIGINO DAL MASO;GIUSEPPE TOFFOLI;JERRY POLESEL;ISABELLA CALIGIURI;FLAVIO RIZZOLIO;VALTER GATTEI;MICHELE AVANZO;VINCENZO CANZONIERI;DIEGO SERRAINO;CAROLINA REDUZZI;MICHELE BARTOLETTI;LUCA MICELI;AGOSTINO STEFFAN;PAOLO BALDO;GIUSEPPE CORONA;MASSIMO CRISTOFANILLI;RICCARDO BOMBEN","1.94;1.78;1.49;1.28;1.27;1.22;1.2;1.11;1.09;1.09;0.94;0.93;0.92;0.91;0.88;0.85;0.83;0.81;0.77;0.74","FABIO PUGLISI;VALTER GATTEI;LORENZO GERRATANA;MICHELE SPINA;JERRY POLESEL;RICCARDO BOMBEN;ANTONELLA ZUCCHETTO;TAMARA BITTOLO;LUIGINO DAL MASO;GIUSEPPE TOFFOLI;LUCIA FRATINO;MICHELE BARTOLETTI;DIEGO SERRAINO;VINCENZO CANZONIERI;AGOSTINO STEFFAN;ISABELLA CALIGIURI;FRANCESCO SOPRACORDEVOLE;FLAVIO RIZZOLIO;GIUSEPPE FANETTI;FILIPPO VIT","27;25;22;18;18;17;15;15;15;14;12;12;12;10;10;10;10;9;9;9","FABIO PUGLISI;ANTONINO CARBONE;LORENZO GERRATANA;LUIGINO DAL MASO;GIUSEPPE TOFFOLI;JERRY POLESEL;ISABELLA CALIGIURI;FLAVIO RIZZOLIO;VALTER GATTEI;MICHELE AVANZO;VINCENZO CANZONIERI;DIEGO SERRAINO;MICHELE BARTOLETTI;LUCA MICELI;AGOSTINO STEFFAN;PAOLO BALDO;GIUSEPPE CORONA;RICCARDO BOMBEN;GIANMARIA MIOLO;ANTONELLA ZUCCHETTO","1.94;1.78;1.49;1.28;1.27;1.22;1.2;1.11;1.09;1.09;0.94;0.93;0.91;0.88;0.85;0.83;0.81;0.74;0.71;0.68","FRANCESCO RASPAGLIESI;FRANCESCO SOPRACORDEVOLE;GIORGIO BOGANI;ANDREA GIANNINI;ENRICO VIZZA;FABIO GHEZZI;VIOLANTE DI DONATO;GIOVANNI SCAMBIA;JING WANG;ANDREA CIAVATTINI;PAOLO VERCELLINI;GIAMPIERO CAPOBIANCO;JVAN CASARIN;MARCO PETRILLO;TULLIO GOLIA D’AUGÈ;ALESSANDRA BEARZ;SANJAY POPAT;ALEXIS B. CORTOT;ANGELA GIRVIN;ANTONINO DITTO","248;244;237;227;227;227;227;212;200;198;187;127;127;127;127;125;112;100;100;100","FRANCESCO SOPRACORDEVOLE;ALESSANDRA BEARZ;FABIO PUGLISI;JERRY POLESEL;ISABELLA CALIGIURI;FLAVIO RIZZOLIO;MICHELE BARTOLETTI;GIUSEPPE TOFFOLI;RENATO CANNIZZARO;ERIKA CECCHIN;STEFANO REALDON;LORENZO GERRATANA;LUIGINO DAL MASO;DIEGO SERRAINO;VINCENZO CANZONIERI;ROSSANA RONCATO;GIUSEPPE FANETTI;KANWAL ASIF;ELENA DE MATTIA;MICHELE SPINA","244;125;90;79;71;69;69;66;65;63;57;56;56;47;47;42;35;34;33;33","VALTER GATTEI;FABIO PUGLISI;LORENZO GERRATANA;JERRY POLESEL;MICHELE SPINA;RICCARDO BOMBEN;LUIGINO DAL MASO;ANTONELLA ZUCCHETTO;TAMARA BITTOLO;GIUSEPPE TOFFOLI;LUCIA FRATINO;DIEGO SERRAINO;MICHELE BARTOLETTI;FRANCESCO SOPRACORDEVOLE;ISABELLA CALIGIURI;FILIPPO VIT;AGOSTINO STEFFAN;GIUSEPPE FANETTI;ERIKA TISSINO;FEDERICA TOFFOLUTTI","25;23;21;19;19;17;15;15;15;14;12;12;11;10;10;9;9;9;8;8","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;SOCIOLOGY;ENGINEERING;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;BUSINESS;ART;GEOGRAPHY;PHILOSOPHY","252;106;28;22;17;13;13;10;10;9;7;6;3;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PATHOLOGY;PALEONTOLOGY;GYNECOLOGY;PHARMACOLOGY;CELL BIOLOGY;RADIOLOGY;UROLOGY;FAMILY MEDICINE;NUCLEAR MEDICINE;BIOINFORMATICS;MEDICAL PHYSICS;PEDIATRICS;PHYSICAL THERAPY","212;134;56;51;48;44;38;36;36;34;23;20;18;14;12;12;10;10;9;9;9;9","CANCER;GENE;CHEMOTHERAPY;LYMPHOMA;POPULATION;CONFIDENCE INTERVAL;COHORT;DISEASE;RETROSPECTIVE COHORT STUDY;ANTIBODY;LEUKEMIA;CLINICAL TRIAL;PROPORTIONAL HAZARDS MODEL;STAGE (STRATIGRAPHY);RANDOMIZED CONTROLLED TRIAL;IMMUNE SYSTEM;RADIATION THERAPY;BIOPSY;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;OVERALL SURVIVAL","145;44;42;38;35;28;21;20;20;18;18;16;16;16;15;14;14;10;10;10;10","BREAST CANCER;IMMUNOTHERAPY;CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;HAZARD RATIO;CERVICAL CANCER;CLINICAL ENDPOINT;METASTASIS;RITUXIMAB;GENE EXPRESSION;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;DIFFUSE LARGE B-CELL LYMPHOMA;CISPLATIN;GENOTYPE;PHASES OF CLINICAL RESEARCH;B CELL;FOLLICULAR LYMPHOMA;ENDOMETRIAL CANCER;MINIMAL RESIDUAL DISEASE;PHENOTYPE;SOFT TISSUE SARCOMA;THYROID CANCER","52;16;15;15;14;13;13;13;12;11;10;10;9;8;8;8;7;7;6;6;6;6;6","METASTATIC BREAST CANCER;CIRCULATING TUMOR CELL;NIVOLUMAB;DNA METHYLATION;IBRUTINIB;BENDAMUSTINE;BRUTON'S TYROSINE KINASE;CARBOPLATIN;HPV INFECTION;IGHV@;TRASTUZUMAB;ESTROGEN RECEPTOR;GENOTYPING;PHARMACOGENETICS;TAMOXIFEN;TRABECTEDIN;CAPECITABINE;CERVICAL INTRAEPITHELIAL NEOPLASIA;COLONOSCOPY;COLPOSCOPY;CORONAVIRUS DISEASE 2019 (COVID-19);GERMINAL CENTER;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;INTERNATIONAL PROGNOSTIC INDEX;TRANSCRIPTOME;VENETOCLAX","19;9;9;8;8;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;BREAST NEOPLASMS;RETROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;MALE;OVARIAN NEOPLASMS;AGED;ADULT;MIDDLE AGED;ITALY;PROSPECTIVE STUDIES;BIOMARKERS, TUMOR;ANTINEOPLASTIC AGENTS;MELANOMA;NEOPLASMS;PAPILLOMAVIRUS INFECTIONS;ANIMALS","139;139;53;36;34;30;20;18;18;17;16;16;15;14;13;12;12;12;12;10","LYMPHOID NEOPLASMS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GYNECOLOGIC ONCOLOGY;RENAL CELL CARCINOMA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;SARCOMA RESEARCH AND TREATMENT;CANCER STEM CELLS AND TUMOR METASTASIS;COLORECTAL CANCER RESEARCH AND TREATMENT;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;MOLECULAR RESEARCH ON BREAST CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;MELANOMA","23;19;13;12;10;8;6;6;5;5;4;4;4;4;3;3;3;3;3;3","BREAST CANCER;CLINICAL ENDPOINT;MANTLE CELL LYMPHOMA;PROGRESSION-FREE SURVIVAL;CANCER RISK;CIRCULATING TUMOR CELL;INTRATUMOR HETEROGENEITY;METASTATIC BREAST CANCER;REGIMEN;HPV VACCINATION;CANCER INCIDENCE;FOLLICULAR LYMPHOMA;TREATMENT;TUMOR EVOLUTION;BENDAMUSTINE;CANCER SUSCEPTIBILITY;CANCER THERAPY;MINIMAL RESIDUAL DISEASE;PALBOCICLIB;CANCER GENOMICS","17;13;11;10;9;9;9;9;9;8;7;7;7;7;6;6;6;6;6;5","BREAST CANCER;CIRCULATING TUMOR;METASTATIC BREAST;CELL CARCINOMA;FONDAZIONE ITALIANA;ITALIANA LINFOMI;CANCER PATIENTS;OVARIAN CANCER;HODGKIN LYMPHOMA;PATIENTS PTS;PHASE II;RENAL CELL;CHRONIC LYMPHOCYTIC;ENDOMETRIAL CANCER;LYMPHOCYTIC LEUKEMIA;METASTATIC RENAL;ABSTRACT P--;LINFOMI FIL;RETROSPECTIVE STUDY;TUMOR CELLS;TUMOR DNA;ADVANCED BREAST;CANCER RISK;HORMONE RECEPTOR;HUMAN PAPILLOMAVIRUS;MULTIPLE MYELOMA;RECTAL CANCER;THYROID CANCER;B-CELL LYMPHOMA;CANCER MBC","42;13;13;12;11;11;10;9;8;8;8;8;7;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;4;4","BREAST CANCER;HR CI;ADVISORY ROLE;MONTHS CI;SURVIVAL PFS;PROGRESSION-FREE SURVIVAL;MEDIAN FOLLOW-UP;SURVIVAL OS;CLINICAL PRACTICE;OVARIAN CANCER;RESEARCH FUNDING;RESPONSE RATE;CDD EXPRESSION;EDUCATIONAL GRANTS;LUNG CANCER;MEDIAN AGE;CANCER PATIENTS;CHRONIC LYMPHOCYTIC;MEDIAN PFS;MULTIVARIATE ANALYSIS;LYMPHOCYTIC LEUKEMIA;MONTHS NA;THYROID CANCER;CONFIDENCE INTERVAL;HAZARD RATIO;PATIENTS TREATED;PRIMARY ENDPOINT;DISEASE PROGRESSION;LEUKEMIC CELLS;LYMPH NODE","65;54;40;35;32;31;28;28;26;20;20;20;19;19;18;18;17;16;16;16;15;15;15;14;14;14;14;13;13;13",117,0.41,6.55,8,1,1,0,8.25,0,1,1,9,1,1,8,0,0,1,4,7,4,0,0,9,9,1,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,4,0.98,1.5,0,1,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"AGOSTINI FRANCESCO;DURANTE CRISTINA;MAZZUCATO MARIO;VICINANZA CARLA","2;2;2;2","CENTRO DI RIFERIMENTO ONCOLOGICO;CENTRA DI RIFERIMENTO ONCOLOGICO","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING","4;2;2","BIOTECHNOLOGY;HEMATOLOGY;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","2;2;2;2;2","5.2 CELLULAR AND GENE THERAPIES","2","A61K35/28;C12N5/0775;C12N13/00","2;2;1","A61K35/28;C12N13/00;C12N2501/135;C12N2509/00;C12N2533/30;C12N5/0663;C12N5/0664;C12N5/0667;C12N5/0668","2;2;2;2;2;2;2;2;2",11,4.8,328.4,4.1,4,0.36,47.18,0,0,3,0,2,0,0,6,0,4,6,0,0,0,0,0,0,8,2,1,10,1,0,0,0,0,0,0,0,0,"Germany;Switzerland;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","11;11;3;2;1;1;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;HEMATOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LYMPHOMA;BREAST CANCER;AGING;DIGESTIVE DISEASES;ESTROGEN;ORPHAN DRUG;PATIENT SAFETY;BIOMEDICAL IMAGING;BIOTECHNOLOGY;COLO-RECTAL CANCER;GENETICS;PREVENTION;PROSTATE CANCER;UROLOGIC DISEASES","11;7;6;5;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1","CANCER","10","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","5;4;3;2;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;MYELOMA;PROSTATE CANCER","4;3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;1.4 CANCER PROGRESSION AND METASTASIS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","5;3;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,"AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS;THE CAMBRIDGE STRUCTURAL DATABASE;SPRINGER NATURE","14;14;10;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3401 ANALYTICAL CHEMISTRY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;3206 MEDICAL BIOTECHNOLOGY;3210 NUTRITION AND DIETETICS;4206 PUBLIC HEALTH","54;27;12;7;6;6;5;5;5;2;2;2;1;1;1","CANCER;RARE DISEASES;BIOTECHNOLOGY;CLINICAL RESEARCH;GENETICS;DIGESTIVE DISEASES;OVARIAN CANCER;PREVENTION;COLO-RECTAL CANCER;DIABETES;HEMATOLOGY;LUNG;LYMPHOMA;NUTRITION;ORPHAN DRUG;REHABILITATION","14;5;4;3;3;2;2;2;1;1;1;1;1;1;1;1","CANCER","29","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;7.1 INDIVIDUAL CARE NEEDS","2;2;2;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","6;2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","12;9;3","BREAST CANCER;SARCOMA;OVARIAN CANCER;COLON AND RECTAL CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","14;5;3;2;2;2;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_CRO",2024,254,18.9448818897638,2.83464566929134,0.255905511811024,0.248031496062992,0.28740157480315,2.71698113207547,1.04838709677419,1.53658536585366,1.19672131147541,0.622047244094488,1,141,42,11,4,0.56,0.17,0.04,0.02,0.81,0.844493867104954,4.58241758241756,0.515748031496063,0.992125984251969,0.519,0.481,0.491,0.496,"FABIO PUGLISI;LORENZO GERRATANA;FLAVIO RIZZOLIO;VINCENZO CANZONIERI;JERRY POLESEL;DIEGO SERRAINO;CAROLINA REDUZZI;FABIOLA GIUDICI;LUIGINO DAL MASO;MICHELINO DE LAURENTIIS;RENATO CANNIZZARO;BARBARA BELLETTI;EVA BLONDEAUX;LUCIA DEL MASTRO;LORENZO FOFFANO;MATTEO LAMBERTINI;LUCIA FRATINO;MICHELE BARTOLETTI;AMI N. SHAH;THOMAS SCATTOLIN","34;24;21;17;17;13;13;12;12;11;11;11;10;10;10;10;9;9;9;9","FLAVIO RIZZOLIO;FABIO PUGLISI;VINCENZO CANZONIERI;LORENZO GERRATANA;JERRY POLESEL;ANTONINO CARBONE;GIUSEPPE CORONA;FABIO DEL BEN;THOMAS SCATTOLIN;ETTORE BIDOLI;ISABELLA CALIGIURI;GIUSEPPE TOFFOLI;BARBARA BELLETTI;FRANCESCA DAL MAS;HELENA BIANCUZZI;DIEGO SERRAINO;FABIANO VISENTIN;NICOLA DEMITRI;FABIOLA GIUDICI;MATTEO MAUCERI","2.34;1.98;1.61;1.5;1.29;1.27;1.08;1.06;1.04;1.04;0.94;0.86;0.85;0.82;0.81;0.79;0.76;0.76;0.75;0.73","FABIO PUGLISI;LORENZO GERRATANA;FLAVIO RIZZOLIO;VINCENZO CANZONIERI;JERRY POLESEL;DIEGO SERRAINO;FABIOLA GIUDICI;LUIGINO DAL MASO;RENATO CANNIZZARO;BARBARA BELLETTI;LORENZO FOFFANO;LUCIA FRATINO;MICHELE BARTOLETTI;GUSTAVO BALDASSARRE;FABIO DEL BEN;ISABELLA CALIGIURI;ALESSANDRA BEARZ;RICCARDO BOMBEN;AGOSTINO STEFFAN;SAMUELE MASSARUT","34;24;21;17;17;13;12;12;11;11;10;9;9;9;9;8;8;8;7;7","FLAVIO RIZZOLIO;FABIO PUGLISI;VINCENZO CANZONIERI;LORENZO GERRATANA;JERRY POLESEL;ANTONINO CARBONE;GIUSEPPE CORONA;FABIO DEL BEN;ETTORE BIDOLI;ISABELLA CALIGIURI;GIUSEPPE TOFFOLI;BARBARA BELLETTI;DIEGO SERRAINO;FABIOLA GIUDICI;AGOSTINO STEFFAN;GUSTAVO BALDASSARRE;LUIGINO DAL MASO;MICHELE BARTOLETTI;ALESSANDRA BEARZ;LUCIA CADORIN","2.34;1.98;1.61;1.5;1.29;1.27;1.08;1.06;1.04;0.94;0.86;0.85;0.79;0.75;0.7;0.67;0.64;0.64;0.59;0.58","ROCCO GALASSO;LAURA BOTTA;ALEXANDER KATALINIC;KAIRE INNOS;PAOLO BAILI;XAVIER TROUSSARD;LUIGINO DAL MASO;ADELE CALDARELLA;CINZIA GASPAROTTI;GIUSEPPE SAMPIETRO;MARGHERITA FERRANTE;MARIA LETIZIA GAMBINO;PAOLA BALLOTARI;STEFANO FERRETTI;STEFANO GUZZINATI;FRANCESCO CUCCARO;GEMMA GATTA;ROBERTA DE ANGELIS;SILVIA ROSSI;ELENA DEMURU","54;52;48;48;48;48;34;30;30;30;30;30;30;30;30;29;29;28;28;27","LUIGINO DAL MASO;RENATO CANNIZZARO;FLAVIO RIZZOLIO;ALESSANDRA BEARZ;DIEGO SERRAINO;FABIO PUGLISI;MICHELE BARTOLETTI;JERRY POLESEL;LUCIA LA MURA;STEFANO REALDON;GIUSEPPE FANETTI;GIUSEPPE TOFFOLI;ISABELLA CALIGIURI;MICHELE AVANZO;MICHELE DAL BO;RICCARDO BOMBEN;VALTER GATTEI;FABIOLA GIUDICI;FEDERICA TOFFOLUTTI;GIUSEPPE CORONA","34;19;18;14;14;12;12;11;11;11;9;9;7;7;7;7;7;6;6;6","FABIO PUGLISI;LORENZO GERRATANA;FLAVIO RIZZOLIO;JERRY POLESEL;VINCENZO CANZONIERI;DIEGO SERRAINO;FABIOLA GIUDICI;LUIGINO DAL MASO;BARBARA BELLETTI;RENATO CANNIZZARO;FABIO DEL BEN;LUCIA FRATINO;MICHELE SPINA;RICCARDO BOMBEN;GUSTAVO BALDASSARRE;MICHELE BARTOLETTI;ALESSANDRA BEARZ;ISABELLA CALIGIURI;GIUSEPPE CORONA;VALTER GATTEI","30;21;19;17;17;13;12;12;11;11;9;9;9;9;9;9;8;8;7;7","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;SOCIOLOGY;MATERIALS SCIENCE;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;ENGINEERING;GEOGRAPHY;PHILOSOPHY;ART;BUSINESS;ENVIRONMENTAL SCIENCE;HISTORY","224;91;34;24;15;13;10;9;9;9;8;7;5;5;3;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;GENETICS;SURGERY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PHARMACOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;GYNECOLOGY;PALEONTOLOGY;ARTIFICIAL INTELLIGENCE;RADIOLOGY;DEMOGRAPHY;PHYSICAL THERAPY;BIOINFORMATICS;INTENSIVE CARE MEDICINE;ORGANIC CHEMISTRY","183;108;62;38;35;32;28;27;25;20;18;18;18;14;12;12;11;11;10;10;10","CANCER;CHEMOTHERAPY;GENE;POPULATION;ANTIBODY;DISEASE;ADVERSE EFFECT;CLINICAL TRIAL;CONFIDENCE INTERVAL;LYMPHOMA;RETROSPECTIVE COHORT STUDY;PROSPECTIVE COHORT STUDY;LUNG CANCER;RADIATION THERAPY;SIGNAL TRANSDUCTION;CATALYSIS;COHORT;IMMUNE SYSTEM;MELANOMA;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY)","137;30;30;23;16;16;14;14;12;12;12;11;10;10;10;9;9;9;9;9;9","BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;OVARIAN CANCER;PROSTATE CANCER;CISPLATIN;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;CANCER CELL;ENDOMETRIAL CANCER;CANCER REGISTRY;CERVICAL CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;EPIGENETICS;MONOCLONAL ANTIBODY;PALLADIUM;PI3K/AKT/MTOR PATHWAY;TUMOR MICROENVIRONMENT;B CELL;DOWNREGULATION AND UPREGULATION;GERMLINE;HAZARD RATIO;HEAD AND NECK CANCER;HODGKIN LYMPHOMA;INFECTIOUS DISEASE (MEDICAL SPECIALTY);METASTASIS;MUTATION;PACLITAXEL;PANCREATIC CANCER;PHASES OF CLINICAL RESEARCH;THERAPEUTIC DRUG MONITORING","56;17;16;11;8;7;7;7;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","METASTATIC BREAST CANCER;HORMONE RECEPTOR;NIVOLUMAB;ESTROGEN RECEPTOR;PEMBROLIZUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);IBRUTINIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;GERMLINE MUTATION;PEMETREXED;TAMOXIFEN;TRASTUZUMAB;ADJUVANT CHEMOTHERAPY;BREAST TUMOR;BRUTON'S TYROSINE KINASE;CA15-3;CARBOPLATIN;CETUXIMAB;DEUBIQUITINATING ENZYME;DNA MISMATCH REPAIR;ERLOTINIB;INTERNATIONAL PROGNOSTIC INDEX;IRINOTECAN;MASTECTOMY;NEOADJUVANT THERAPY;PANCREATIC DUCTAL ADENOCARCINOMA;SELECTED REACTION MONITORING;SEROUS OVARIAN CANCER;SEX HORMONE-BINDING GLOBULIN;TRABECTEDIN","19;6;6;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MIDDLE AGED;AGED;MALE;ADULT;AGED, 80 AND OVER;BREAST NEOPLASMS;RETROSPECTIVE STUDIES;ITALY;YOUNG ADULT;OVARIAN NEOPLASMS;PROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS;CELL LINE, TUMOR;PROGNOSIS;ADOLESCENT;ANIMALS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","149;104;76;49;48;48;47;29;20;19;15;14;11;10;9;9;9;8;8;8","CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;LYMPHOID NEOPLASMS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GYNECOLOGIC ONCOLOGY;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;MOLECULAR RESEARCH ON BREAST CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MELANOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GLIOMAS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HER2 SIGNALING IN BREAST CANCER TREATMENT;RENAL CELL CARCINOMA;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER","10;10;9;8;8;7;7;7;6;5;5;4;4;4;4;4;4;4;4;3","BREAST CANCER;CANCER GENOMICS;CANCER RISK;CANCER SUSCEPTIBILITY;CLINICAL ENDPOINT;MELANOMA;INTRATUMOR HETEROGENEITY;METASTATIC BREAST CANCER;PROGRESSION-FREE SURVIVAL;CROSS-SECTIONAL STUDY;DERMOSCOPY;MOLECULAR PROFILING;PALBOCICLIB;BREAST CANCER SCREENING;CANCER;CANCER THERAPY;CDK4/6 INHIBITORS;CHEMOTHERAPY;DIETARY PATTERNS;HEALTHY EATING INDEX","20;9;7;7;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4","BREAST CANCER;METASTATIC BREAST;CANCER PATIENTS;OVARIAN CANCER;ABSTRACT PO--;CIRCULATING TUMOR;LUNG CANCER;TUMOR DNA;CELL CARCINOMA;COLORECTAL CANCER;COMPLEXES BEARING;ENDOMETRIAL CANCER;CANCER MBC;CELL LUNG;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;PROSTATE CANCER;CLINICAL OUTCOMES;ESTROGEN RECEPTOR;HODGKIN LYMPHOMA;HORMONE RECEPTOR;INDIVIDUAL PATIENT;MEET-URO STUDY;MULTIPLE MYELOMA;OBSERVATIONAL STUDY;PHASE II;POOLED ANALYSIS;POPULATION-BASED STUDY;ANTICANCER ACTIVITY;CANCER CELLS","45;15;12;11;10;10;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3","BREAST CANCER;PUBMED SCOPUS;CROSSREF PUBMED;GENETIC TESTING;GENETIC COUNSELING;OVARIAN CANCER;LYNCH SYNDROME;CLINICAL PRACTICE;ENDOMETRIAL CANCER;HR CI;CLIN ONCOL;ONCOL -CROSSREF;SUPPORTING INFORMATION;PROGRESSION-FREE SURVIVAL;COLORECTAL CANCER;LUNG CANCER;CLL CELLS;DISEASE PROGRESSION;LYNCH ALERT;MEDIAN MONTHS;SURVIVAL OS;SURVIVAL PFS;CANCER CELL;CLINICAL TRIALS;CURE PREVALENCE;PATIENTS TREATED;ADVERSE EVENTS;CANCER BC;CANCER PATIENTS;GYNECOLOGICAL CANCERS","38;33;32;32;23;21;18;17;16;16;15;15;15;14;13;13;12;12;12;12;12;12;11;11;11;11;10;10;10;10",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,8,310,1.19,0,0,19.33,0,0,1,0,1,0,0,1,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Switzerland;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","3;3;2;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;GENETICS;HEMATOLOGY;LUNG CANCER;LYMPHOMA;PATIENT SAFETY;RARE DISEASES","3;2;2;2;1;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","2;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
